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Abstract
During the past 50 years, pharmaceutical coating has gone through the transition from
sugar coating to organic solvent coating and aqueous coating. Since the 1990s, aqueous
coating has largely phased out organic solvent coating as the dominate coating method for
pharmaceutical dosage forms due to the toxicity and environmental related concerns
caused by the organic solvents. On the other hand, although prevailing, aqueous coating
has other major limitations such as higher energy consumption and longer processing
time than the solvent coating. Powder coating has the benefits of both, being
environmentally friendly, energy efficient and short processing time, while equally
effective in modifying drug release profiles. Consequently, powder coating is pointing to
the future as the next breakthrough in pharmaceutical coating.
Involving three steps including preheating of the dosage forms, electrostatic deposition of
coating powders and film formation (curing), powder coating has been studied to tablet
coating with easily coated polymers. The objectives of the present study are to expand
powder coating to more difficult coating materials such as ethylcellulose and cellulose
acetate, as well as more difficult dosage forms including small pellets, and in particular,
osmotic controlled release tablets.
As a water-insoluble polymer, ethylcellulose (EC) is a commonly used coating material
for sustained drug release. However, it is very difficult to coat by powder coating due to
its high glass transition temperature (Tg). The present study was successful to coat tablets
with fine particles of EC in a rotatable pan coater. With the proper addition of
plasticizers, a continuous and uniform coating film was formed. Pore forming agent was
added in the coating formulation to adjust the permeability of the coating film to allow a
more controlled drug release rate.
Currently, small pellets are coated by solvent coating or aqueous coating in a fluidized
bed with a larger amount of fluidizing hot air than a pan coater, leading to an extremely
high energy consumption. The present study utilized the pan coater instead of a fluidized
bed to coat small pellets with powder coating, leading to a significant energy savings by

avoiding the use of large amount of fluidizing hot air required to fluidize those pellets and
to evaporate the organic solvent or water. Three different coating formulations containing
Eudragit® EPO, Eudragit® RS/RL and Acryl EZE were developed to achieve immediate
release, sustained release and delayed release, respectively.
Particularly, as the only oral drug delivery system capable of achieving constant drug
release rate, osmotic drug delivery system (ODDS) is considered as the ultimate ideal
drug delivery system. However, only organic solvent coating can be currently used to
coat ODDS due to the high Tg of the coating materials. The present study successfully
applied powder coating to coat ODDS with cellulose acetate (CA), resulting in a
continuous, uniform and functionally acceptable coating film. Both elementary and
porosity ODDS were achieved by using this powder coating. Following zero order drug
release kinetics, drug release rate from powder coated ODDS varied with different
coating levels while was independent with other factors such as drug delivery orifice
diameter, pH vale of the release media and agitation speed. Considering that ODDS is the
most promising controlled drug release system, the success of powder coating ODDS is a
big breakthrough in pharma coating.
To fully illustrate the powder coating process, in-depth characterization was carried out to
investigate the coating powder deposition and film formation, and their influence factors.
Positively related to the coating efficiency, powder deposition was found to be the key of
the whole process, which can be promoted by preheating the dosage forms, spraying
suitable liquid plasticizer and applying electrostatics for the powder spray. A curing step
is necessary after coating powder adhesion to allow deposited particles to coalesce and
form a continuous coating film. Finer coating powders, higher curing temperature and
longer curing time would lead to a more uniform and smoother coating film.

Keywords
Pharmaceutical solid dosage forms, powder coating, tablets, pellets, osmotic drug
delivery system, ethylcellulose, cellulose acetate, liquid plasticizer, sustained release,
controlled release, enteric coating, coating powder adhesion, film formation, drug release.
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1

General introduction

1.1 Introduction
In the pharmaceutical industry, solid dosage forms, including tablets, pellets, and
capsules, are always coated to enhance drug’s physical and chemical properties, to
achieve taste masking and also to modify the drug release profiles. Nowadays liquid
coating methods, including solvent coating and aqueous coating, are widely used in the
pharmaceutical industry to obtain the coating film of the solid dosage forms. In the
solvent coating process, coating polymers and other excipients are dissolved into an
organic solvent to form a coating solution, which is sprayed onto the surface of the solid
dosage forms to form a coating film by evaporating the organic solvent. The film
formation from organic solvent coating occurs by a loss of organic solvent during the
drying process and contact of individual polymer molecules [1, 2]. As a result, solvent
coating can form a very uniform coating film. However, it can also cause many problems
due to the presence of organic solvent such as toxicity and environmental concerns.
Besides, the concentration of the coating solution cannot be very high owing to the
viscosity limitation, leading to a long processing time to achieve high coating thickness.
As a result of toxicity and environmental concerns, aqueous coating started to dominate
in 1990s and remains the preferred approach in the present pharmaceutical industry. For
water soluble polymers, the coating process and film formation mechanism are the same
as organic solvent coating. For water-insoluble polymers, the coating process and film
formation are different. Coating polymers and additives are firstly ground into fine
powders. After being mixed together, those fine powders are dispersed into water to form
a coating powder suspension. This suspension is then sprayed onto the surface of the solid
dosage forms, followed by water evaporation using hot air and curing to allow the
polymer particles coalescing into a homogeneous film. Plasticizers are often added into
the coating formulation to reduce the glass transition temperature (Tg) of the coating
polymer [2]. Although there is no toxicity and environmental related problems for
aqueous coating, it still possesses many limitations. First, water is much harder to
evaporate compared to organic solvent, leading to a much longer processing time and

2

much higher energy consumption. Also hot air and its huge handling system are
necessary to evaporate water, which could further increase the overall cost. In addition,
aqueous coating is not appropriate for the moisture sensitive drugs.
In order to overcome those disadvantages caused by organic solvent and water in the
coating process, dry coating technologies have been recently developed and reported.
These technologies include photocuring coating, supercritical fluid spray coating, hotmelt coating and dry powder coating [3-5]. For the photocuring coating, supercritical
coating and hot melt coating, specific coating conditions and suitable coating materials
are necessary but unfortunately both are very limited. Consequently, those technologies
cannot be widely applied in the pharmaceutical industry. For dry powder coating, liquid
plasticizers have to be sprayed onto the surface of the solid dosage forms to reduce
minimum film formation temperature but surplus plasticizer can possibly lead to very soft
or sticky film. So a careful balance needs to be reached between the plasticizer
concentration for a sufficient coat thickness and that for a flexible and dry coat. And also
the coating powder feeding cannot be well controlled and it is difficult to get a smooth
and thickness uniform coating film.
Compared to those dry coating technologies, electrostatic powder coating has gained
more attention owing to its distinct advantages, such as short coating process, highly
valued for energy savings, and significant reduction of overall operating cost. And most
importantly, electrostatic powder coating can enhance the coating powder adhesion so as
to increase the coating efficiency dramatically and also can well control the coating
powder feeding and achieve a much more uniform coating film both on coating thickness
and surface morphology than other dry coating methods. Earlier attempts on electrostatic
coating were mainly carried out by the Phoqus Ltd. Unfortunately, those advantages have
been compromised by the complicated coating process and added cost of the coating
apparatus, offsetting any cost benefit to switching from liquid coating to powder coating,
since their technology requires the use of completely different coating equipment. The
pharmaceutical companies would prefer to accept a powder coating process operated in a
simpler coating apparatus that can be easily adapted from their present apparatus, such as
pan coaters, for liquid coating.
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Researchers in our group designed and developed a novel electrostatic powder coating
technology [6] with an apparatus similar to the traditional pan coating system. This
technology gained more attention due to the higher coating efficiency with simpler
coating process and little change needed when adapting from the present apparatus. By
using this technology, several easily coating materials have been applied on tablet coating
[7-9].
However, more work will need to be carried out to fully illustrate this novel electrostatic
powder coating technology. Firstly, this technology needs to be expanded to those coating
materials with high glass transition temperature (Tg), for example, ethylcellulose and
cellulose acetate, which is quite difficult to be coated by powder coating.
In addition, coating of small solid dosage forms, such as pellets, still relies on the organic
solvent coating or aqueous coating using a fluidized bed with large amount of fluidizing
hot air, causing extremely high energy consumption. Powder coating of small pellets in a
simpler apparatus could bring lots of benefits, overcoming those limitations related to the
organic solvent and water, and significantly reducing the overall coast by avoiding use of
large amount of fluidizing hot air.
Particularly, as the most promising oral drug delivery system, osmotic drug delivery
system (ODDS) can only be coated with organic solvent coating due to the high glass
transition temperature (Tg) of the coating polymers. Much previous work has been done
on powder coating, but none of it focused on the ODDS. It would be a big breakthrough if
the ODDS tablets could be successfully coated with powder coating.
Last but not the least, the electrostatic powder coating process needs to be characterized
more in-depth in order to illustrate the coating powder adhesion and film formation, and
their influence factors.

1.2 Objectives
Corresponding to the needs mentioned above, the present study focuses on the following
objectives:
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To coat tablets with micronized ethylcellulose by using a novel electrostatic
powder coating technology to achieve sustained drug release, optimizing the
coating parameters so as to form a continuous and uniform coating film.



To expand powder coating to small solid dosage forms such as pellets, optimizing
the coating process and developing different coating formulations to modify drug
release profiles.



To utilize powder coating for an osmotic drug delivery system (ODDS), focusing
on the coating formulation development so as to achieve drug controlled release
with a constant release rate. Also to clarify the drug release mechanism from those
powder coated ODDS.



To in-depth characterize the electrostatic powder coating process, illustrating the
coating powder adhesion and film formation and their influence factors.

1.3 Thesis structure
This thesis contains eight chapters, organized in the following structure.


Chapter 1 gives a brief introduction on the background of this study, introducing
the needs of the present study. Also research objectives and thesis structure as
well as major contributions are also given in this chapter.



Chapter 2 provides a detailed review on drug release types and drug release
mechanism as well as the development of pharmaceutical coating, particularly on
the solventless coating methods which were reported recently, introducing both
advantages and limitation for each coating technology.



Chapter 3 expands powder coating to coat tablets with micronized ethylcellulose
to achieve sustained drug release, optimizing the coating parameters and curing
conditions so as to form a continuous and uniform coating film and achieve a
desirable drug release time period by adjusting the coating level and the pore
former ratio in the coating formulation.
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Chapter 4 expands powder coating for small pellets with three different coating
formulations to alter drug release profiles, optimizing the coating parameters and
curing conditions so as to form a continuous, uniform and functionally acceptable
coating film.



Chapter 5 applies powder coating to coat elementary ODDS tablets with cellulose
acetate to achieve drug controlled release, optimizing the coating parameters and
curing conditions so as to form a continuous and uniform coating film and to
obtain desirable drug controlled release profiles.



Chapter 6 focuses on powder coating of porosity osmotic pump tablets with
cellulose acetate. Pore forming agent was added in the coating formulation to
create micropores on the coating film (semipermeable membrane), achieving drug
controlled release uniformly through the whole membrane instead of one orifice
(elementary ODDS).



Chapter 7 characterizes the film formation mechanism in the powder coating
process and also clarifies the influence factors that affect the coating powder
adhesion and film formation in the coating process. Also a screen method for the
liquid plasticizer with different coating materials is provided in this chapter.



Chapter 8 summarizes this project, giving conclusions and providing
recommendations for the future work.

1.4 Major contributions
This project expanded a novel electrostatic powder coating technology to more difficult
coating materials such as ethylcelluse and cellulose acetate, and also to more difficult
solid dosage forms including small pellets, osmotic drug delivery system (ODDS). More
specifically the contributions are as follows:
Firstly, powder coating was applied to coat tablets with powdered ethylcellulose,
successfully achieving sustained drug release. This study found TEC is an effective liquid
plasticizer for the ethylcellulose, not only reducing the glass transition temperature but
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also increasing the conductivity of the tablets, leading to enhanced coating powder
adhesion and better film formation. Lactose also has a plasticizing effect on
ethylcellulose, promoting film formation during the curing process. In addition, pore form
agents could be added in the coating formulation to adjust the drug release rate.
Small solid dosage forms, such as pellets, were successfully coated by powder coating
using a pan coater instead of fluidized bed, significantly reducing energy consumption
and avoiding organic solvent and/or water related issues. Three different coating
materials were applied to alter the drug release profiles with an optimized coating
parameters and curing conditions. Compared to the present pellet coating method (liquid
coating in a fluid bed), this electrostatic powder coating with a rotatory pan has many
advantages.
Particularly, the present study made a breakthrough on the coating of osmotic drug
delivery systems (ODDS). Presently, ODDS could only be practically coated by organic
solvent coating. While in this project, both elementary osmotic pump tablets and porosity
osmotic pump tablets were successfully formed by using powder coating with cellulose
acetate. Both water soluble drug (salbutamol sulfate) and water insoluble drug
(ibuprofen) were used as the model drugs. Drug controlled release was successfully
achieved with a desirable time period (12 hours or 24 hours). Drug release mechanisms
from those electrostatic powder coated ODDS were also discussed in this study. Influence
factors that could affect the drug release rate were also clarified.
More in-depth, the electrostatic powder coating process was characterized and fully
illustrated by clarifying the coating powder adhesion and film formation, and their
influence factors. Also this study provided a screening method for selecting liquid
plasticizer for powder coating with different coating materials.
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2

Literature review

2.1 Drug release types
According to the release profile, drug release could be commonly classified as
immediate/fast release, sustained/ controlled release and delayed release (Figure 2.1).
Drug release profiles could be altered by coating the dosage forms based on the properties
of drug and therapeutic target.

Drug release (%)

100 %

Immediate
release

Sustained/controlled release

Delayed release
2 hours

Time

Figure 2.1 Drug release types

2.1.1 Immediate/fast release
Immediate/fast release means that a drug (API) could be released immediately after the
drug entering into the gastrointestinal tract (GI tract) without any extension. This type of
release is suitable for those drugs that could be used to treat acute diseases such as heart
attack, hypertensive urgencies, etc. Coating for immediate release dosage forms aims to
achieve taste and/or odor masking, drug protection from light and also for aesthetic
purpose, etc.
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Figure 2.2 Molecular structure of hydroxypropyl methylcellulose [1]
Water-soluble polymers are usually used as the coating materials in the immediate release
coating. Common water soluble coating materials include hydroxypropyl methylcellulose
(HPMC), hydroxypropyl cellulose, polyvinyl alcohol, polyvinylpyrrolidone--vinyl acetate
copolymer and polyvinyl alcohol--polyethylene glycol copolymer.

2.1.2 Sustained/controlled release
For sustained/ controlled release dosage forms, which is also referred to as extended
release, the drug could be released at a predetermined rate in order to maintain a desirable
plasma drug concentration for a specific period of time. By doing so side effects
associated with high peak plasma concentrations could be eliminated or reduced. Also
sustained release could decrease the dosing frequency and enhance the patient’s
adherence to the therapeutic regimen [2]. An example of an in vitro dissolution profile
from such sustained release systems compared to that of an immediate release product is
shown in Figure 2.1.
Sustained release can be achieved through coating of dosage forms with water-insoluble
polymers such as ethyl cellulose, polymethacrylate copolymers and polyvinyl acetate.
Eudragit® RS /RL are copolymers with quaternary ammonia groups derived from esters
of acrylic and methacrylic acid, which is widely used for sustained release coating of
pharmaceutical dosage forms. Drug release from those coated dosage forms is controlled
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by diffusion. When the coated dosage forms enter the gastrointestinal (GI) tract, fluid of
the GI tract diffuses into the core through the polymer coating film, causing the drug to
dissolve and leading to a much higher concentration of drug inside the core compared to
the outside. This concentration gradient will let the drug release from the inside of the
core to the outside of the dosage form by the passive diffusion. In order to obtain a
sustained release profile, the coating film should possess sufficient mechanical strength to
withstand the hydrostatic pressure caused by the fluid diffused into the core, otherwise
film cracking would occur, leading to a burst drug release.

Figure 2.3 Molecular structure of ethyl cellulose [1]
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Figure 2.4 Molecular structure of Eudragit® RL and Eudragit® RS [3]
Rate of drug release could be affected by the following factors. First of all, film thickness
plays a key role in controlling the drug release rate. Assuming that coating films have
similar densities, thicker coating films create a longer, more tortuous diffusional pathway,
making it slower for the drug to come out [4, 5]. Water solubility of the drug could also
impact the rate of drug release. Drugs with high solubility release much faster than those
slightly soluble or insoluble [2, 6, 7]. In order to increase the rate of drug release, water
soluble materials could be added into the coating formulation to form micropores in the
coating film to promote drug release.
Osmotic drug delivery system (ODDS) nowadays has become the most promising drug
delivery system (DDS) for the reason that it could achieve zero order drug release
kinetics and drug release is independent from pH value, agitation speed or other GI tract
factors. ODDS also need a coating film with water-insoluble polymers to obtain the
controlled drug release. However, the drug release is controlled by the osmotic pressure
gradient rather than passive diffusion. The ODDS core contains osmotic agent(s), which
can create osmotic pressure after the GI fluid diffusing into the core. And the drug will be
released through a delivery orifice or micropores on the coating film governed by the
osmotic pressure. Similar with the diffusion controlled release system, thickness of the
coating film also plays a key role in controlling the drug release rate in ODDS. Cellulose
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esters including cellulose acetate and ethylcellulose are widely used as the coating
materials to form the coating film of ODDS [8-13]. Eudragit® RS /RL [14] was also used
as the coating material to form the semipermeable membrane of the ODDS pellets. The
developed ODDS dosage forms include elementary osmotic pump [15-17], push-pull
osmotic pump [18-20], sandwiched osmotic pump [21, 22] and porosity osmotic pump
[23-25].

2.1.3 Delayed release
Delayed release could be achieved by enteric coating with pH sensitive coating polymers.
Those polymers wouldn’t dissolve in the gastric fluid with low pH value (pH=1.2), so the
drug couldn’t come out. However, after the enteric coated dosage forms entering the
intestine with a high pH value (pH=6.8), the coating film will dissolve immediately and
drug will be completely released in a very short time. Enteric coating could provide drug
protection from acid and enzymes in stomach with low pH value. Also it could eliminate
the irritation or harmful effects of some drugs to stomach. In addition, enteric coating
could achieve drug target absorption in the intestinal.
Enteric coating materials include nature polymers such as shellac [26] and synthetic
polymers such as poly(styrene-alt-maleic anhydride)-ethanol [27], hydroxypropyl
methylcellulose acetate succinate [28], HPMCP and Eudragit® L [29, 30].

Figure 2.5 Molecular structure of Eudragit® L 100-55
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2.2 Drug controlled release: mechanisms and principles
Based on the drug release mechanism, drug controlled release systems are classified into
diffusion, erosion and osmotic controlled systems.

2.2.1 Diffusion controlled release
For diffusion controlled release systems, drug molecules release out of the dosage forms
through a polymer membrane or matrix, which is driven by diffusion (a process of
moving molecules from a solution of high concentration to low concentration). Diffusion
controlled release systems could be classified into reservoir system, also called “coreshell system” and matrix system or called “monolithic system”.
For the reservoir system (Figure 2.6), the drug is located in the center of the dosage
forms, where barrier materials (often polymers) form an outlayer membrane surrounding
this drug depot to control drug release rate [31].

Drug core
Polymer barrier membrane
Figure 2.6 Schematic representation of diffusion controlled drug delivery
system (reservoir system)
Matrix system (Figure 2.7) is also called “monolithic system” or “one-block system”. In
this drug delivery system, drug is homogeneously distributed throughout a polymer
matrix. Drug release rate is controlled by diffusion from the polymer and decreases as a
function of time and distance.
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Polymer matrix
Drug
Figure 2.7 Schematic representation of diffusion controlled drug delivery
system (matrix system)

2.2.2 Erosion/Degradation controlled drug release
For this drug controlled release system, the drug can be loaded into the system by two
ways. First one is that the drug can be physically trapped in the polymer matrix. By doing
this, the drug could be released with the erosion of the polymer matrix. Or the drug could
be chemically adhered to a backbone of a polymer, where the drug could be released
when the chemical bond holding the polymer and the drug is broken down.
According to the erosion location, erosion/ degradation controlled drug release system
could be further classified as surface erosion and bulk erosion.
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Figure 2.8 Schematic representation of erosion controlled drug delivery
system (bulk erosion) [32]
If water penetrated into the polymer matrix more rapidly than hydrolysis could occur,
chain scission would be initiated everywhere in the matrix, leading to a bulk erosion
(Figure 2.8). On the other hand, for the hydrophobic polymers, it is difficult for water to
enter the whole matrix and the erosion would start from the surface (Figure 2.9).
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Figure 2.9 Schematic representation of erosion controlled drug delivery
system (surface erosion) [32]

2.2.3 Osmotic controlled drug delivery system (ODDS)
As one of the fundamental phenomena in biology, osmosis is the movement of a solvent
across a semipermeable membrane toward a higher concentration of solute. Osmotic flow
can be generated when two solutions with different solute concentrations are separated by
a semipermeable membrane, restricting the solute but allowing passage of the solvent
molecules (Figure 2.10 A.1). The solvent flow across the semipermeable membrane is
directed to compensate differences in solute concentrations, leading to a hydrostatic
pressure difference across the semipermeable membrane (Figure 2.10 A.2).

Figure 2.10 Principle of osmotic flow [33]
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Osmotic drug delivery system (ODDS) consists of an osmotic core containing the drug
and osmotic agent(s) surrounded by a semipermeable membrane with delivery orifice(s),
which delivers the agent by an osmotic process at a controlled rate.
The first idea of ODDS came from Rose and Nelson, they proposed an osmotic dispenser
[34] that is capable of delivering a drug solution with a relatively constant rate. Later in
1970s, Takero Higuchi and Felix Theeuwes improved the osmotic dispenser [35, 36] and
developed an elementary osmotic pump tablet [15], cooperated with the Alza
Corporation, which is the first practical example of an osmotic pump based drug release
system [37]. US8029822 B2 [38] used cellulose esters as the coating materials in the
embodiment to achieve rupturing controlled release from the preformed passageways.
US8703193 B2 [39] provided a controlled porous ODDS of high permeable drugs
containing a porous semipermeable membrane which was formed by cellulose acetate and
the added pore-forming agents. By doing so gastro-intestinal (GI) irritation could be
minimized or eliminated.
As the only drug delivery system that could release a drug with a constant rate, ODDS
has gained tremendous attention as a promising drug carrier owing to its distinct
characteristics, such as zero order drug release kinetics, independent drug release of pH
and other physiological parameters.

2.3 Historical development of pharmaceutical coating
As an old pharmaceutical process, coating of solid dosage forms has seen significant
advances in both development of coating materials and the equipment design during the
past 50 years [40]. Pharmaceutical coating has undergone transition from sugar coating in
conventional pans to film coating based on organic solvent and water in perforated
coating pans or in modern fluidized beds with high drying efficiencies. At present,
aqueous film coating has replaced organic film coating in the dominate position of
pharmaceutical coating due to the toxicity and environmental related concerns caused by
the organic solvent. On the other hand, it still possesses many limitations such as much
longer processing time and much higher energy consumption than solvent coating, and
inappropriate for the moisture sensitive drugs. So recently many solventless or dry
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coatings have been developed and reported to avoid using organic solvent and water.
Among those reported solventless coatings, powder coating has the benefits of both
solvent coating and aqueous coating, being environmentally friendly, energy efficient and
short processing time, while equally effective in modifying drug release profiles.
Consequently, powder coating is pointing to the future, as the next breakthrough in
pharmaceutical coating.

Sugar
coating

Solvent
coating

Aqueous
coating

Powder
coating

Figure 2.11 Historical development of pharmaceutical coating

2.3.1 Sugar coating
Beginning in the 19th century, sugar coating is mainly used to increase the palatability of
bitter medicaments [41]. In total, there are four steps in a sugar coating procedure,
including sealing, subcoating, syruping and polishing. Although sugar coating could
produce a very elegant product, its limitations are obvious. With a complicated coating
process, the processing time of sugar coating could last up to five days, making it difficult
for the application. And also sugar coating requires the operators with a high level of
expertise. In addition, it is difficult to standardize the coating procedure. And the
possibility of bacterial and mold growth in sugar solutions, sealing the tablets before
coating and a lack of automation in the process led to the search for alternative coating
methods [42].
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2.3.2 Solvent coating
The development of polymer industry, particularly novel polymer synthesis and
preparation, led to a big progress in pharmaceutical coating. A wide variety of coating
materials, for example, the cellulose derivatives, made it possible for the appearance of
film coating. Solvent film coating firstly appeared in 1930 and was commercially
available in 1954 by Abbott Laboratories. They used a fluidized bed coating column
based on the Wurster principle [43]. Later a rotatory pan coating system was developed
for the tablet coating with organic solvent.

Organic solvent

Polymers
pigments
excipients

Dissolved

Solution

Spraying

Evaporating

Figure 2.12 Solvent coating process
Coating polymers and other excipients were mixed and dissolved into an organic solvent
to form a coating solution, which is then sprayed onto the surface of the solid dosage
forms. The coating film was formed after the evaporation of organic solvent.
Promoting by the design and development of more efficient and precise coating apparatus
and also by the introduction of many polymers, film coating developed rapidly and
significantly changed pharmaceutical coating. It not only offered an increased process
control, and better reproducibility, but also can be applied on a variety of dosage forms
including larger ones like tablets and smaller ones like pellets and beads.
However, film coating based on solvent suffer from many limitations. First of all, organic
solvents are toxic and flammable, causing toxicity and environmental related issues. Also
the concentration of coating solution cannot be too high due to the viscosity limit,
otherwise it may block the spray nozzle. As a result, it takes a very long processing time
to achieve a thick coating film. In addition, the whole process needs a large amount of
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organic solvents and the after-treatment and recovery of the organic solvent are very
expensive, which could significantly increase the overall cost.

2.3.3 Aqueous coating
Those disadvantages of organic solvent coating make the film coating based on aqueous
more acceptable for the pharmaceutical industry and it remains the domination position in
the present industry. Aqueous coating uses the existing coating pans, which is the same as
solvent coating. The only difference is that water is used to dissolve or disperse the
coating materials. For water soluble coating polymers, the coating process and film
formation mechanism are the same as solvent coating. For water insoluble coating
materials, coating polymers as well as additives and excipients are first milled into very
fine particles and then a mixture of those fine particles are dispersed into water to form a
coating dispersion. An atomizing nozzle was used to spray this coating dispersion onto
the surface of the solid dosage forms, followed by a water evaporation process.
Simultaneously, coating particles coalesced together and fused into a coating film with
the heat provided by hot air.

Water

Polymers
pigments
excipient
Dispersed

Dispersion

Spraying

Curing

Figure 2.13 Aqueous coating process for water-insoluble coating polymers
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Figure 2.14 Schematic presentation of the film formation mechanism of
(a) aqueous coating (b) and solvent coating
In the aqueous coating process (water insoluble coating materials), coating polymer is
present as a number of discrete particles in a wet state. Those wet particles would have to
coalesce, deform and fuse together to form a coating film. Capillary force between
particles and substrate caused by the water evaporating could significantly promote the
coalescence of particles. Hot air is necessary in the coating process to carry out the
moisture and to provide heat for the deformation and fusion of coating particles.
Although aqueous coating now remains as the preferred coating method compared to
solvent coating, it still possesses a number of disadvantages. First of all, it takes a much
longer time for water to be evaporated compared with organic solvent, leading to a much
longer processing time. Also water evaporation needs much more energy consumption. In
addition, hot air handling and equipment cleaning would further increase the overall cost
of the process. Last but not the least, aqueous coating is not suitable for the moisture
sensitive drugs.
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2.4 Solventless coating
In order to overcome those limitations caused by the solvent or water, many efforts have
been made to develop solventless coating technologies. Those reported solventless
coating technologies include compression coating, photocuring coating, supercritical fluid
coating, hot-melt coating, dry powder coating.

2.4.1 Compression coating
Compression coating, also named press coating, is mainly applied for the coating of
tablets [44]. It is comprised of a drug core and an outer shell. The drug core is enclosed in
the outer shell and thus different drug release patterns can be modulated by the selection
of inner drug cores and outer layer materials. Also, the outer shell has great influence on
the mechanical strength and stability of the coated tablets.
In the compression coating process, the mixture of core formulation is firstly compressed
into an inner layer core and then coating material(s) is compressed around the core to
form an outer layer film. The main problem for the compression coating is that the
coating thickness is not uniform owing to the reproducibility issues of placement of the
core in the center [42, 45], which is called a decentralized core. In order to overcome this
limitation, Ozeki et al. developed a one-step dry- coated (OSDRC system) [46] tablet
manufacturing method. The OSDRC-system does not require preparation of core tablets
beforehand, allowing dry-coated tablets be made in a single process.
However, its use has largely been restricted to specific applications due to the problem of
large coating thickness, which could limit the drug loading.

2.4.2 Photocuring coating
Photocuring coating involves a free-radical polymerization reaction of photocurable
materials to form a crosslinked network [47-49]. There are three major components in
photocuring systems including a UV/visible light source, specially functionalized liquid
prepolymers or monomers, and an initiator [42].
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Figure 2.15 Schematic process of photocuring coating
This coating process can be performed rapidly at room temperature or below, which is
suitable for temperature sensitive drugs. It is the only reported chemical approach so for
to form the coating film. Both tablets coating and pellets coating can be achieved with
this technique. But this coating method is not suitable for the photosensitive drugs. Also
its use is limited by the specific photocurable materials and coating equipment.
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2.4.3 Supercritical fluid coating

Figure 2.16 Supercritical state
When both the temperature and pressure of a substance are greater than its critical
temperature (TC) and critical pressure (PC), this state is defined as the supercritical state.
The thermal and physical properties of supercritical fluids fall in between pure liquids and
gases. In a supercritical state, many properties of the substance including the density,
viscosity, diffusivity, and other physical properties, such as solvent strength and dielectric
constant, can be varied in a range from gas-like to liquid-like [42].
In the supercritical fluid coating process, the coating materials are solubilized in
supercritical fluid (such as carbon dioxide) in a vessel with high pressure. The drugs
(active agents) are dispersed in the supercritical solution. When the suspension is rapidly
expended, the solvent power of carbon dioxide is reduced, leading to a precipitation of
coating materials onto the surface of the drug particles dispersed in the medium. This is
called rapid expansion of supercritical solutions (RESS) [50], which is the most common
supercritical fluid process in pharmaceutical applications. For this method, the coating
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materials must be soluble in supercritical fluid such as carbon dioxide and also the drug
must be insoluble in the supercritical fluid.
Supercritical fluid coating can be used to coat small particles uniformly by encapsulating
each core with coating materials under a supercritical condition. However, the application
of this coating method is limited due to the poor solubility of most coating materials in
supercritical fluid and also the requirement of the core to be insoluble.

2.4.4 Hot-melt coating
For the hot-melt coating, coating materials are applied in their molten state. The coating
process includes several steps. Firstly, the coating equipment is warmed, and then
substrate is preheated. Coating materials are melted and sprayed onto the surface of the
substrate, followed by the cooling step to allow the film formation.

Figure 2.17 Schematic process of hot-melt coating
Lipids were reported as excellent coating agents for hot-melt coating due to their low
melting point. A number of works have been reported so far [51, 52]. Those works
include coating waxes [53], vegetable oils and their derivatives [54], polyoxylglycerides
[55] and fatty acids [56] for the purpose of sustained release, taste masking, ect.
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Figure 2.18 Schematic process of the hot-melt coated particles: the
deposition of lipid droplets (white) at the surface of the substrate (blue) [51]
However, hot melt coating method is only suitable for the drug with stable properties at
or below the congealing point of the coating materials.

2.4.5 Powder coating
For the powder coating, coating polymers and other excipients are first milled into fine
particles and then a mixture of those fine particles are sprayed onto the surface of the
solid dosage forms, followed by an oven curing step to allow film formation. Basically
there are two steps in dry powder coating process: coating powder adhesion to the surface
of solid dosage forms and film formation. The coating powder adhesion is the key for the
whole dry powder coating method because a better powder adhesion could lead to a high
coating efficiency. Kablitz et al. [57] concluded that the film formation for dry powder
coating was resulted from viscous flow and particles deformation, which could be
improved by combination of plasticizers and heat.
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Many reported powder coating technologies [28, 57-60] used liquid plasticizers to
facilitate coating powder adhesion and film formation for the reason that those liquid
plasticizers could not only reduce the glass transition temperature of coating polymers, so
as to decrease the curing temperature to protect drugs, but also provide the capillary force
between the coating particles and the dosage forms, significantly promoting coating
powder adhesion. The coating process can be seen as Figure 2.19.

Figure 2.19 Schematic process of plasticizer dry powder coating
Water could also be used as liquid plasticizer in the dry powder coating process. Obara et
al. [28] reported that the quality of the coating film could be significantly improved by
spraying a small amount of water or hydroxypropyl methylcellulose (HPMC) solution to
the HPMCAS-coated spheres. Other reports [58] also found that film formation could be
obviously accelerated by moisture. Also the smoothness and integrity of coating film
could be optimized by spraying different amount of moisture. This is similar to the
aqueous coating process in which water plays a key role of coalescing agent, facilitating
the coalescence of coating particles and the fusion of polymer chains.
While for those dry powder coating technologies, surplus liquid plasticizers sprayed onto
the surface of the solid dosage forms can possibly lead to very soft or sticky film, so a
careful balance needs to be reached between the plasticizer concentration for a sufficient
coat thickness and that for a flexible and dry coat. And also the coating powder feeding
cannot be well controlled and it is difficult to get a smooth and thickness uniform coating
film. And a coating process that involves water still isn’t suitable for the moisture
sensitive drugs.
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Cerea et al. [61] developed a totally dry powder coating method without using any
solvent or water in the coating process. As shown in Figure 2.20, the coating apparatus
includes a rotating disk, an infrared lamp, a single screw powder feeder, a temperature
probe and a glass cover. Firstly, the solid dosage forms were loaded into the system and
preheated by the infrared lamp for a certain time period. Then the coating powders were
fed into the surface of the dosage forms by using the motorized single screw feeder to
achieve the coating powder adhesion. The infrared lamp positioned on the top of the
spheronizer was the only heating source which could be used to promote the coating
powder adhesion as well as to provide heat for the curing and film formation.

Figure 2.20 Schematic representation of the laboratory scale spheronizer
used for the powder coating process: (1) rotating disk; (2) infrared lamp; (3)
powder feeder; (4) temperature probe; (5) coating cores; (6) glass cover
In this coating process, Eudragit® EPO (a copolymer based on dimethylaminoethyl
methacrylate and methacrylates) was used as the coating material due to its low glass
transition temperature.
This technology provided a totally dry coating method without using any solvent or water
in the coating process, but similar with hot-melt coating, it is only suitable for the drugs
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that are not temperature sensitive and coating materials with very low glass transition
temperature.

2.5 Electrostatic powder coating
The concept of electrostatic powder coating came out in the 1950s in USA, and now it is
widely used in the metal and wood finishing industries.
In the electrostatic powder coating process (Figure 2.21), dry powders are charged by an
electrostatic spray gun and then move and adhere to the grounded substrate surface
without using any solvent or water. And then the grounded substrate with deposited
coating powder is put in an oven and cured for a certain period of time under high
temperature to allow film formation.

Coating powder spraying
Electrostatic spray gun

Oven curing

High voltage generator

Coating particles
Negatively charged Coating particles

Grounded substrate

Figure 2.21 Schematic representation of electrostatic powder coating
process
Three steps are involved in the coating powder deposition process [62]. Firstly, charged
particles are sprayed onto the surface of the grounded substrate with combination of
mechanical forces and electrostatic attractions. And then particles accumulate on the
substrate before the repulsion force of the deposited particles against the coming particles
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increase and exceed the electrostatic attraction of the grounded substrate to the coming
particles. Finally, once the said repulsion force becomes equivalent to the said attraction,
particles cannot deposit any more [63].
In order to successfully carry out the electrostatic spraying process, a powder charging
unit is needed and the particles of coating material should be able to be charged. Also
there should be a grounded conductivity substrate. According to the charging mechanism,
basically there are two types of electrostatic spray units, corona charging and tribo
charging. Corona charging process involves the electrical breakdown and ionization of air
by imposing a high voltage on a sharp pointed needle-like electrode. As a result, there
will be an electrical field between the gun and substrate which can promote the coating
powder adhesion. When powder particles passing through the gun, they will pick up those
negative ions on their way to the substrate. While tribo charging is related with the
principle of frictional charging associated with the dielectric properties of solid materials.
Consequently, there are no free ions and electrical field between electrostatic gun and the
substrate.
For the coating process by tribo charging gun, the movement of coating particles between
the gun and the substrate is mainly governed by the mechanical force, which is produced
by the air blowing the powder towards the substrate from the tribo gun. While for the
corona charging gun, besides the mechanical force, electrical force will enhance the
movement of coating particles from the gun towards the substrate owing to the presence
of electrical field between the charging gun and the grounded substrate.
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Figure 2.22 Effect of electrical conductivity on powder deposition
in electrostatic powder coating process
In the electrostatic powder coating process, the solid dosage forms must possess certain
conductive properties or be modified to be conductive owing to the significant influence
to the coating powder deposition on solid dosage forms. As shown in Figure 2.22, for
more conductive dosage forms, the electrical charge of the deposited particles will
dissipate quickly due to the grounding, so that additional layers of coating powder can be
attracted and deposited onto the dosage form surface. For the less conductive dosage
forms, electrical charge of the deposited particles will not dissipate and tends to build up
on the surface of the dosage forms, which will impede further deposition of coating
powder. 1×109 Ωm is said to be the maximum electrical resistivity to allow the above
process to happen [57]. Unfortunately, for most of the pharmaceutical solid dosage forms,
the electrical resistivity is much higher than 1×109 Ωm because they contain the
excipients with high electrical resistivity.
There are several methods to decrease the electrical resistivity of the solid dosage forms.
First, the solid dosage forms can be wetted with water, because the layers of moisture
increase the electrical conductivity. In the coating process, this can be performed by
exposing solid dosage forms to high humidity for a very short time before coating. The
electrical conductivity of solid dosage forms can be increased by adding some certain
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excipients such as dicalcium phosphate and ionic salts (1-3%) due to their conductive
properties [42]. Surface modification with polar groups (e.g., quaternary ammonium
compounds) could also increase the electrical conductivity of the solid dosage forms.
These compounds can be dissolved in volatile solvent and then applied to the surface
where it deposits as a thin film after solvent evaporation, which can absorb moisture from
the atmosphere and forms an electrically conductive layer [64].

2.5.1 Film formation mechanism
The film formation mechanism for organic and aqueous-based systems is fundamentally
different [58]. For the conventional solvent coating, coating materials, mixed with other
excipients including additives and pigments, are molecularly dissolved in the appropriate
organic solvent to form a coating solution, which is then sprayed onto the surface of the
solid dosage forms. Film formation is achieved by a loss of solvent and contact of
individual polymer molecules. In the aqueous coating process, a dispersion of coating
materials and other excipients is sprayed onto the surface of the solid dosage forms. After
the evaporation of water, particles of coating materials have to coalesce into a
homogeneous film. Film formation of polymer particles in the dry state results from
deformation and viscous flow [57, 65, 66]. Solid or liquid plasticizers always have to be
added to decrease the glass transition temperature of the coating polymers. For aqueous
coating, capillary force also plays a significant role in coating particle coalescence and
film formation [67].
Similar to aqueous coating, film formation of dry powder coating also relies on the
deformation and viscous flow of coating polymers [30, 57]. As being reported from
previous studies, softening, melting and curing are the principal stages in the film
formation during dry powder coating [68-70]. In those reported dry powder coating
process, the substrates are often preheated above the glass transition temperature of the
coating polymers so that the polymer powders can easily soften and adhere to the
substrate. It was reported [69] that melt surface tension plays a decisive role in the film
formation in dry powder coatings process. The surface tension could be controlled and
adjusted by modifying coating formulations, for example, add some leveling additives to
the formulations.
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Liquid plasticizer is commonly added before spraying coating powders in dry powder
coating processes to reduce the glass transition temperature (Tg) of coating polymer and
enhance coating powder adhesion [28, 57, 58, 60, 61]. Further studies [67, 71] suggested
that those liquid plasticizers could also promote capillary forces between the coating
particles, leading to enhanced coating powder adhesion and increased coating efficiency.
Obara [28] suggested that the use of a second liquid component in the dry coating process
could reduce the contact angle of the liquid on the polymer and promote capillary forces
between the polymer particles and the dosage forms.
The film formation mechanism in electrostatic powder coating process is similar with
other dry coating technologies. However, by applying electrostatic spraying process,
coating powder adhesion will be significantly promoted by the combination use of
electrical and mechanical forces, hence coating efficiency would be increased
dramatically. Also coating powder adhesion and film formation could be further
enhanced by increasing the conductivity of solid dosage forms and coating powders. It
has been reported that surface tension would promote coating powders’ flow and
coalescence while viscosity would retard it [72]. Consequently, a better surface coverage
and uniform coating film could be formed by adding some flow modifiers (e.g., polyvinyl
butyral and cellulose acetate butyrate) in the coating formulation to reduce the viscosity
of the melted polymer [64].
Particle size of coating powders will also play a critical role to the film formation in the
electrostatic powder coating process. Misev [62] carried out a study on the relationship
between charging efficiency and particle size and obtained the following equation:
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1  2 r
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 r  1 
 m max 0 d p 
In the equation, E is the electric field to which the particles are subjected, ε0 is the
permittivity of free space while εr is the relative permittivity of powder particles, ρ0 is the
density of the particle and dp is the particle diameter. According to this equation, a higher
charging efficiency could be achieved by using a smaller coating particle. Also a smaller
particle has a larger specific surface area, which could make the wetting much easier by
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the liquid and softening and melting by heat, so as to enhance the coating powder
adhesion and film formation. Basically fine powder with a diameter less than 100 µm is
preferable for dry powder coating. While more uniform and thickness controlled coating
film could be achieved by applying ultrafine powders (less than 30 µm). However, those
ultrafine powders are Group C powder, which is cohesive with poor flowability. In order
to prevent the agglomeration and effectively improve the flowability of ultrafine powders,
flow agent with nano-size could be added into the coating formulation [73-75].

2.5.2 Processing apparatus
Phoqus Ltd., which has been, in recent years, devoting great efforts to design both
apparatus and formulations for electrostatic powder coating. Their approach involves
design of a dry powder coating apparatus to increase coating efficiency by increasing
electrostatic attractions, to overcome the difficulty of charging poorly electrically
conductive pharmaceutical solid dosages and to increase the mobility of relatively small
sized particles with irregular shapes.
One of the apparatus (Figure 2.23) designed by Phoqus Ltd. includes two occluding
rotary drums, two electrostatic spray guns, two infrared ray-based fusion stations: infrared
ray heater, two cooling stations, a tablet feeding chute and a tablet collection chute. This
apparatus can make every tablet effectively grounded and can direct and restrict the
charged particles onto the surface of tablet core without spraying onto the surrounding, so
that the coating efficiency can be significantly improved. And also, the two sides of a
tablet can be coated with different formulation or different color. However, not all the
charged particles are deposited onto the tablet core because the drum will also receive
some, leading to a waste of coating powder. Also cleaning the apparatus is time
consuming, which could increase the overall cost.
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Figure 2.23 Schematic of an electrostatic coating apparatus for solid
dosage forms. (10) tablet feeding chute; (12, 12’) rotary drum; (16, 16’)
electrostatic spraying gun; (18, 18’) tray to hold particles; (20, 20’) infrared
ray heater; (22) tablet collection [76-79]
US 20120012055 [80] reported an electrostatic coating apparatus (Figure 2.24) for
pharmaceutical solid dosage forms. The apparatus contains a plurality of platens, each
platen being arranged to hold a plurality of tablets. And each platen comprises an
electrically conducting platen base and an electrically conducting platen shield located on
the platen base. Consequently, the apparatus can control the electrostatic application of
the powder more effectively by establishing an electrical difference between the platen
base and the platen shield during the coating process.
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Figure 2.24 Perspective view of a solid dosage form and a platen shield [80]
US 20060099350 [81] designed a pattern on a solid dosage form, in which powder
material can be applied in the pattern to the solid dosage forms. There is a mask with an
aperture between a source of the powder material and the solid dosage form so that the
powder materials can be applied to the dosage forms through the mask.
US 6806017 [82] introduced another electrostatic coating apparatus based on a
photoconductive drum. The charged powder material is firstly applied to the
photoconductive drum and transferred to an intermediate belt and then to a solid dosage
forms. By doing this, it can provide an arrangement in which the location of the
deposition of the powder material can be closely controlled, enabling coating powder
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deposition on a solid dosage form in a precise pattern. Also it can facilitate the powder
deposition on a three dimensional surface.
Compared to the conventional coating process, those apparatuses designed by Phoqus
Ltd. do have many advantages. First of all, those apparatuses can handle the dosage forms
individually and gently so that dosage forms can be less robust. The coating process is
continuous and can be performed at ambient conditions. And coating film formed by this
technology is quite uniform with a significantly increased coating efficiency and well
controlled coating film thickness. Also, tablets could be coated with different color or
formulation. Unfortunately, those advantages have been compromised by the complicated
coating process and added cost of the coating apparatus, offsetting any cost benefit to
switching from liquid coating to powder coating, since their technology requires the use
of completely different coating equipment. In addition, adoption of new equipment not
only incurs extra capital costs, but also introduces additional complications in operation.
The pharmaceutical companies would prefer to accept a powder coating process operated
in a simpler coating apparatus that can be easily adapted from their present apparatus,
such as pan coaters, for liquid coating.
Zhu [83, 84] designed and developed a novel electrostatic powder coating technology
with an apparatus similar to the traditional pan coating system (Figure 2.25).
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Figure 2.25 A pan coater apparatus for powder coating solid dosage forms
According to this invention, a pan coater representation is shown generally at 30 in Fig. 6.
This coating apparatus (30) includes a rotary coater chamber (32), which is electrically
grounded and holds the solid dosage forms (28), an atomizer (34) for spraying the
plasticizer, an electrostatic spray gun (36) for spraying the film forming polymer powder,
and a heating source (38) for heating the solid dosage contents in chamber (32).
This invention provides a method to coat solid dosage forms without using any solvent or
water. The coating process comprises several steps (Figure 2.26). Firstly, solid dosage
forms are loaded into the rotatable, electrically grounded coating pan and preheated for a
certain period of time. And then a spraying cycle including a film forming polymer
powder spraying and liquid plasticizer spraying is performed to allow coating powder
deposition. The last step is curing. After coating powder deposition, solid dosage forms
will remain in the coating pan for a certain period of time under a certain temperature to
allow the film formation.
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Figure 2.26 Schematic of electrostatic powder coating process
This invention possesses many advantages. First of all, the processing time is much
shorter than the traditional liquid coating due to the absence of solvent or water in the
process. As a result, the coating efficiency is significantly improved since there is no need
to evaporate solvent or water in the process. Furthermore, the coating thickness or coating
level can be regulated in a wide range through changing the charging voltage or
plasticizer feed without causing any other issues such as sticky film.

2.5.3 Coating formulations
For electrostatic powder coating technology, the development of coating formulation
should take the charging process into consideration to form a desirable coating film. In
other words, coating powder in the formulation should be able to be charged by the
electrostatic spray gun. Also, similar to other coating processes, coating powder
deposition and film formation are critical for the formulation design. For the ultrafine
powder, additives may be necessary to prevent coating powder agglomeration.
Besides the great efforts in apparatus designing, Phoqus also devoted itself in coating
formulation designing and development, aiming to make the coating powder more easily
charged or more suitable for the electrostatic powder coating process so as to improve the
coating quality and efficiency [85, 86]. In their coating process, of Eudragit® RS was used
as the film formation material and the active ingredients could be in the tablet core or in
the coating or both depending on their nature and use. When the active ingredients were
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applied in the coating, the amount of them could be accurately controlled, leading to
improved dose reproducibility.
US 6372246 [87] developed a coating formulation containing micronized polyethylene
glycol (PEG) for the electrostatic powder coating process. PEG material, with a
molecular weight in the range of 1,000 to 20,000 and a melting point in the range of 5063°C, was micronized by jetmill, to a particle size of 1-100μm, preferably 5-10μm and
then was triboelectrically charged and deposited onto the dosage forms. This invention
related to a technology of reversing negative charge of medicaments so that they can be
electrostatically deposited on a negatively charged substrate. The coating film formed by
PEG will not delay the dissolution of drug products. Also this coating formulation and
process can provide a pharmaceutically elegant cosmetic coating film.
Qiao [88] developed a coating formulation containing of Eudragit® RS and RL to achieve
drug sustained release. In this study, ibuprofen was used as the API (active
pharmaceutical ingredient), triethyl citrate (TEC) was used as the plasticizer. The coating
formulation also contained talc powder as anti-tack agent. Before coating, particle size of
Eudragit® RS and RL as well as talc were reduced by using a grinder mill and after
which, the average particle size was 18.4 μm, 16.5 μm, and 28.9 μm, respectively. The
tablets were loaded into the coating pan and preheated first. And then coating powder
were sprayed onto the surface of the tablets with liquid plasticizer, followed by a curing
step to allow the film formation. According to this study, the drug release rate from
electrostatic powder coated tablets could be adjusted by changing the coating level
(weight gain) or of Eudragit® RS/RL ratio. Similarly in equipment and procedure,
Eudragit® L 100-55 [30] was used as the coating material to form an enteric coating film.

2.6 Summary
Pharmaceutical dry powder coating technology has developed noticeably over the last
decade. Particularly electrostatic powder coating, which has gained tremendous attention
due to its phenomenal advantages such as high coating efficiency, uniform coating film
and low overall cost, has become the most promising pharmaceutical dry coating
technology. Despite the difficulty related with the weak conductivity of solid dosage
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forms, the benefits of electrostatic dry powder coating have been encouraging researchers
to devote efforts to make breakthrough in such area. Technologies and formulations
developed by Phoqus Ltd. are quite impressive, but the additional cost of complicated
equipment and IR curing step has limited its use in commercial applications. The novel
electrostatic powder coating technology developed by Zhu’s group has been able to
differentiate itself from other counterparts owing to its simpler coating apparatus that can
be easily adapted from the present apparatus such as pan coater systems for liquid
coating.
However, more work still need to be carried out to fully illustrate this novel electrostatic
powder coating technology. Firstly, this technology needs to be expanded to those coating
materials with high glass transition temperature (Tg), for example, ethylcellulose and
cellulose acetate, which is quite difficult to be coated by powder coating. In addition,
coating of small solid dosage forms, such as pellets, still relies on the organic solvent
coating or aqueous coating using a fluidized bed with large amount of fluidizing hot air,
causing extremely high energy consumption. Powder coating of small pellets in a simpler
apparatus could bring lots of benefits, overcoming those limitations related to the organic
solvent and water, and significantly reducing the overall coast by avoiding use of large
amount of fluidizing hot air. Particularly, as the most promising oral drug delivery
system, osmotic drug delivery system (ODDS) can only be coated with organic solvent
coating due to the high glass transition temperature (Tg) of the coating polymers. Many
previous work have been done on powder coating, but none of them focusing on the
ODDS. It would be a big breakthrough if the ODDS tablets could be successfully coated
with powder coating. Last but not least, the electrostatic powder coating process needs to
be characterized more in-depth in order to illustrate coating powder adhesion and film
formation, and their influence factors.
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3

Tablet Coating – Sustained Drug Release

In this chapter, tablets were successfully coated with ultrafine ethylcellulose powders by
using a novel electrostatic dry powder coating technology and sustained drug release was
successfully achieved. The angle of repose (AOR) of the ultrafine powders of
ethylcellulose was significantly reduced by adding nano sized colloidal silicon dioxide,
indicating a significant improvement of flowability. Variations in charging voltage of the
electrostatic gun had a significant influence on the coating powder adhesion and coating
efficiency. Lactose and triethyl citrate (TEC) were used as the solid and liquid plasticizers
to reduce the glass transition temperature (Tg) of ethylcellulose. The presence of liquid
plasticizer could also increase the electrical conductivity of drug tablets so as to promote
the coating powder adhesion. Other factors that affect the film formation include curing
time and curing temperature. The permeability of the EC coating film was adjusted with
the addition of pore forming agent (PVA-g-PEG) in the coating formulation, leading to a
more controlled drug release rate.

3.1 Introduction
In pharmaceutical industry, solid dosage forms are commonly coated with polymers to
achieve drug sustained release [1, 2], to alleviate the side effects caused by the high drug
plasma concentration due to the immediate release. Several polymers are commercially
available for sustained release coating like acrylic acid derivatives, poly (vinyl acetate)
and cellulose derivatives, such as ethylcellulose. Among those, ethylcellulose is
particularly appropriate for the sustained release coating due to its excellent robust
properties such as nontoxic, nonallergenic and nonirritant [3, 4]. It can be applied either
from organic solvent solutions or from aqueous dispersions. For solvent coating,
ethylcellulose as well as other excipients are dissolved into an organic solvent to form a
coating solution and then the solution is sprayed onto the surface of the solid dosage
forms to form the coating film by evaporating the solvent. This method can obtain a very
smooth and uniform coating film. However, the presence of the organic solvent could
cause safety and environmental issues. For aqueous coating, ethylcellulose particles,
pigments and additives are firstly milled into fine powders and mixed together and then
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they are dispersed into water to form a coating suspension, which is sprayed onto the
surface of solid dosage forms to form a coating film by evaporating the water. Aqueous
coating remains the preferred approach to obtain the coating film with ethylcellulose
because it can eliminate those environmental related problems caused by the organic
solvent. However, it still possesses many limitations such as higher energy consumption
and longer processing time with hot air handling and equipment cleaning. Also aqueous
coating is not suitable for the moisture sensitive drugs.
In order to overcome these limitations, several earlier attempts of dry coating methods
have been reported, trying to coat solid dosage forms with ethylcellulose (EC). Lin [5]
used a direct compression method to coat tablets with micronized EC to form the outer
layer of the tablet core. In this coating process, the tablet core was precisely positioned in
the center of the die, encapsulated by the EC powder and then they were compressed to
form the out layer film. This is a total dry coating method without using any solvent or
water and it could form a very thick coating film with very high coating efficiency.
However, the thickness of the film was reported to be not uniform owing to the difficulty
of placing the core tablet in the center of the die.
Different from Lin’s work, Nantharat Pearnchob and Roland Bodmeier [6] developed a
dry powder coating technology to coat dosage forms with micronized ethylcellulose
particles, which was further optimized by Ildikó Terebesi and Roland Bodmeier [7]. In
their technology, the coating formulation contained two components, one was a powder
mixture (coating polymer plus talc) and the other was a mixture of liquid materials
(plasticizer plus binder solution). They were sprayed separately into a coating chamber of
a fluidized bed coater, followed by an oven-curing step under different conditions (6080◦C, 2-24 h). Although drug extended release was achieved by using this coating
technology, it was unable to form a uniform coating film and acceptable surface
morphology of the coated pellets. Also the oven curing temperature is too high (up to
80◦C) and the curing time is too long (up to 24 h), making it difficult for the industrial
application.
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Researchers of Particle Technology Research Centre (PTRC) in Western University
developed a novel electrostatic dry powder coating technology by combination of
plasticizer, electrostatic and heat to promote the coating powder adhesion and film
formation under a lower curing temperature with a shorter processing time. The
electrostatic coating method is adapted to create an electrical field between the
electrostatic gun and grounded solid dosage forms, directing the flow of coating powders
so as to enhance the coating powder adhesion on the solid dosage forms. Also the coating
film is more uniform due to a better distribution of deposited coating powders resulting
from the repulsive force among the charged particles.
The objectives of this chapter is to coat tablets with powdered ethylcelluose using this
electrostatic powder coating technology to achieve sustained drug release, and also to
characterize influences of plasticizers including liquid and solid ones on the film
formation in the electrostatic powder coating process.
The Figure 3.1gives an outline of this chapter.

Tablet core preparation

Mixing
Granulation
Compression

Coating formulation

Electrostatic powder coating

Ethylcellulose

Coating powder size reduction
Flowability improvement of micronized coating powder
Coating process

Dissolution test

Sustained drug release

Temperature
Curing time
Plasticizers
Charging voltage

Film formation

Figure 3.1 Schematic diagram of study on drug sustained release from
electrostatic powder coated tablets with EC powder
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3.2 Materials and methods
3.2.1 Materials
Ethylcellulose was provided by Colorcon, Inc. (US). Talc powder was purchased from
Mallinickrodt Baker Inc. (Canada). Triethyl citrate (TEC) was purchased from Caledon
Laboratories Ltd. (Ontario, Canada). Lactose was obtained from GlaxoSmithKline, Inc.
(Canada). Colloidal silicon dioxide (AEROSIL® 200 Pharma) was donated by Evonik
Degussa Corporation (Germany). Salbutamol sulfate was provided by Nanjing
Pharmaceutical Factory (Nanjing, China). Avicel® Microcrystalline cellulose PH-102 was
purchased from FMC Corporation (USA), plasdone K-29/32 was purchased from ISP
technologies, INC. and Magnesium Stearate was purchased from Alfa Aesar
(Massachusetts, USA). Placebo tablets were obtained from Pathon (Ontario, Canada).
PVA-g-PEG (PVA-PEG graft copolymer, Kollicoat® IR) was purchased from BASF
(Ludwigshafen, Germany).

3.2.2 Particle size reduction and analysis
A blade grind mill was used to reduce the particle size of coating materials, after which a
particle size analyzer (TSI Corporation, Model 3603, Shoreview, MN, USA) was used to
confirm the particle size of the coating particles. The average particle size in this study is
the size at 50 % of total weight fraction, which is given by Table 3.1.

Table 3.1 Average particle size of coating powders
Materials

Average particle size (µm)

Ethylcellulose

25.8

Lactose

29.1

PVA-g-PEG

21.8

Talc

28.6
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3.2.3 Angle of repose (AOR)
In order to characterize the flowability of coating powers before and after the size
reduction and also to investigate the influence of nano sized additives on the flowability
of ultrafine powders, measurement of the angle of repose was carried out using a PT-N
Hosokawa Powder Characteristic Tester, following the standardized testing procedures of
ASTM D6369-08 (ASTM Standard D6369-08, 1999). As the largest angle at which
powders could pile up, angle of repose is related to the powder’s cohesiveness and
internal friction. And it is widely used to characterize the flow properties of powders.
During each test, a powder sample was first loaded onto a screen mounted with a vibrator.
Under the screen there is a mounted funnel, which is used to let the powder sample fall
through down to a plate which was aligned with the funnel. Powder flow rate could be
controlled and adjusted by changing the vibration intensity. When the whole plate was
covered with the powders, angle of repose was obtained by measuring the largest angle
between the powder pile surface and the horizontal plane. In order to achieve an accurate
result, each test was repeated 3 times and the average was used.

3.2.4 Differential scanning calorimetry (DSC)
Glass transition temperature of pure coating materials (ethylcellulose) and the mixture of
coating materials with plasticizers (TEC and lactose) at different weight ratio were
investigated using the differential scanning calorimetry (DSC) analysis (Mettler Toledo,
DSC822, Mississauga, Canada). The weight for each sample was 10 mg and nitrogen was
used as the test atmosphere. The heating rate for the test was 2 ◦C /min over the
temperature range of 20 to 200 ◦C.

3.2.5 Tablets preparation
The component of the tablets core, which can be seen as the table 3. 2, includes drug
(salbutamol sulfate), sodium chloride, microcrystalline cellulose, PLASDONE® K-29/32
(PVP) and magnesium stearate. A mixture of drug, sodium chloride, microcrystalline
cellulose and PLASDONE® K-29/32 (PVP) were dry granulated using a high shear
granulator (Mechanomill MM-20N, OKADA SEIKO Co. Ltd, Iwate, Japan) and then
mixed with magnesium stearate, after which the powder mixture was compressed into
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convex tablets with 5 mm (diameter) concave punches using a single punch tablet
machine (Shanghai Tianxiang & Chentai Pharmaceutical Machinery Co. Ltd, Shanghai,
China). The weight for each tablet is 160±2 mg.
Table 3.2 Optimized formulation of the tablet core
Ingredient

% w/w

Salbutamol Sulfate

60%

Microcrystalline cellulose PH102

30%

PLASDONE® K-29/32 (PVP)

9%

Magnesium stearate

1%

3.2.6 Electrical resistivity tests
After loaded in the pan coater, the tablets were preheated for 10 minutes. Then liquid
plasticizer (TEC) was sprayed onto the surface of the tablets (0.50 g/min). At different
spraying time intervals (0, 1, 2 and 3 min), given number of tablets were taken out from
the pan coater and were tested to measure the electrical resistivity using an electrometer
(Keithley 610B, Keithley instruments, Inc., USA). These tests were operated three times
for the accuracy.
In order to measure the electrical resistivity of the tablets, we made a very simple
equipment, shown as Figure 3.2. Drill a hole (cylinder) on an organic glass plate with a
certain diameter and prepare two poles (Cu, cylinder with the same diameter) welded
with cables. Then fix one of the poles on one side of the hole, put the tablet (cylinder with
the same diameter) into the hole and then cover the tablet with the other pole (make it
contact with the tablet), connect those two poles with the electrometer used in our lab
(Keithley 610B, Keithley instruments, Inc., USA) to measure the electrical resistivity of
the tablet.
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Figure 3.2 Schematic diagram of electrical resistivity tester

3.2.7 Electrostatic powder coating process
The electrostatic powder coating process (Figure 3.3) was performed in a laboratory scale
pan coating system, which consists of a rotatory coating pan, a powder feeder, an
electrostatic spray gun (Nordson Corporation, USA) and liquid plasticizer spray system.
After being loaded into the coating pan, tablets (60 g placebo tablets and 20 g salbutamol
sulfate tablets) were preheated for 10 min at a certain temperature. Then a certain amount
of liquid plasticizer was sprayed onto the surface of the tablets, followed by the spray of
coating powders by the electrostatic spray gun immediately to achieve coating powder
adhesion. The process of loading liquid plasticizer and coating powder can be repeated
several times to obtain a higher coating level. After finishing the coating powder
adhesion, keep the temperature of the coating pan for a certain period of time to allow
deposited coating particles to coalesce and form a uniform coating film.
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Electrostatic spray gun

Coating particles
High voltage generator
Negatively charged Coating particles
Coating powder
deposition

Liquid plasticizer spraying

Curing

Figure 3.3 Schematic of the electrostatic powder coating process
Table 3.3 gives the formulations of the coating powder, which contains ethylcellulose,
talc powder, nano silica and pigment. The coating level (%) was calculated from the
weight gain of coated tablets divided by the weight of uncoated tablets. Placebo tablets
were used to maintain the volume of the substrates so that the drug tablets could be
conserved.
Table 3.3 Formulation of the tablet coating with EC
Ingredient (% w/w)
Formulation

Ethylcellulose

Lactose

PVA-g-PEG

Talc

SiO2, Pigment

A

75%

5%

0%

18%

1%, 1%

B

70%

5%

C

65%

10%

D

60%

15%

3.2.7.1

Optimization of coating process parameters

In the electrostatic coating process, charging voltage of the electrostatic gun and the
amount of sprayed liquid plasticizer are the two main parameters that affect the coating
powder adhesion rate (weight gain of the loaded tablets divided by the total weight of
sprayed coating powders). In order to obtain a good coating powder adhesion rate,
experiments with different charging voltage and liquid plasticizer spray rate were carried
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out. Table 3.4 gives the details parameters. For each experiment, tablets (60 g placebo
tablets and 20 g salbutamol sulfate tablets) were loaded into the coating pan and were
preheated for 10 min at a predetermined temperature. And then liquid plasticizer was
sprayed onto the surface of the tablets with a predetermined flowrate with different
spraying time, followed by the spraying of coating powders with a predetermined
charging voltage. After 10 min, compressed air was used to blow away the redundant
powders in the coating pan and then those drug tablets were taken out and weighed to
calculate the coating powder adhesion rate.
Table 3.4 Coating process parameters of tablet coating with EC
Charging voltage (kV)

0, 20, 40, 60, 70

Liquid plasticizer flow rate (g/min)

0.5

Liquid plasticizer spray time (min)

0, 1, 2, 3, 4

Pan speed during coating (rpm)

28-32

Pan speed during curing (rpm)

10-15

3.2.7.2

Optimization of curing parameters

After coating powder adhesion, a curing step is needed to turn the deposited coating
particles into a continuous coating film. In this process, curing temperature and curing
time are the two critical parameters. In order to clarify the influences of curing
temperature and curing time on the film formation, experiments with different curing
conditions were carried out. Table 3.5 gives the curing condition details for each
experiment.
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Table 3.5 Curing parameters of tablet coating with EC
Curing temperature (◦C)

Curing time (h)

40

0

50

0

60

0

40

1

50

1

60

1

40

2

50

2

60

2

3.2.8 Scanning electron micrographs
Scanning electron microscopy (SEM) was used to observe the coating film achieved by
the electrostatic powder coating process. Samples were firstly sputter coated with gold for
120 seconds using Emitech K550 sputter coater (Emitech Ltd., Ashford, UK) and then
they were observed with a scanning electron microscope at 5.0 kV (S-2600N Hitachi,
Ontario, Canada).

3.2.9 Calibration curve of drug
A standard stock solution with a concentration of 200 ppm (μg/ml) was prepared by
dissolving salbutamol sulfate in PBS solution with a pH value of 7.2. And then it was
diluted with pH 7.2 PBS solution separately to obtain the solution with a concentration of
5, 10, 20, 50, 80, 100, 120 respectively. A 8453 UV-Visible Spectrophotometer (Agilent
Technologies, Mississauga, Canada) was used to find the maximum absorbance, which is
at 276 nm. Then the absorbance was obtained at 276 nm against pH 7.2 PBS solution as
blank. The calibration curve was prepared by plotting absorbance versus concentration
(ppm) of salbutamol sulfate.
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The calibration curve of salbutamol sulfate at the wavelength of 276 nm is shown as
Figure 3.4. This curve would be used to calculate the unknown concentrations of
salbutamol sulfate released from electrostatic powder coated tablets.
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Figure 3.4 Calibration curve of salbutamol sulfate
in PBS with a pH 7.2 at 276 nm

3.2.10

Dissolution tests

Drug dissolution tests were performed by following the United States Pharmacopeia
(USP) apparatus (Apparatus 2, paddle; Huanghai Rcz-6c2, Shanghai, China). The release
media were 900 mL of pH 7.2 phosphate buffer solution. By using a 10 mL syringe,
samples were withdrawn and filtered (refills with the same amount of fresh release
medium) at predetermined intervals and assayed using an 8453 UV-Visible
Spectrophotometer (Agilent Technologies, Mississauga, Canada) at a wavelength of
276nm.
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3.2.11

Stability tests

Electrostatic dry powder coated tablets with ethylcellulose and Eudragit® RS/RL were
placed in HDPE vials (75 mL) and sealed with aluminum film and then were stored at
40◦C /75% RH for 1 month. The dissolution tests of those powder coated tablets before
and after storage were examined.

3.2.12

Statistical analysis

In the present study, all the experimental results were expressed as mean ± Standard
Deviation (S.D.) values. While in the stability tests, “similarity factor” f2 was used to
compare the drug release profiles before and after storage. The value of f2 is between 0 to
100, if f2 is larger than 50 (between 50 to 100), these two release profiles were considered
to be similar. If f2 is close to 100, the two release profiles were considered as identical.
The following equation gives the method to calculate the f2.
0.5


 1 n

2
f 2  50 log 1   Rt  Tt    100



 n t 1


(3.1)

In this equation, n is the total number of sampling times, Rt and Tt is the accumulated
drug release percentage at time t for the reference and test products, respectively.

3.3 Sustained release from ethycellulose coated tablets
3.3.1 Flowability improvement of ultrafine coating powders
Presently, the powder size in electrostatic powder coating varies mainly in a range from
40 to 60 µm, leading to a rougher film than liquid coating. Also for electrostatic powder
coating, ultrafine powder is more uniform in charging deposited particles [8]. This is
mainly because ultrafine powders have greater particle numbers and higher specific
surface area but less mass. So there has been a strong trend to use ultrafine powders
(smaller than 30 µm) to improve the surface quality of the final product [9-12]. However,
the poor flowability of ultrafine powders cause many problems in the electrostatic powder
coating process such as poor fluidization and uneven transportation and spray. Zhu and
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Zhang [13, 14] developed an innovative ultrafine powder coating technology, which uses
paint powders with mean particle diameter less than 20 µm and also introduced a series of
criteria during the processes of manufacturing powders on how to choose and blend flow
additives so as to control the flow properties. This novel technology has many advanced
features in surface quality and it is ready for commercial use [12].
For the pharmaceutical coating, it is not necessary to make the coating surface as fancy as
automobile industry, but a uniform coating film is still needed to modify the drug release
profiles and to control the drug release rate. In this project, ultrafine coating powders
were used for all of the coating processes. Before being applied in the coating
formulation, the flowability of those ultrafine powders needs to be improved first.
Nanoparticles are widely used to promote the flowability of ultrafine powders. It is
effective but the mechanism is still not very clear. Some researchers suggested that those
nanoparticles act as a neutralizer of electrostatic charge [15]. Some others proposed
another explanation that those nanoparticles could roll between the ultrafine powders as
lubricants, reducing the internal friction of them so as to improve the flowability [16, 17].
Another explanation, which is more widely accepted so far, said that those nanoparticles
could reduce the van der Waals force between two fine particles by either increasing the
separation distance [18] or increasing the local radius of curvature and increasing the
hardness at the contact of two fine particles [19].
AEROSIL® 200 Pharma is a high purity amorphous anhydrous colloidal silicon dioxide
(CSD) for use in pharmaceutical products, which is produced by Evonic Inc. in Germany.
It fulfils the analytical requirements of the currently valid versions of the United States
Pharmacopeia (USP/NF), European Pharmacopeia (Ph. Eur.) and Japanese Pharmacopeia
(JP) and it is tested and certified according to pharmacopoeia methods. It is widely used
in the current pharmaceutical industry to improve the flow properties of fine powders.
Jonat and Hasenza [20] did a study on the effect of colloidal silicon dioxide types (CSD)
on the flow characteristics of microcrystalline cellulose (MCC) under different mixing
conditions using the angle of repose method. Their results indicated that adding some
colloidal silicon dioxide types (CSD) could significantly reduce the angle of repose of
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MCC, from 47o to between 36 o and 38 o, which was further supported by SEM images
and AFM measurements.

Table 3.4 Particle size and angle of repose of EC powder
before and after size reduction
Particle size (µm)

Angle of repose (°)

Before size reduction

75.3±2.51

36.2±0.68

After size reduction

25.8±1.94

47.1±0.56

In the present study, we also choose the colloidal silicon dioxide (AEROSIL® 200
Pharma) as the additives to improve the flowability of the micronized coating powders.
Those nano particles were added and blended into a micronized coating powder to form
modified samples, which were further characterized to obtain the angle of repose.
Table 3.4 gives the particle size and angle of repose before and after size reduction of the
EC powders. The effect of the nano particle ratio on the angle of repose of the micronized
coating powders is shown by Figure 3.5.

63

Figure 3.5 The effect of nano particle (colloidal silicon dioxide) ratio
on the angle of repose of micronized EC powders
As shown in Figure 3.5, the original angle of repose of the micronized coaitng powders
without adding nano particles is around 47.2°, which is very high for the electrostatic
coating process. When the nano particle ratio was firstly increased from 0 to 1% (w/w,
based on the weight of coating powder), the angle of repose of coating powders was
significantly reduced to 41.2°. This is because nanoparticles could reduce the van der
Waals force between two fine particles by increasing the separation distance [18], which
could be shown as Figure 3.6. With further increase in the nanoparticle ratio, the angle of
repose was not decreased any further and remained around 41.5°.
In order to minimize or eliminate the agglomeration and the formation of the large
clumps in the coating formulation, the angle of repose of the coating powder needs to be
lower than 42° [21]. So for the coating powders with EC, the nanoparticle ratio needs to
be at least 0.5%.
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Nano particles

Micronized coating
particles
Figure 3.6 Schematic representation of the interparticle forces that can
affect the flowability of micronized coating powder. Left: without adding
nanoparticles; Right: with AEROSIL® colloidal silicon dioxide

In order to confirm the flowability improvement of coating materials, SEM micrographs
of micronized EC with and without nano CSD particles were observed. As shown in
Figure 3.7 A, without adding nano CSD particles, there are some obvious particle
agglomerations with a nonuniform particle distribution. On the other hand, after adding
nano CSD particles Figure 3.7 B, particle agglomerations became less and the distribution
of those fine particles is more uniform.
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Figure 3.7 SEM micrographs of EC fine powders before (A) and after (B)
adding AEROSIL® colloidal silicon dioxide

3.3.2 Glass transition temperature reduction by plasticizers
Plasticizer is commonly used in the pharmaceutical industry due to its excellent ability to
reduce the glass transition temperature (Tg) of coating polymers so as to guarantee that
that the coating process can be performed in a relatively low temperature.
Ethylcellulose is widely used in the pharmaceutical industry and can form a hard, robust
film when coated onto solid dosage forms. While because the glass transition temperature
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(Tg) of ethylcellulose is too high (129.8◦C), both solid and liquid plasticizers are added
into the coating formulation to reduce the glass transition temperature (Tg) and also to
make coating film of ethylcellulose elastic and less brittle. Triethyl citrate (TEC) and
lactose are reported as efficient plasticizers for ethylcellulose [22].
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Figure 3.8 Effect of plasticizers on the glass transition temperature of EC
Figure 3.8 shows the reduction of the glass transition temperature (Tg) of ethylcellulose
by TEC and lactose using differential scanning calorimetry (DSC). The glass transition
temperature (Tg) of ethylcellulose was dramatically reduced from 129.8◦C to 48◦C by
increasing the TEC’s ratio from 0% to 50%. When further increasing TEC’s ratio to 75%,
Tg of ethylcellulose was slightly decreased to 42 ◦C. And when increasing the lactose’s
ratio from 0% to 20%, Tg of ethylcellulose was declined from 129.8 ◦C to 51◦C and was
further reduced to 46◦C by increasing the lactose’s ratio to 30%. By adding lactose in the
coating powder and spraying TEC onto the surface of tablets can guarantee that the film
formation could occur under a relatively low temperature.
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3.3.3 Coating powder adhesion
The present study utilized the electrostatic spray gun to feed the coating powder into the
coating pan. The coating particles were firstly negatively charged at the tip of the gun by
a high voltage and generated an electrical field between the tip of the gun and the
grounded coating pan, which can direct the powder flow along the direction of the
electrical field to the surface of the tablets. In this case, the drug tablets loaded in the
coating pan should be electrically conductive to ensure that they are grounded so as to
allow further particle deposition. The maximum electrical resistivity that meet the above
requirement is 1×109 Ωm [23]. Unfortunately, the electrical resistivity of tablets used in
the present study is 1×1016 Ωm, which is too high for the electrostatic spray coating
process.
However, it was found that by spraying a certain amount of liquid plasticizer in the
coating process, the electrical resistivity of tablets could be reduced dramatically. As
shown in Figure 3.9, the electrical resistivity of drug tablets declined from 1×1016 Ωm to
1×108 Ωm by increasing the spraying time of TEC from 0 to 3 minutes with a given flow
rate (0.50 g/min), which is suitable for the electrical spraying coating process.
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Figure 3.9 The effect of liquid plasticizer (TEC)
on electrical resistivity of drug tablets
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Figure 3.10 The effect of charging voltage
on the coating powder adhesion rate
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The influence of charging voltage on the coating powder adhesion rate is shown in Figure
3.10. When the charging voltage was increased from 0 to 60 kV, coating powder adhesion
rate increased from 62.5% to 92.1%. While when the charging voltage was further
increased to 70 kV, there was no more increase for the coating powder adhesion rate. The
coating powder adhesion obtained at 0 V reflected the particle adhesion caused by liquid
plasticizer. Spraying liquid plasticizer onto the surface of the tablets generated capillary
force between the interface of liquid plasticizer and coating powders, which could
promote the coating powder adhesion. Higher coating powder adhesion rate obtained with
increasing the charging voltage to 60 kV indicates that the coating powder adhesion was
enhanced by the electrical field between the tip of the electrostatic gun and the coating
pan. The coating powder adhesion rate was not increased after the electrical charge
reached a certain value, this is because higher charging voltage means more free ions
produced, leading to an increase of the cumulative charge of the coating layer and back
ionization, which could reduce the powder deposition.

Powder adhesion ratio (%)

100

80

60

Charging voltage: 60 kV
Plasticizer flowrate: 0.5 g/min
Temperature: 60°C

40

20

0

1

2

3

Liquid plasticizer spray time (min)

Figure 3.11 The effect of liquid plasticizer
on the coating powder adhesion rate
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Besides the charging voltage of the electrostatic spray gun, liquid plasticizer could also
do a big influence on the coating powder adhesion. As shown in Figure 3.11, when there
was no liquid plasticizer sprayed, the coating powder adhesion rate was only 21 % with a
charging voltage of 60 kV, which is too low to produce a good coating film. When the
liquid plasticizer spray time was increased from 0 min to 2 min, the coating powder
adhesion rate was significantly increased from 21 % to 83.2 %. When further increasing
the liquid plasticizer spray time to 3 and 4 min, the coating powder adhesion rate was
slightly increased to 92.1 % and 93.3 %, respectively. But in the coating process, when
the liquid spray time was 4 min, sticky film was observed. So the spray time could be
optimized as 3 min.
From Figure 3.9, Figure 3.10 and Figure 3.11 we conclude that both charging voltage of
the electrostatic spray gun and the liquid plasticizer have a big influence on the coating
powder adhesion rate. The charging voltage of electrostatic spray gun could be optimized
as 60 kV according to Figure 3.10. While for the liquid plasticizer, when its flow rate is
0.5 g/min, the spray time needs to be 2 min or more than 2 min to guarantee a high
enough electrical conductivity of the tablets so as to achieve a high coating powder
adhesion rate. However, sticky film was observed when the spray time was increased to 4
min. Consequently, the liquid plasticizer spray time could be optimized as 3 min with a
flowrate of 0.5 g/min.

3.3.4 Film formation
Film formation in dry powder coating occurs when the curing temperature is higher than
or close to the Tg of the coating polymer [23]. As the most critical parameters, curing
temperature and curing time can have a big impact on the film formation process in the
dry powder coating technology. The surface morphology of the coated tablets with
different curing temperature and curing time was observed using a scanning electron
microscope (SEM).
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Figure 3.12 SEM micrographs of dry EC powder coated tablets: (A) 40◦C,
120 min; (B) 50◦C, 120 min; (C) 60◦C, 120 min
As shown in Figure 3.12, when the curing temperature was low (Figure 3.12A, 40 ◦C), the
deposited particles are clearly visible, indicating an uncured film with rough pores on the
surface. As the curing temperature increased to 50 ◦C (Figure 3.12B), deposited particles
were less clear but there are still some boundaries in the film. When the curing
temperature was increased to 60 ◦C (Figure 3.12C), boundaries between particles
disappeared and the coating film became smooth and uniform.
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Figure 3.13 SEM micrographs of dry EC powder coated tablets: (A) 60 ◦C, 0
min; (B) 60 ◦C, 60 min; (C) 60 ◦C, 120 min
Curing time also has a significant influence on the film formation in the electrostatic
powder coating process. From Figure 3.13 we can conclude that a longer curing time
leads to a more uniform and smoother coating film.

3.3.5 Drug release from dry powder coated tablets
The drug release profiles from dry powder coated tablets with different coating
formulations and curing conditions were investigated through the dissolution tests.
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Figure 3.14 Drug release profiles from EC powder coated tablets at different
coating levels (Lactose 5%; Pore former 5%; 60 ◦C, 120 min)
As shown in Figure 3.14, drug release finished within 1 hour from uncoated tablets. For
dry ethylcellulose powder coated tablets with a coating level of 1% and 1.7%, drug
release was completed within 4 hours and 12 hours, respectively. By further increasing
the coating level to 2.8%, drug release rate was much slower and only 75% of drug
released within 24 hours. Drug release from film controlled dosage forms is governed by
the diffusion through an intact polymeric coating film as well as diffusion through water
filled cracks, which can be induced by a mechanically unstable coating film [4].
Immediately after the tablets contact with aqueous media, water diffuses into the tablets
and an increasing hydrostatic pressure is generated inside the tablets. If this hydrostatic
pressure exceeds the mechanical stability of the film coating, film cracks will be formed
and drug release does not have to diffuse through the polymer network, leading to a
greatly accelerated release rate (1%, 1.7%). When the coating level is high enough
(2.8%), the coating film is mechanically stable and can withstand the hydrostatic pressure
built up inside the tablet core. Consequently, drug release was well controlled by the
diffusion through the coating film and allowed a much slower release rate.
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Solid plasticizer also could be used in the powder coating process to reduce the coating
temperature and promote the film formation during the curing step. In the present study,
lactose was used as solid plasticizer and drug release profiles from powder coated tablets
with different lactose ratio in the coating formulation could be seen as Figure 3.15. When
the lactose was not used in the coating process, coating film with a coating level of 2.8%
couldn’t withstand the hydrostatic pressure caused by the water diffused into the core.
There was a burst release at around 2 hours and drug release completely within 10 hours.
When 3% lactose was added into the coating formulation, coating film became better and
stronger than those without lactose, drug release could be prolonged to 24 hours. And
when the lactose ratio was further increased to 5%, coating film became much stronger,
leading a constant drug release rate and only allowing 50% drug release within 24 hours.
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Figure 3.15 Drug release profiles from EC powder coated tablets with
different lactose ratio
(Coating level 2.8%; Pore former 0%; 60◦C, 120min)
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Figure 3.16 Drug release profiles from EC powder coated tablets with
different pore former ratio (Coating level 2.8%; Lactose 5%; 60◦C, 120min)
As a pore former, PVA-g-PEG was added into the coating formulation to adjust the drug
release profiles. In contrast to the frequently used pore former hydroxypropyl
methylcellulose (HPMC), PVA-g-PEG does not cause flocculation of the coating
dispersions (aqueous coating) and can also provide a long-term stable drug release
profile, even upon open storage under stress conditions [3, 4]. In the present study, the
inclusion of pore formers in the coating formulation appears to assist the drug release. As
shown in Figure 3.16, variations in pore former content in coating formulation had
significant effect on the drug release profiles from dry powder coated tablets. For the
tablets coated without pore former, the drug only released 49% within 24 hours. While by
increasing the pore former content from 5% to 10%, the drug released 77% and 100%,
respectively. When the pore former content was further increased to 15%, drug release
was completed within 12 hours. The increased pore former content can create more
channels and more opportunity of water permeation through the film, leading to an
increase of drug release rate.
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The influence of curing temperature and curing time on the film formation was confirmed
by the dissolution tests. As shown in Figure 3.17, when the curing temperature was low
(40 ◦C, 50 ◦C), drug release completed within 6 hours and 14 hours, indicating a
mechanically unstable coating film. While when the curing temperature was 60 ◦C, drug
release was prolonged to 24 hours. This is because higher curing temperature allows
completed film formation and mechanically stable coating film.
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Figure 3.17 Influence of curing temperature on drug release
from EC powder coated tablets
(Lactose 5%; Pore former 10%; Coating level 2.8%; Cured for 120min)
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Figure 3.18 Influence of curing time on drug release
from EC powder coated tablets
(Lactose 5 %; Pore former 10%; Coating level 2.8 %; Curing at 60 ◦C)
As shown in Figure 3.18, when there was no curing step (0 min), drug release was
completed within 2 hours, indicating that the coating film was mechanically unstable.
When the curing time was increased to 60 min, drug release was completed within 12
hours, which means the coating film became stronger than uncured ones. While when the
curing time was further prolonged to 120 min, drug release was extended to 24 hours.
This is because longer curing time allows completed film formation and mechanically
stable coating film.
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Figure 3.19 Relationship between coating level and drug release time
(Lactose 5%; Pore former 5%; 60 ◦C, 120 min)
Drug release from electrostatic powder coated tablets can be influenced by coating level,
pore former ratio, curing temperature and time. With the same curing temperature and
time, drug release rate could be adjusted and controlled by changing the coating level or
pore former ratio in the coating formulation. Figure 3.19 & Figure 3.20 give a
relationship between drug release time needed for both 100% release and 50% release and
coating level and pore former ratio. Those figures can tell a prediction on drug release
profiles with different coating level and pore former ratio and also can predict in which
coating levels and pore former ratios drug could be released within a target period of time
such as 12 and 24 hours. For example, in Figure 3.19, when the pore former ratio is 5% in
the coating formulation and the curing temperature and time are 60 ◦C and 120 min, drug
release could be designed within 24 hours at a coating level around 2.5%.
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Figure 3.20 Relationship between pore former ratio (w/w) and drug release
time (Coating level 2.8%; Lactose 5%; 60◦C, 120 min)

3.4 Stability of the electrostatic powder coated tablets
The drug release profiles of electrostatic dry powder coated tablets (cured at 60◦C for 120
min) before and after storage are shown in Figure 3.21. And the similarity factor f2 values
are shown in Table 3.5.
For EC coated tablets, there was no significant difference in the drug release profiles
before and after storage with different coating levels. The similarity factor f2 values are
84.14, 84.32 and 83.83 for coating level of 1%, 1.7% and 2.8%, respectively, indicating
that those electrostatic powder coated tablets with EC fine powder exhibited an excellent
stability over 1 month at 40 ◦C /75% RH.
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Figure 3.21 Release profile of salbutamol sulfate from powder coated
tablets with EC cured at 60 ◦C, 120 min
(*: after storage at 40 ◦C, 75% RH for 1 month)
Table 3.5 Similarity factor f2 values between drug release profiles
before and after storage with different coating levels (EC)
Coating level

f2

1%

84.14

1.7%

84.32

2.8%

83.83

3.5 Conclusion
Using a novel electrostatic dry powder coating technology, ultrafine ethylcellulose
powers was successfully coated onto tablets to obtain drug sustained release over a
prolonged time period. The flowability of the ultrafine coating powders could be
significantly improved by adding nano sized colloidal silicon dioxide. By utilizing an
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electrostatic gun, an electrical field between the gun and the tablets was created to direct
the movement of coating powders towards the tablets, leading to a better coating powder
adhesion. Lactose and TEC are two effective plasticizers for ethylcellulose that could
significantly reduce its glass transition temperature (Tg), thus film formation could be
achieved under a relatively low temperature. Also spraying liquid plasticizer could
increase the electrical conductivity of tablets so as to promote the coating powder
adhesion through the electrostatic gun. Film formation could be enhanced by increasing
curing temperature or prolonging curing time. Sustained drug release was successfully
achieved and the drug release rate could be adjusted by changing the coating level or by
altering the pore former ratio in the coating formulation. Ethylcellulose powder coated
tablets exhibited an excellent stability over 1 month at 40 ◦C /75% RH. Based on these
results, this novel electrostatic powder coating provides a competent dry coating method
to coat tablets with ultrafine powder of ethylcellulose.
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4

Pellet Coating – Immediate, Sustained and Delayed
Drug Release

The present study aims to apply a novel electrostatic powder technology to coat small
pellets with different coating materials. Piroxicam, a non-steroidal anti-inflammatory
drug, was used as the active pharmaceutical ingredient (API). Eudragit® EPO, Eudragit®
RS /RL and Acryl EZE were used as the coating materials to achieve immediate release,
sustained release and delayed release, respectively. Three steps including preheating,
powder adhesion and curing were carried out to form the coating film while liquid
plasticizers were used to decrease the glass transition temperature of coating powders and
also served to reduce the electrical resistivity of pellets. Results of SEM indicated coating
film could be better formed by increasing curing temperature or extending curing time.
Dissolution tests showed that three different drug release profiles, including immediate
release, sustained release and delayed release, were achieved by this coating technology
with different coating formulations. The dry powder coated pellets using this developed
technology exhibited an excellent stability with 1 month at 40 ◦C /75% RH. The coating
procedure could be shortened to within 120 minutes and the use of fluidized hot air was
minimized, both cutting down the overall cost dramatically compared to organic solvent
coating and aqueous coating. All results demonstrated that the novel electrostatic dry
powder coating method is a promising technology in the pharmaceutical coating industry.

4.1 Introduction
In the pharmaceutical industry, solid dosage forms including tablets and pellets are
commonly coated to achieve taste masking, chemical and physical protection and
modification of drug release characteristics. Presently, liquid coating is most widely used,
where the coating materials are dissolved /dispersed into organic solvent /water to form a
solution /suspension, then spayed onto solid dosage forms to achieve a coating film.
Organic solvent based coating can make the film formation faster and more uniform due
to the dissolved nature of coating polymers. However, the toxicity of organic solvent does
decrease the safety of the drug and cause environmental related problems. As a result,
aqueous coating, where water is used as the solvent, started to dominate in 1990s and
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remains the preferred approach in the pharmaceutical industry. Nevertheless, aqueous
coating still possesses many limitations such as longer processing time and higher energy
consumption. Also aqueous coating is not appropriate for the moisture sensitive APIs.
On the other hand, coating of smaller solid dosage forms like pellets, being solvent
coating or aqueous coating, is currently carried out in a fluid bed coater in the present
pharmaceutical industry, because those small pellets are very easy to agglomerate and
that prevents uniform coating. Based on the spraying location, there are three different
types fluid bed coaters including top-spray, side-spray and bottom spray. The bottomspray is named as the Wurster apparatus that invented by Wurster in 1966 [1]. Today, it is
one of the most common coating equipment for pellets coating in the pharmaceutical
coating industry.

Figure 4.1 Schematic representation of a fluid bed with Wurster insert apparatus
As shown in Figure 4.1, a typical the Wurster apparatus consists of a spray nozzle located
at the bottom that is used for the spraying of coating solution, a Wurster tube that is
placed in the center of the column and a distributor plate. In the coating process, the
pellets are firstly fluidized and then coated by spraying the coating solutions into the
column with the spray nozzle. The fluidized pellets could be circulated between the
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Wurster tube and the outside of the column due to the unique structure, leading to a more
uniform and continuous coating film. However, there are many limitations for this pellet
coating equipment. First of all, in order to fluidize those small pellets and also to carry
moisture out of the system, a large amount of hot fluidizing air is necessary, dramatically
increasing the energy consumption and also the overall operation cost. Also, for the
solvent coating method, long processing time is needed in order to obtain a desirable
coating level owing to the viscosity limit of the coating solution.
Different from the Wurster fluidized bed, Watano [2] designed a rotating fluidized bed
coater to coat very small solid dosage forms using the aqueous coating method. In their
study, fine particles (Geldart Group C powder) were used as the core particles, which
were coated with HPLC aqueous solution. As shown in Figure 4.2, this rotating fluidized
bed consists of a rotatable cylinder covered with meshes, a plenum chamber and a filter
placed at the center of the cylinder. During the coating process, the fine particles were
first fluidized with the support of a strong centrifugal force. Then the aqueous solution
was sprayed through the nozzle located on the central filter. This study provided a new
method to coat very small solid dosage forms. However, it still possesses many
limitations. First of all, large amount of fluidizing hot air is necessary to maintain the
fluidization of the fine particles and also to evaporate the moisture, significantly
increasing the energy consumption and overall operation cost. The processing time is still
very long due to the difficulty of evaporation of water.
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Figure 4.2 Schematic diagram of the rotating fluidized bed coater
Driven by these issues, many efforts have been made to develop alternative coating
techniques to reduce or avoid the use of organic solvents as well as water [3-8]. Details of
each coating technology can be found in the following reviews [9-12].
Some of the earlier attempts [3, 5, 13-15] used liquid plasticizers in the coating process to
wet the dosages surface, promoting the adhesion of coating powders. Also the liquid
plasticizer could reduce the glass transition temperature of coating materials to enhance
the film formation under a lower temperature. However, surplus plasticizer can possibly
lead to very soft or sticky film, so a careful balance needs to be reached between the
plasticizer concentration for a sufficient coat thickness and that for a flexible and dry
coat. Cerea et al. [16] developed a dry powder coating technology without using any
solvent or plasticizer. In this coating technology, a lab-scale spheronizer was used as the
coater with a motorized single screw powder feeder and an infrared lamp positioned on
the top of the spheronizer as a heating source. Coating powders were continuously spread
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onto the tablets by the powder feeder and film formation was completed in a following
curing step in a static oven at 80 ◦C for 12 h. The advantage of this technology is that
there is no sticky film due to the absence of liquid plasticizer. While the long curing time
(12 h) and high curing temperature (80 ◦C) make it hard to apply in the industry.
Among these earlier attempts of dry powder coating technology, researchers in
Bodmeier’ group tried to coat small dosage forms in a Wurster fluidized bed with the
support of liquid plasticizer [5, 13, 17]. In their study, pellets with a diameter of 0.71-0.85
mm were coated with different coating materials to achieve drug immediate release,
sustained release and delayed release. During the coating process, small pellets were
firstly loaded into the bed, followed by the spraying of liquid plasticizers and feeding of
coating powders. The plasticizers and coating powders were introduced into the bed
separately to obtain a good coating powder adhesion. After the adhesion of the coating
powders was finished, the pellets were unloaded and transported to a curing step for
another 2 h to 24 h under the predetermined temperature. Those studies provide a method
to coat small pellets using a powder coating technology with the support of liquid
plasticizers in a traditional Wurster apparatus. However, similar with liquid coating
methods using Wurster apparatus, a large amount of fluidizing hot air is necessary during
the coating process in order to fluidize those small pellets, increasing the energy
consumption and overall cost. Also this is not a continuous coating process, during which
a curing step is needed in a different piece of equipment. This could significantly increase
the processing time. Also the curing temperature and curing time need to be well
controlled, otherwise a sticky coating film would be obtained because there is no
fluidization or tumbling for the pellets during the curing step.
Kablitz [18] designed and developed a new dry powder coating technology to coat small
pellets using a rotatory fluid bed. In their coating process, the usage of organic solvents
and water was completely avoided. An enteric coating film was achieved by using
hydroxypropyl methylcellulose acetate succinate (HPMCAS) as the coating material
without adding talc as anti-tacking agent. As shown in Figure 4.3, the coating process was
performed in a rotary fluid bed with a gravimetric powder feeder achieving an exact
dosage in contrast to a volumetric powder feeder. The coating powders and plasticizers
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were fed into the rotatory fluid bed simultaneously with a three-way nozzle, which was
aligned tangential to the pellet bed movement feeding. This dry coating technology has
many advantages. Firstly, the usage of organic solvents and water was completely
avoided during the coating process. Although it still need fluidizing hot air to fluidize the
small dosage forms, the amount of which has been reduced dramatically due to the good
design. And also the feeding of coating powders and plasticizers could be done
simultaneously, which could not only increase the coating efficiency but also could
reduce the processing time.

Figure 4.3 Schematic of a rotary fluid bed granulator: (1) rotor disc; (2) air
slit; (3) pellet bed (square view); (4) threeway nozzle; (5) powder feeder
Unfortunately, those advantages have been compromised by the complicated coating
process and added cost of the coating apparatus, offsetting any cost benefit to switching
from liquid coating to powder coating, since their technology requires the use of
completely different coating equipment. In addition, adoption of new equipment not only
incurs extra capital costs, but also introduces additional complications in operation. The
pharmaceutical companies would prefer to accept a powder coating process operated in a
simpler coating apparatus that can be easily adapted from their present apparatus, such as
pan coaters, for liquid coating.

90

Electrostatic coating has gained tremendous attention as a promising alternative to liquid
coating in many industries, owing to its advantages in energy saving, high transfer
efficiency, and environmental friendliness [19]. However, application of electrostatic
coating in pharmaceutical industry is very limited due to the much weaker electrical
conductivity of solid dosages. In order to overcome the limitations of those previous
attempts, the authors’ group developed a novel dry powder coating technology [6]. By
spraying certain amount of liquid plasticizer onto the surface of the solid dosage forms,
the electrical resistivity can be dramatically decreased so that the electrostatic coating
method can be adapted to form an electrical field between the electrostatic gun and the
grounded substrate, which can direct the powder flow and enhance deposition of charged
particles. Also a more uniform coating film could be promoted by this technology due to
the better distribution of deposited particles caused by the repulsive force among the
charged particles. This dry coating technology utilizes the same coating pan that was
commonly used for solvent as well as aqueous coating, so that no major equipment
change would be required with the shift to the new powder coating technology. This
technology has been successfully applied on the larger solid dosage forms like tablets for
all common drug release profiles including immediate release [8], sustained drug release
[20] and delayed drug release [21].
The objective of present study is to coat small pellets by using this novel electrostatic dry
powder coating technology in a pan coater with different coating formulations to
modulate drug release profiles.
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Figure 4.4 Schematic diagram of pellet coating study

4.2 Materials and methods
4.2.1 Materials
Piroxicam pellets with a particle size of 0.9mm-1.18mm were provided by Gaocheng
Biotech& Health CO., LTD. Eudragit® EPO, Eudragit® RS/RL, Eudragit® L100-55 and
Colloidal silicon dioxide (AEROSIL® 200 Pharma) were donated by Evonik Degussa
Corporation (Germany). Acryl EZE was provided by Colorcon, Inc. (US). It is an enteric
coating material containing Eudragit® L100-55 developed by Colorcon, Inc. Talc powder
was purchased from Mallinickrodt Baker Inc. (Canada). Triethyl citrate (TEC) and PEG
400 were obtained from Caledon Laboratories Ltd. (Ontario, Canada) and EMD
Chemicals Inc. (Ontario, Canada), respectively.

4.2.2 Particle size reduction and analyses
Particle size reduction of coating materials was achieved by using a blade grind mill. A
particle size analyzer (TSI Corporation, Model 3603, Shoreview, MN, USA) was used to
confirm the particle size of the coating particles. The particle size at 50 % of total weight
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fraction was used as the average particle size. Table 4.1 gives the average particle size of
coating powder used in the present study.

Table 4.1 Average particle size of coating powder
Coating powder

Average particle size (µm)

Eudragit® EPO

23.3

Eudragit® RS

48.7

Eudragit® RL

39.7

Acryl EZE

20.8

Talc powder

28.9

4.2.3 Thermal analysis of coating polymers
Differential scanning calorimetry (DSC) analysis (Mettler Toledo, DSC822, Mississauga,
Canada) was used to investigate the glass transition temperature of raw coating materials
and the mixture of coating materials with plasticizers (TEC and PEG 400) of different
weight ratio (plasticizer/ coating materials). Samples with a weight of 10 mg were tested
under nitrogen atmosphere with a heating rate of 2 ◦C /min over the temperature range of
20 to 200 ◦C.

4.2.4 Angle of repose (AOR)
Measurement of the angle of repose was carried out to characterize the flowability of
coating powers before and after the size reduction and also to investigate the influence of
nano sized additives on the flowability of the three different coating powders by using a
PT-N Hosokawa Powder Characteristic Tester, following the standardized testing
procedures of ASTM D6369-08 (ASTM Standard D6369-08, 1999).
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4.2.5 Electrical resistivity tests
A batch of 100 g piroxicam pellets was loaded in the pan coater and preheated for 10
minutes. Then liquid plasticizer, with a flow rate of 0.50 g/min, was sprayed onto the
surface of the pellets. A given number of pellets was taken out from the pan coater at
different spraying time intervals (0, 1, 2 and 3 min) to test the electrical resistivity using
an electrometer (Keithley 610B, Keithley instruments, Inc., USA). These tests were
operated three times for the accuracy.

4.2.6 Coating equipment and process
D
B
A

C

Ground
Figure 4.5 Schematic of the electrostatic powder coating system
(A) liquid plasticizer spray system, (B) coating pan,
(C) electrostatic spray gun, (D) powder feeder

As shown in the Figure 4.5, the coating system includes a rotatory coating pan, a liquid
plasticizer spray system, an electrostatic spray gun and a powder feeder. The rotatory
coating pan, the same as commonly used for the organic/aqueous coating in the pharma
industry, is electrically grounded. The liquid plasticizer spray system includes a metering
pump and an atomizing nozzle. The electrostatic spray gun is applied to regulate and
charge the coating powder and uniformly spray them onto the surface of the dosage forms
preloaded in the pan.
The coating process was performed in three steps. A batch of 100 g pellets were firstly
loaded into the coating pan and preheated to a given temperature. Then a given amount of
liquid plasticizer was sprayed onto the surface of the pellets. It is followed immediately
by spraying dry coating powder. If necessary, repeat those two steps for several times
until enough particles were deposited on the surface of the pellets. The temperature of the
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coating pan was maintained as required until the particles deposited on the pellets were
cured to produce a uniform coating film.
The coating level (%) of the pellets could be obtained from the weight gain of coated
pellets divided by the weight of uncoated ones, which is shown in the following equation:

Coating level (%) =

weight of coated pellets - weight of uncoated pellets
* 100%
weight of uncoated pellets

Table 4.2 Coating parameters of pellet coating
Pellet loading

60 g

Charging voltage

60 kV

Liquid plasticizer flow rate

0.5 g/min

Liquid plasticizer spray time

2 min for the first spraying, 0.5 min for the rest

Atomizing air pressure

100-120 kPa

Nozzle diameter

0.25 mm

Powder feed rate

2 g/min

Powder feed time

3 min

Pan speed during coating (rpm)

35-40

Pan speed during curing (rpm)

20-25

Curing temperature

30 ◦C, 40 ◦C and 50 ◦C

Curing time interval

0 min, 60 min and 120 min

4.2.7 Scanning electron micrographs
The surface morphology of the dry powder coated pellets was investigated by the
scanning electron microscopy (SEM). After sputter coated with gold for 120 s using
Emitech K550 sputter coater (Emitech Ltd., Ashford, UK), samples were observed with a
scanning electron microscope at 5.0 kV (S-2600N Hitachi, Ontario, Canada).
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4.2.8 Calibration curve of piroxicam
The drug release standard curves of piroxicam at the wavelength of 334 nm, 354 nm and
353 nm are shown in Figure 4.6, Figure 4.7 and Figure 4.8, respectively. The curves are
served for the calculation of unknown concentrations of piroxicam samples collected
from the in-vitro drug release testing.
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Figure 4.6 Standard curve of piroxicam (wavelength=334 nm)
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Figure 4.7 Standard curve of piroxicam (wavelength=353 nm)
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Figure 4.8 Standard curve of piroxicam (wavelength=354 nm)
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4.2.9 Drug release profiles
Drug release profiles from dry powder coated pellets were obtained by the dissolution
tests, performed following the United States Pharmacopeia (USP) apparatus (Apparatus
2, paddle; Huanghai Rcz-6c2, Shanghai, China). The release media were 900 mL of 0.1N
HCl solution for Eudragit® EPO coated pellets and 900 mL of pH 7.2 phosphate buffer
solution for Eudragit® RS/RL coated pellets. For Acryl EZE coated pellets, the release
media were 750 mL of 0.1N HCl solution for the first 2 hours and then pH 6.8 phosphate
buffer solution by adding 250 mL of 0.2 M tribasic sodium phosphate solution for
additional 2 hours. At predetermined intervals, samples were withdrawn by a 10 mL
syringe and followed by refills with the same amount of fresh release medium. After
being filtered, samples were assayed using an 8453 UV-Visible Spectrophotometer
(Agilent Technologies, Mississauga, Canada) at a wavelength of 334 nm, 354 nm and 353
nm at pH 1.2 HCl solution (0.1N), pH 7.2 phosphate buffer solution and pH 6.8
phosphate buffer solution, respectively.

4.2.10

Stability test

Dry powder coated pellets with three different coating materials cured at 50 ◦C for 120
minutes were placed in HDPE vials (75 mL) and sealed with aluminum film and then
were stored at 40 ◦C /75% RH for 1 month. The dissolution tests of pellets before and
after storage were examined.

4.2.11

Statistical analysis

Similar with previous chapters, mean ± Standard Deviation (S.D.) values were also used
to express the experimental results in this chapter. Also the “similarity factor” f2 was used
to compare the drug release profiles before and after storage in the stability tests. The
following equation could be used to calculate the value of “similarity factor” f2.
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(4.1)

In this equation, n is the total number of sampling times, Rt and Tt is the accumulated
drug release percentage at time point t for the reference and test products, respectively.
The value of f2 is between 0 to 100, if f2 is larger than 50 (between 50 to 100), these two
release profiles were considered to be similar. If f2 is close to 100, the two release profiles
were considered as identical.

4.3 Coating and film formation
4.3.1 Flowability improvement
Nano sized particles of colloidal silicon dioxide (AEROSIL® 200 Pharma) was used as
the additives to improve the flowability of the micronized coating powders [22-25].
Those nano particles were added and blended into the micronized coating powder to form
a modified sample, which was further characterized to obtain the angle of repose.
Table 4.3 gives the particle size and angle of repose before and after size reduction of the
three different coating powders. The angle of repose of the coating powders was
significantly reduced by adding nano sized colloidal silicon dioxide, indicating an
improvement of flowability of the coating powders. This table also shows that 0.5 %
additive based on the weight of coating powder gives the lowest angle repose, which
would be used in the following coating formulations.
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Table 4.3 Particle size and angle of repose of coating powders
before and after adding nano additives
Angle of repose (°)

Coating

Particle size

material

(µm)

0% additive

0.5% additive

1% additive

1.5% additive

Eudragit® E PO

23.3

46.2±1.24

40.74±0.94

40.98±0.88

41.03±0.76

Eudragit® RS

48.7

41.3±0.63

40.02±0.69

-

-

Eudragit® RL

39.7

42.8±0.81

40.11±0.71

-

-

Acryl EZE

20.8

47.5±1.38

41.03±0.86

41.12±0.91

41.09±0.87

4.3.2 Coating temperature reduction
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Figure 4.9 Effect of plasticizer ratio (% w/w, based on polymer) on the glass
transition temperature of the polymer (A) Eudragit®EPO with PEG 400;
(B) Eudragit®RL/RS with TEC; (C) Acryl EZE with PEG 400
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Liquid plasticizer plays a key role in the pharmaceutical industry due to its excellent
ability to reduce the glass transition temperature and brittleness and increase flexibility of
the coating polymers. As polymers with very small molecular weight, liquid plasticizers
can be incorporated with long chains of the coating polymers and enlarge the free volume
between the chains and makes it easier to move. As a result, the glass transition
temperature of the polymer can be dramatically decreased. PEG 400 and TEC are widely
used in the pharmaceutical industry due to their distinguished plasticizing properties,
health friendliness and low cost. Some previous reports [8, 20, 21] indicated that PEG
400 was an efficient plasticizer for the Eudragit® EPO and Acryl EZE while TEC was an
efficient for Eudragit® RL and Eudragit® RS by studying their surface properties and
compatibility with both tablet core and coating materials.
Figure 4.9 shows the reduction of the glass transition temperature of the coating polymers
by different liquid plasticizers using differential scanning calorimetry (DSC). The glass
transition temperature of Eudragit® EPO was reduced from 53 to 31 ◦C by increasing PEG
400 weight ratio from 0 to 25% (Figure 4.9 A). By increasing the TEC weight ratio from
0 to 45%, the glass transition temperature of Eudragit® RL and Eudragit® RS was
dramatically decreased from around 60 to below 30 ◦C (Figure 4.9 B). For Acryl EZE, its
glass transition temperature declined from 127 to 55 ◦C (Figure 4.9 C) by increasing the
PEG 400 weight ratio from 0 to 100 %.
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4.3.3 Coating powder adhesion
Powder feeder

Electrostatic spray gun

Coating powder
Negative charged coating powder
Ground

Figure 4.10 Coating powder adhesion process for pellet coating
As has been demonstrated in section 2.2, the electrostatic dry powder coating technology
utilizes an electrical field to enhance the deposition of coating powder. As shown in
Figure 4.10, the coating particles are firstly negatively charged at the tip of the
electrostatic spraying gun by a high voltage, after which the electrical field between the
tip of the spray gun and the grounded coating pan is generated. Then the charged coating
particles would flow along to adhere onto the surface of the tumbling pellets following
the direction of the electrical field. In this process, the surface of drug pellets loaded in
the coating pan should be electrically conductive to ensure that they are grounded,
otherwise the electrical charge tends to build up on the pellets so as to impede further
particle deposition. 1×109 Ωm is said to be the maximum electrical resistivity to allow the
above process to happen. However, for some of the pharmaceutical solid dosage forms
including drug pellets used in this study, the electrical resistivity is higher than 1×109
Ωm, which is too high for the electrostatic spray coating process.
Fortunately, the presence of liquid plasticizer in the coating process could provide
substantial support to reduce the electrical resistivity of the drug pellets. As shown in
Figure 4.11, the original electrical resistivity of drug pellets is around 1×1016 Ωm, and
with the increase the spraying time of liquid plasticizer (TEC and PEG 400) from 0 to 3
minutes with a given flow rate (0.50 g/min), the electrical resistivity of pellets declined
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dramatically from 1×1016 Ωm to 1×107 Ωm-1×108 Ωm, which is suitable for the electrical
spraying coating process. The reduction of electrical resistivity was hypothesized as an
increase of surface conduction with the presence of liquid plasticizer [26].
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PEG 400
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1E7
0

1

2

3

Time (min)
Figure 4.11 The effect of liquid plasticizer on electrical resistivity of pellets
(Liquid plasticizer flow rate: 0.5 g/min, temperature: 50 ◦C)

4.3.4 Film formation
Film formation in the dry powder coating process resulted from the deformation and
viscous flow of deposited polymer particles when the temperature is higher than the glass
transition temperature (Tg) of the coating polymer [14].
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Figure 4.12 SEM micrographs of dry Eudragit® EPO powder coated
piroxicam pellets curing at 50 ◦C for different time intervals
(A) 0 min, (B) 60 min, (C) 120 min
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Figure 4.13 SEM micrographs of dry Acryl EZE powder coated piroxicam
pellets curing for 120 min at different temperatures:
(A) 30 ◦C, (B) 40 ◦C, (C) 50 ◦C

The effect of curing time and temperature on the film formation was examined by the
scanning electron microscopy (SEM). As shown in Figure 4.12, there was slight film
formation at the start of curing due to the low glass transition temperature of Eudragit®
EPO and relatively high content of plasticizers in the initial coating powder adhesion
stage (Figure 4.12 A), but some of the deposited particles are still clearly visible on the
surface of the pellet. After curing for 60 min (Figure 4.12 B), a rough film is formed
though there are some clear boundaries in the film. When curing time is increased to 120
min (Figure 4.12 C), boundaries between particles disappeared and the film became
uniform and smooth. Figure 4.13 provides similar results with different curing
temperatures (30, 40, and 50 ◦C). By increasing the curing temperature from 30 to 40 and
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50 ◦C, the boundaries between particles become less and less and film tends to be more
uniform. As the glass transition temperature of Acryl EZE is much higher than Eudragit®
EPO’s (Figure 4.9 A&C), the film formation of Acryl EZE is harder than Eudragit® EPO
under the same coating conditions (Figure 4.12 and Figure 4.13).

4.4 Immediate release coated with Eudragit® EPO
Immediate drug release leads to a rapid dissolution of the drug after oral administration,
which can quickly release the drug to into the human body through the GI tract, making
the drug effective to the site immediately. One of the most common reasons for the
coating of immediate drug release solid dosage forms is taste masking. Among the
common used immediate release coating materials, Eudragit® EPO has a good
performance on taste masking. Furthermore, Eudragit® EPO is able to dissolve in gastric
solutions up to pH 5.5 [16]. This implies that it is insoluble in the saliva, but will dissolve
in the stomach rapidly.
Table 4.4 Coating formulation for immediate release with Eudragit® EPO
Ingredient

Composition (wt/wt, %)

Eudragit® EPO

20.0

Talc

79.0

Colloidal silicon dioxide

0.5

Pigment

0.5

Table 4.4 gives the coating formulation for immediate release with Eudragit® EPO. Talc
powder was added into the coating formulation to prevent sticky coating film. In the
preliminary experiments we found that it was very easy to get sticky coating film if the
talc powder was not enough. Consequently, the ratio of talc powder was increased to 79%
of the total coating formulation.
In order to investigate the influence of coating level on the drug release profile from
Eudragit® EPO coated piroxicam pellets, those pellets were coated with two coating
levels (the lower coating level is 8.28 % and the relatively higher coating level is 19.86
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%). The surface morphology of powder coated pellets with two different coating levels
were observed by SEM, the results are shown in Figure 4.14. After the coating powder
adhesion, pellets with both of the two coating levels were cured under 50 ◦C for 120 min.
As shown in Figure 4.14, all the deposited coating particles disappeared and a continuous
and uniform coating film was formed for both coating levels, indicating that variations in
coating level didn’t contribute to the difference of surface morphology under 50 ◦C curing
for 120 min.

Figure 4.14 SEM micrographs of Eudragit® EPO coated piroxicam pellets
curing at 50 ◦C, 120 min with different coating level: (A) 8.28%, (B) 19.86%
The drug release profiles from dry powder coated pellets with different coating materials
were investigated through the dissolution tests. For the pellets coated by the Eudragit®
EPO (Figure 4.15), drug release was completed within one hour and variations in coating
level had no significant effect on drug release. This is because Eudragit® EPO is soluble
in medium at a pH below 5.5.
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Figure 4.15 Drug release profile from powder coated pellets
with Eudragit® EPO

4.5 Sustained release coated with Eudragit® RS/RL
Sustained drug release could be achieved by coating the solid dosage forms with certain
coating materials, allowing drug to release over an extended period of time to achieve
prolonged therapeutic effect after oral administration. Eudragit® RL and Eudragit® RS are
two commonly used coating materials for sustained release coating, both of which contain
ethyl acrylate, methyl methacrylate and a small amount of methacrylic acid ester with
quaternary ammonium groups (trimethyl-ammonioethyl methacrylate chloride) that
function as salts to assure the permeability of the film.
Table 4.5 gives the coating formulation for sustained release with Eudragit® RS/RL.
Three different coating formulations were designed with different Eudragit® RS/RL ratio
in order to investigate its influence on the drug release rate.
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Table 4.5 Coating formulation for sustained release
with Eudragit® RS and Eudragit® RL
Ingredient (% w/w)
Formulation

Eudragit® RS

Eudragit® RL

A

53.33%

26.67%

B

40.00%

40.00%

C

26.67%

53.33%

Talc

SiO2, Pigment

19.00%

0.5%, 0.5%

4.5.1 Coating level
Similar with immediate release coating, the influence of coating level on the surface
morphology and drug release profiles were investigated by coating the piroxicame pellets
with three different coating levels, which are 13.8 %,17.9 % and 23.5 %. Results are
shown as the following figures.
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Figure 4.16 SEM micrographs of Eudragit® RS/RL (1:1) coated pellets curing
at 50 ◦C, 120 min with different coating levels: (A) 13.8%, (B) 17.9%, (C)
23.5%, (D) surface morphology of coating level 13.8% pellets
Figure 4.16 shows the surface morphology of Eudragit® RL and Eudragit® RS coated
pellets with three different coating levels. Obviously the variations of coating levels
contribute to the difference of the surface morphology. With the increase of the coating
level, the surface of the coating film became more uniform. Specifically, the surface of
the lower coating levels (13.8 % and 17.9 %) coated pellets still exhibited some pores,
indicating a non-uniform coating film. This might be caused by the less amount of
coating materials, which was not enough to form a thick and dense coating film.
Increasing the coating level (with coating level of 23.5 %) could easily overcome this
phenomenon. Pellets with the highest coating level have the smoothest and most uniform
coating film.
The SEM micrograph of the cross section area of powder coated pellets with the coating
level of 17.9 % and 23.5 % is shown as Figure 4.17. The powder coated piroxicam pellets
were covered by a continuous coating film.
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Figure 4.17 SEM micrographs on the cross-section area of Eudragit® RS/RL
(1:1) coated pellets curing at 50 ◦C for 120 min
(A: coating level=17.9%, B: coating level=23.5%)
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Figure 4.18 Drug release profile from powder coated pellets
with Eudragit® RS/RL at different coating levels
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Coating level not only has an influence on the surface morphology of the coating film,
but also could have a big impact on the drug release from the powder coated pellets. Drug
release profiles from Eudragit® RL/RS (1:1) coated pellets cured under 50 ◦C for 120 min
are shown in Figure 4.18. Compared to the immediate release coating, the drug release
from Eudragit® RL/RS coated pellets was extended to more than 10 hours, indicating that
sustained drug release has been achieved. The difference of coating level contributed
significantly to the variability of drug release rate. For the pellets with a coating level of
13.8%, drug release was finished within 10 hours. And when increasing the coating level
to 17.9%, the cumulative release was 80% after 12 hours. When further increasing the
coating level to 23.5%, only 30% of the drug came out from the pellets after 12 hours.

4.5.2 Eudragit® RS /Eudragit® RL ratio
The difference between Eudragit® RS and Eudragit® RL is that they have different amount
of quaternary ammonium groups, consequently having a different permeability of coating
film. Since Eudragit® RL has double content of quaternary ammonium groups as
Eudragit® RS has, the coating film of Eudragit® RL would have higher permeability. As a
result, it can be easily predicted that drug release rate from Eudragit® RL coated pellets
would be faster than from Eudragit® RS coated pellets. A desirable drug release rate
could be achieved by adjusting the ratio of Eudragit® RS and Eudragit® RL in the coating
formulation. In order to investigate the influence of the ratio of Eudragit® RS/ Eudragit®
RL, three different coating formulations with different ratio of Eudragit® RS/RL (1:2, 1:1,
2:1, mass ratio) under two different coating levels were developed and coated onto the
piroxicam pellets.
Figure 4.19 shows the results of drug release profiles from powder coated pellets with a
coating level of 13.8 % at different Eudragit® RS/ RL ratios. With the increase of the
Eudragit® RS ratio in the coating formulation, drug release rate became slower and drug
release completed within 6, 10 and 12 hours for the Eudragit® RS/ RL ratio of 1:2, 1:1
and 2:1, respectively. This could be explained by less quaternary ammonium groups that
Eudragit® RS has so as to have less permeability of the coating film.
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Figure 4.19 Drug release profile from powder coated pellets with Eudragit®
RS/RL at different RS: RL ratios (Coating level: 13.8%)
The effect of Eudragit® RS/RL ratio on drug release profiles could be confirmed by the
results of drug release from powder coated pellets with a higher coating level. Shown as
Figure 4.20, with a same release time period of 12 hours, the drug released 100 %, 75 %
and 53 % for Eudragit® RS/RL ratio of 1:2, 1:1 and 2:1, respectively. Similarly, with a
coating level of 13.8 %, more Eudragit® RS in the coating formulation resulted in a
slower drug release rate.
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Figure 4.20 Drug release profile from powder coated pellets with Eudragit®
RS/RL at different RS: RL ratios (Coating level: 17.9%)

4.6 Delayed release coated with Acryl EZE
Enteric coating could delay the drug release rather than release immediately after oral
administration, eliminating stomach irritation and drug decomposition by the acid and
enzymes [21, 27-34]. The coating materials for delayed drug release are pH dependent
with high acid resistance. One of most commonly used coating materials that could
achieve delayed drug release is Acryl-EZE, containing an effective component Eudragit®
L 100-55. Acryl EZE is fully formulated for an aqueous acrylic enteric coating system for
the application of an enteric film coating to solid dosage forms such as tablets, granules
and beads [35-37]. Earlier studies using Acryl EZE as the coating materials to achieve
drug delayed release focused on the liquid coating method, mainly aqueous coating,
which possesses many limitations that have been discussed in the previous section. The
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present study provides a new method to coat small dosage forms like pellets with Acryl
EZE using a novel electrostatic powder coating technology.
Table 4.6 gives the coating formulation for delayed release with Acryl EZE. Because
Acryl EZE is fully formulated developed for enteric coating of solid dosage forms, only
flowability additives (colloidal silicon dioxide) and pigment were added in the present
coating formulation.
Table 4.6 Coating formulation for delayed release with Acryl EZE
Ingredient

Composition (wt/wt, %)

Acryl EZE

99.0

Colloidal silicon dioxide

0.5

Pigment

0.5

In order to investigate the surface morphology of Acryl EZE coated pellets with different
coating levels, scanning electron microscope (SEM) micrographs were employed in the
present study. As shown in Figure 4.21, the coating films for both coating levels (10.83 %
and 26.22 %) are relatively uniform and continuous with few boundaries and porous. The
variations of the coating level didn’t contribute to the difference of surface morphology of
Acryl EZE powder coated pellets cured at 50 ◦C for 120 min.
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Figure 4.21 SEM micrographs of Acryl EZE powder coated pellets curing at
50 ◦C, 120 min (A) Coating level of 10.83 %, (B) Coating level of 26.22 %
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Figure 4.22 Drug release profile from powder coated pellets with Acryl EZE
And for the drug release rate from Acryl EZE powder coated pellets (Figure 4.22), drug
didn’t release or released very little within the first 2 hours in 0.1 N HCl solutions and
then came out immediately after adjusting the pH from 1.2 to 6.8 by adding Na3PO4
solution and the difference of coating level didn’t change the drug release profiles. In
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order to achieve sufficient acid resistance, 3-4 mg/cm2 polymer weight gain is commonly
applied to the dosage forms with organic coating [38]. For the dry powder coating
technology in this study, a coating level of 26.22% (8.34 mg/cm2) was firstly obtained to
meet the requirement of acid resistance and then decreased the coating level to 10.83%
(3.45 mg/cm2), which is as low as liquid coating’s but with a shorter processing time and
a lower overall cost.

4.7 Stability of powder coated pellets
The drug release profiles of dry powder coated pellets (cured at 50◦C for 120 min) with
three different coating materials before and after storage are shown in Figure 4.23, Figure
4.24 and Figure 4.25. There was no significant difference in the drug release profiles, and
all the similarity factor f2 values between release profiles of piroxicam from powder
coated pellets with three different coating materials are larger than 50, which means the
dry powder coated pellets exhibited excellent stability over 1 month at 40◦C /75% RH.
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Figure 4.23 Drug release profile from powder coated pellets with Eudragit®
EPO at 50 ◦C, 120 min (*: after storage at 40 ◦C, 75% RH for 1 month)

Table 4.7 Similarity factor f2 values between release profiles of piroxicam
from Eudragit® EPO coated pellets before and after storage
Coating level

f2

8.28 %

80.16

19.86 %

84.14
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Figure 4.24 Drug release profile from powder coated pellets with Eudragit®
RL/RS at 50 ◦C, 120 min (*: after storage at 40 ◦C, 75% RH for 1 month)

Table 4.8 Similarity factor f2 values between release profiles of piroxicam
from Eudragit® RL/RS coated pellets before and after storage
Coating level

f2

13.8%

79.49

17.9%

81.01

23.5%

84.92
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Figure 4.25 Drug release profile from powder coated pellets with Acryl EZE
at 50 ◦C, 120 min (*: after storage at 40 ◦C, 75% RH for 1 month)

Table 4.9 Similarity factor f2 values between release profiles of piroxicam
from Acryl EZE coated pellets before and after storage
Coating level

f2

10.83%

81.09

26.22%

78.24
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4.8 Conclusion

Figure 4.26 Pictures of electrostatic powder coated pellets
(A): Eudragit® EPO, (B): Eudragit® RS/RL, (C): Acryl EZE
In the present study, small solid dosage forms (pellets) were successfully coated with a
traditional pan coating system using a novel electrostatic dry powder coating technology.
Three different coating formulations were developed for the pellet coating to achieve
immediate release, sustained release and delayed release.
The particle size of the coating powder was first reduced and the flowability of those fine
coating powders was improved by adding 0.5% nano additives (colloidal silicon dioxide)
in the coating formulation.
Different liquid plasticizers were used for different coating materials to reduce the glass
transition temperature of coating polymers to allow film formation at a low temperature
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and also served to decrease the electrical resistivity of the drug pellets to allow the
deposition of coating powder on the surface of pellets.
The results of SEM illustrated that better film could be formed with longer curing time
and/ or higher curing temperature. Dissolution tests indicated that drug release profiles
from those powder coated pellets could be altered as immediate release, sustained release
and delayed release with suitable coating formulations. For immediate release and
delayed release, coating level didn’t contribute to the difference of surface morphology as
well as drug release profiles. However, for sustained release, coating level had a big
impact on the drug release profiles and also the surface morphology. Higher coating level
led to a better and more uniform coating level and resulted in a slower drug release rate.
For Eudragit® RL/RS powder coated pellets, the drug release rate could also be influenced
by the ratio of Eudragit® RL/RS in the coating formulation, more Eudragit® RL led to a
faster drug release rate due to the high permeability of the coating film formed by
Eudragit® RL.
The pellets coated by the developed novel electrostatic dry powder coating technology
exhibited an excellent stability with 1 month at 40◦C /75% RH.
Compared with other coating methods for small solid dosage forms, the present coating
technology has many advantages. First of all, the usage of fluidized hot air could be
avoided in the present coating technology, which could dramatically cut the overall cost
compared to the organic as well as aqueous coating method. Also the coating procedure
could be shortened to less than 120 minutes, which is much faster than other dry powder
coating technologies. In addition, the equipment and apparatus employed in this coating
technology are similar with the ones in the present pharmaceutical industry, which is
much more acceptable for the pharmaceutical companies when adapting the liquid
coating methods. In a word, the present dry powder coating technology is well developed
and promising in pharmaceutical coating industry.
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5

Osmotic Controlled Release- Elementary Tablet Coating

A novel electrostatic powder coating was applied to coat elementary osmotic pump
tablets with powdered cellulose acetate (CA) using a pan coater system. Both water
soluble drug (salbutamol sulfate) and water insoluble drug (ibuprofen) were use as the
model drugs. Three steps including preheating, powder adhesion and curing were
performed to achieve a smooth and uniform coating film which was used as the
semipermeable membrane of the osmotic pump tablets. Triethyl citrate (TEC) was found
to be an effective liquid plasticizer for elementary osmotic pump tablet coating, not only
reducing the glass transition temperature of coating polymer (CA), but also increasing the
electrical conductivity of those elementary osmotic pump tablets, both of which lead to an
enhanced coating powder adhesion and film formation. SEM indicated that the uniformity
of coating film varied significantly with the difference of curing time and temperature.
The drug release profiles showed that a zero-order drug release was achieved and drug
release could be controlled over a desirable period of time, such as 12 hours or 24 hours.
Also the drug release rate was influenced significantly by the coating level while was
independent of the pH value of release media, agitation speed and the orifice diameter.

5.1 Introduction
Conventional drug delivery is usually administered two or three times a day, which
cannot control drug release rate, leading to large fluctuation in drug plasma concentration.
It won’t be effective when the drug plasma concentration is lower than minimum
effective concentration (MEC), while it will cause side effect when close to or higher
than, the maximum safe concentration (MSC). Constant plasma level can offer a
therapeutic advantage for many drugs in terms of both efficacy and tolerance of the
treatment. Sustained release, some others also refer it as “controlled release”, is designed
to release a drug at a slower rate in order to maintain a more desirable drug concentration
for a longer period of time. However, it still cannot achieve a constant drug concentration
over a specific period of time. Consequently it cannot avoid side effects.
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Figure 5.1 Drug plasma concentration profiles
for different drug delivery systems
Osmotic drug delivery system, which is the only drug delivery system that could achieve
a constant drug plasma concentration over a specific period of time, is the most promising
drug delivery system. Since it was first reported almost 60 years ago [1], osmotic drug
delivery system (ODDS) has gained tremendous attention due to its excellent ability of
controlling the drug release rate over a long period of time. As shown in Figure 5.2, the
numbers of articles and patents that relate to ODDS has significantly increased during the
past 20 years, particularly the past 10 years. A great summary of these kinds of work can
be seen in an excellent review by Malaterre [2]. A typical osmotic drug delivery system
includes an active pharmaceutical ingredient (API), osmotic agent(s), semipermeable
membrane and drug delivery orifice(s). Upon the osmotic pump tablets contacting with
aqueous media, water diffused into the system and osmotic pressure will be generated
inside, which governs drug release from the delivery orifice at a constant rate. Compared
to other drug delivery systems, ODDS own a set of distinct advantages. First of all, the
drug release rate in this system can be governed only by the osmotic agent, which means
that drug release is independent of the drug’s chemical properties, of the patient’s
physiological factors or concomitant food intake [2]. Also, the design of the osmotic
delivery system is simple and easy to operate.
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Figure 5.2 Publications related to ODDS
(source: ISI web of Sciences, Pubmed and EMBASE; micropatent,
espacenet; end date, March 2016)
As discussed in section 2.2.3, the drug release from ODDS is controlled by an osmotic
pressure generated inside the ODDS core. As one of the fundamental phenomena in
biology, osmosis is the movement of a solvent across a semipermeable membrane toward
a higher concentration of solute. An osmotic flow is generated when two solutions of
different solute concentrations are separated by a semi-permeable membrane rejecting the
solute on the one hand, but allowing passage of the solvent molecules on the other hand
[3].
The first idea of ODDS came from Rose and Nelson, they proposed an osmotic dispenser
[4] that is capable of delivering drug solution with a relatively constant rate. Later in
1970s, Takero Higuchi and Felix Theeuwes improved the osmotic dispenser [5, 6] and
developed an elementary osmotic pump tablet [7], cooperated with the Alza Corporation,
which is the first practical example of an osmotic pump based drug release system [2].
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Figure 5.3 Schematic diagram of elementary osmotic pump
As shown in Figure 5.3, an elementary osmotic pump consists of the drug, osmotic agent
and semipermeable membrane. Also there is a drug delivery orifice on the semipermeable
membrane, which could be obtained by mechanical drilling or laser drilling methods.
When these elementary ODDS were upon the release media, water would immediately
diffuse into the core through the semipermeable membrane, dissolving the osmotic agents
and generating osmotic pressure. Then the drug was dissolved and pushed out by the
osmotic pressure through the delivery orifice.
Currently, only solvent coating process can be applied to achieve the semipermeable
membrane of the ODDS because coating polymers that can be formed to a semipermeable
membrane have a very high Tg (184.39 ◦C for cellulose acetate), which is too high for the
aqueous coating. The use of organic solvent suffers from the environmental,
toxicological, cost- and safety-related issues. Also the concentration of the coating
solution cannot be too high due to the limitation of viscosity, leading to low coating
efficiency. In addition, the organic solvent needs to be vaporized in the coating process,
which is energy and time consuming and could increase the overall cost.
Recently many efforts have been made to develop solventless coating technologies
including compression coating, hot-melt coating, supercritical fluid coating and
photocuring coating, which have been summarized in the following reviews [8-10], but
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none of them has been applied to form the semipermeable membrane of the ODDS. Also
it is difficult to apply those technologies in the pharmaceutical industry owing to their
own limitations.
The concept of electrostatic powder coating came out in the 1950s in USA, and now it is
widely used in the metal and wood finishing industries. In this coating process, dry
powders are firstly charged by an electrostatic spray gun and then move and adhere to the
grounded substrate surface. Then the grounded substrate with deposited coating powder is
put in an oven and cured for a certain period of time under high temperature to allow film
formation. Compared to other solventless coating technologies, electrostatic powder
coating has many distinctive advantages such as short coating process, highly valued for
energy savings, and significantly reduced of overall operation cost. Most importantly,
electrostatic powder coating can enhance the coating powder adhesion so as to increase
the coating efficiency dramatically and also can well control the coating powder feeding
and achieve a much more uniform coating film both on coating thickness and surface
morphology.
The objective of the present study is to utilize electrostatic powder coating to form the
semipermeable membrane of the elementary ODDS with powdered cellulose acetate
(CA), and to characterize the coating powder adhesion and film formation and their
influence factors in the electrostatic coating process. Both water soluble and water
insoluble drugs would be used as the model drug so as to analyze the drug release from
electrostatic powder coated elementary ODDS.
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Figure 5.4 Schematic diagram of elementary ODDS study

5.2 Materials and methods
5.2.1 Materials
Salbutamol sulfate and ibuprofen were provided by Nanjing Pharmaceutical Factory
(Nanjing, China) and Patheon (Mississauga, Ontario, Canada), respectively. Cellulose
Acetate was donated by the Eastman Chemical Company (Kingsport, Tennessee, USA).
Plasdone K-29/32 was purchased from ISP technologies, INC. Sodium Chloride was
provided by EMD Chemicals Inc. (Gibbstown, NJ, United States). Avicel®
Microcrystalline cellulose PH-102 was purchased from FMC Corporation (Philadelphia,
Pennsylvania, United States) and Magnesium Stearate was purchased from Alfa Aesar
(Haverhill, Massachusetts, USA). Placebo tablets were obtained from Patheon

132

(Mississauga, Ontario, Canada). Triethyl citrate (TEC) was purchased from Caledon
Laboratories Ltd. (Georgetown, Ontario, Canada). Colloidal silicon dioxide (AEROSIL®
200 Pharma) was donated by Evonik Degussa Corporation (Essen, North RhineWestphalia, Germany). Talc was purchased from Mallinickrodt Baker Inc. (Center
Valley, Pennsylvania, United States).

5.2.2 Preparation of the osmotic pump tablets
The component of the tablets core includes drug (Salbutamol Sulfate/ ibuprofen), sodium
chloride, microcrystalline cellulose, PVP and magnesium stearate. The formulation of the
osmotic pump tablets core can be seen in Table 5.1.
Table 5.1 Formulation of osmotic pump tablets core
Ingredient

% w/w

Salbutamol sulfate / Ibuprofen

20%

Sodium chloride

30%

Microcrystalline cellulose PH102

43%

PVP

6.5%

Magnesium stearate

0.5%

Those components were mixed using a granulator (Mechanomill MM-20N, OKADA
SEIKO Co. Ltd, Iwate, Japan) with a speed of 300 rpm for 6 min, followed by adding
magnesium stearate and mixing for another 3 min with same speed. The ready
formulation was then compressed into tablets by using a tablet machine with one punch
(5 mm in diameter) (Shanghai Tianxiang & Chentai Pharmaceutical Machinery Co. Ltd,
Shanghai, China). The weight for each tablet is 180±2 mg.

5.2.3 Particle size reduction and analysis
Particle size reduction of cellulose acetate was complicated by a combination use of a jet
mill and blade grind mill, prior to use. Particle size of the coating materials was
confirmed by a particle size analyzer (TSI Corporation, Model 3603, Shoreview, MN,
USA). The particle size at 50 % of total weight fraction was used as the average particle
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size. The average particle size of cellulose acetate and talc powder was 26.7 and 28.9 μm,
respectively.
Table 5.2 Average particle size of coating materials
Materials

Average particle size (µm)

Cellulose acetate

26.7

Talc

28.9

5.2.4 Angle of repose (AOR)
Measurement of the angle of repose was carried out to characterize the flowability of
coating powers before and after the size reduction and also to investigate the influence of
nano sized additives on the flowability of CA powders by using a PT-N Hosokawa
Powder Characteristic Tester, following the standardized testing procedures of ASTM
D6369-08 (ASTM Standard D6369-08, 1999).

5.2.5 Differential scanning calorimetry (DSC)
The glass transition temperature of cellulose acetate and mixture of coating material and
plasticizer (TEC) with different ratios were confirmed by differential scanning
calorimetry (DSC) analysis (Mettler Toledo, DSC822, Mississauga, Canada). The
samples (8-12mg) were tested at a heating rate of 2 ◦C /min over the temperature range of
20 to 200 ◦C under nitrogen atmosphere.

5.2.6 Electrical resistivity test
A batch of 20 g of osmotic pump tablets and 60 g of placebo tablets were loaded in the
pan coater and preheated for a certain time. Then liquid plasticizer (0.6 g/min) was
sprayed onto the surface of the tablets. At different spraying points (0, 1, 2, 3 and 4min),
three tablets were taken out and used as sample to test the electrical resistivity using an
electrometer (Keithley 610B, Keithley instruments, Inc., USA). These tests were operated
in duplicate.
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5.2.7 Powder coating process
E

B

A

D

C

Ground

Figure 5.5 Schematic diagram of the electrostatic powder coating system
(A) Liquid plasticizer, (B) liquid plasticizer metering pump,
(C) coating pan, (D) electrostatic spray gun, (E) powder feeder
A laboratory scale electrostatic dry powder pan coater system was used to complete the
powder coating process. This coating system includes a stainless steel pan of 14 cm
diameter and four aluminum baffles inside the wall to promote a better tumbling
movement of the tablets, an electrostatic spray gun, a powder feeder and a liquid spray
nozzle (Figure 5.5).
The coating process includes three steps. First is preheating. Before coating, placebo
tablets and osmotic pump tablets were mixed together and loaded into the coating pan and
then preheated for 20 min at certain temperature. Second is the powder adhesion. In this
process, liquid plasticizer and powder were fed into the coating pan alternately. Firstly,
the liquid plasticizer was sprayed onto the surface of the tablets for a predetermined time
period. The flowrate of liquid plasticizer can be controlled by a liquid metering pump
(Fluid Metering Inc., USA). Then a predetermined amount of coating powders was fed
and sprayed on the surface of the tablets immediately after the feeding of liquid
plasticizer using an electrostatic spray gun (Nordson Corporation, USA). The last step is
curing and film forming. After the feeding of liquid plasticizer and coating powder, the
tablets were further cured for a predetermined time to allow film formation. In this
process, curing time and temperature are two critical parameters. Table 5.4 gives the
coating process parameters.
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The coating level (%) of the tablets could be obtained from the weight gain of coated
tablets divided by the weight of uncoated tablets. Placebo tablets were used to maintain
the volume of substrates and conserve osmotic pump tablets at the same time.
The coating powder contains CA, talc powder, nano silica and pigment. The formulation
can be seen in Table 5.3.
Table 5.3 Formulation of the coating powder
Ingredient

% w/w

Cellulose acetate

80%

Talc powder

19%

Pigment

0.5%

SiO2 (Nano)

0.5%

Table 5.4 Coating process parameters of elementary ODDS coating
Tablet loading

60 g

Charging voltage

0 kV, 20 kV, 40 kV, 60 kV, 70 kV

Liquid plasticizer flow rate

0.8 g/min

Liquid plasticizer spray time

0 min, 1 min, 2 min, 3 min and 4 min

Atomizing air pressure

300-320 kPa

Nozzle diameter

0.25 mm

Powder feed rate

3 g/min

Powder feed time

2 min

Pan speed during coating (rpm)

28-32

Pan speed during curing (rpm)

10-15

Curing temperature

40 ◦C, 50 ◦C and 60 ◦C

Curing time interval

0 min, 60 min and 120 min
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5.2.8 Scanning electron micrographs
Scanning electron microscopy (SEM) was used to investigate the surface morphology of
the dry powder coated tablets with different coating conditions. Under an argon
atmosphere, samples were firstly sputter coated with gold for 120 s using Emitech K550
sputter coater (Emitech Ltd., Ashford, UK), and then were observed with a scanning
electron microscope at 5.0 kV ×3.0k (S-2600N Hitachi, Ontario, Canada). We also
observed the cross-sectional part the film, by doing so the thickness of the film with
different coating levels could be evaluated.

5.2.9 Creation of drug delivery orifice
There are several methods to create a delivery orifice in the osmotic drug delivery system
including mechanical drill [11], laser drilling [12, 13], indentation [14, 15]. In this study,
we use a mechanical drill method to create the drug delivery orifice with different
diameters (200 µm, 500 µm and 900 µm).

5.2.10

Calibration curves of salbutamol sulfate and ibuprofen

The calibration curve of salbutamol sulfate was already obtained in Chapter 3, which can
be seen in Figure 3.4.
For ibuprofen, a standard stock solution with a concentration of 200 ppm (μg/ml) was
prepared by dissolving ibuprofen in PBS solution with a pH value of 7.2. And then it was
diluted with pH 7.2 PBS solution separately to obtain the solution with a concentration of
12.5, 25, 50, 80, 100, 160 respectively. A 8453 UV-Visible Spectrophotometer (Agilent
Technologies, Mississauga, Canada) was used to find the maximum absorbance, which is
at 222 nm. Then the absorbance was obtained at 222 nm against pH 7.2 PBS solution as
blank. The calibration curve was prepared by plotting absorbance versus concentration
(ppm) of ibuprofen.
The calibration curve of ibuprofen at the wavelength of 222 nm is shown as Figure 5.6.
This curve would be used to calculate the unknown concentrations of ibuprofen released
from electrostatic powder coated elementary ODDS.
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Figure 5.6 Calibration curve of ibuprofen in PBS with a pH 7.2 at 222 nm

5.2.11

Dissolution tests

The release profile of the drug from osmotic pump tablets before and after being coated
with various coating conditions was obtained using the United States Pharmacopeia
(USP) apparatus (Apparatus 2, paddle; Huanghai Rcz-6c2, Shanghai, China). Phosphate
buffer solution with different pH value (1.2, 5.8 and 7.2) was chose as the release media.
The release tests with 6 tablets in 6 vessels with 900 ml release media were performed at
37 ◦C at a certain stirring speed. A 10 ml syringe was used to withdraw samples from
each vessel at predetermined intervals and then fresh medium with equal volume was
injected into the vessels. Samples were assayed using an 8453 UV-Visible
Spectrophotometer (Agilent Technologies, Mississauga, Canada) at a wavelength of 276
nm for salbutamol sulfate and 222 nm for ibuprofen.
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5.2.12

Stability test

Electrostatic dry powder coated elementary ODDS (both salbutamol sulfate and
ibuprofen) cured at 60 ◦C for 120 minutes were placed at in HDPE vials (75 mL) and
sealed with aluminum film and then were stored at 40 ◦C /75% RH for 1 month. The
dissolution tests of those elementary ODDS before and after storage were examined.

5.2.13

Statistical analysis

Similar with Chapter 3, the experimental results in this chapter were also expressed as
mean ± Standard Deviation (S.D.) values. While the “similarity factor” f2 was not only
used to compare the drug release profiles before and after storage in the stability tests, but
also was used to compare the drug release profiles with different orifice diameters, pH
values and agitation speed. The following equation could be used to calculate the value of
“similarity factor” f2.
0.5


 1 n

2
f 2  50 log 1   Rt  Tt    100



 n t 1


(5.1)

In this equation, n is the total number of sampling times, Rt and Tt is the accumulated
drug release percentage at time point t for the reference and test products, respectively.
The value of f2 is between 0 to 100, if f2 is larger than 50 (between 50 to 100), these two
release profiles were considered to be similar. If f2 is close to 100, the two release profiles
were considered as identical.

5.3 Coating and film formation
5.3.1 The plasticizing effect of the liquid plasticizer
Plasticizer is widely used in pharmaceutical industry due to its excellent ability to
increase flexibility and to reduce the brittleness, glass transition temperature (Tg) of the
polymers [16]. As reported in the previous literature, the film formation in dry powder
coating technology is achieved through the deformation and viscous flow of polymer
particles when the temperature is below the glass transition temperature (Tg) [17].
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However, some polymers, which are widely used as the functional coating materials in
pharmaceutical industry, have a relatively high Tg. For instance, cellulose acetate is
commonly used as the water-insoluble semipermeable membrane of osmotic dosage
forms, while its glass transition temperature (EastmanTM Cellulose Acetate 398-10) is
around 184◦C. In order to apply this material in the electrostatic dry powder coating
process, liquid plasticizer is necessary to decrease the Tg under a safe range for the drugs.
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Figure 5.7 Plasticizing effect of liquid plasticizers on the coating powder
Tg of pure CA and the mixture of CA and liquid plasticizers of TEC with different ratio
were investigated by DSC. The plasticizing effect of the liquid plasticizer can be seen in
the Figure 5.7. The Tg of pure CA was 184 ◦C. With the increase of plasticizers/CA ratio,
the Tg of CA decreased dramatically. When the ratio increased to 0.8, the Tg of CA
decreased to 49◦C, which was suitable for the electrostatic dry powder coating process.

5.3.2 Flowability improvement
Nano sized particles of colloidal silicon dioxide (AEROSIL® 200 Pharma) were used as
the additives to improve the flowability of the micronized cellulose acetate powders.

140

Those nano particles were added and blended into the micronized coating powder to form
a modified sample, which were further characterized to obtain the angle of repose.
Table 5.5 gives the particle size and angle of repose before and after size reduction of the
cellulose acetate powders. The angle of repose of the CA powders was significantly
reduced by adding nano sized colloidal silicon dioxide, indicating an improvement of
flowability of the coating powders. This table also tells that 0.5% additive based on the
weight of coating powder gives the lowest angle repose, which would be used in the
following coating formulations.

Table 5.5 Particle size and angle of repose of cellulose acetate powder
before and after adding nano additives
Coating material
Cellulose acetate

Angle of repose (°)

Particle
size (µm) 0% additive

0.5% additive 1% additive

1.5% additive

26.7

40.94±0.64

41.08±0.77

48.4±1.11

41.02±0.68

5.3.3 Powder adhesion
In the electrostatic spray powder coating process, the electrical field is used to assist the
powder adhesion. With an electrostatic spray corona charging gun, the coating powder
could be firstly negatively charged and then followed by the electrical field between the
electrostatic gun and the grounded coating pan to the direction of the electrical force and
then deposited onto the surface of the rotated osmotic pump tablets. Apparently the
osmotic pump tablets should have a low enough electrical resistivity (below 1×109 Ωm)
[17] to allow the above process happen. Unfortunately, the electrical resistivity of these
osmotic pump tablets was extremely high and larger than 1×1015 Ωm.
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Figure 5.8 The effect of liquid plasticizer
on the electrical resistivity of osmotic pump tablets
(Liquid plasticizer: TEC, flow rate: 0.5 g/min, temperature: 60◦C)
In this study, liquid plasticizer was sprayed onto the surface of the tablets to decrease the
electrical resistivity. Figure 5.8 showed the relationship between the amount of liquid
plasticizer and the electrical resistivity of the tablets. From this figure, we can see that
without liquid plasticizer, the electrical resistivity of these osmotic pump tablets was
larger than 1×1015 Ωm. While with the increase of the liquid plasticizer sprayed, the
electrical resistivity decreased dramatically and when the spray time increased to 4 min,
the electrical resistivity decreased to less than 108 Ωm, which could be very suitable for
the electrostatic dry powder coating process.
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Figure 5.9 The effect of charging voltage
on the coating powder adhesion rate
Charging voltage of the electrostatic gun and the liquid plasticizer are two critical factors
that could have a big influence on the coating powder adhesion during the electrostatic
powder coating process. The influence of charging voltage on the coating powder
adhesion rate is shown in Figure 5.9. When the charging voltage was increased from 0 to
60 kV, coating powder adhesion rate was increased from 58.8% to 90.1%. While further
increasing the charging voltage to 70 kV, the coating powder adhesion rate didn’t
increase any more. As we discussed before, the coating powder adhesion obtained at 0 V
reflected the particle deposition caused by sprayed liquid plasticizer. Spraying liquid
plasticizer onto the surface of the tablets could generate capillary force between the
interface of liquid plasticizer and coating powders, enhancing and promoting the coating
powder adhesion. Higher coating powder adhesion rate obtained with increasing the
charging voltage to 60 kV indicates that the coating powder adhesion was enhanced by
the electrical field between the tip of the electrostatic gun and the coating pan. The
coating powder adhesion rate was not increased after the electrical charge reached a
certain value. This can be explained by the increased cumulative charge of the coating
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layer and back ionization caused by the higher charging voltage, which could reduce the
powder deposition.
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Figure 5.10 The effect of liquid plasticizer
on the coating powder adhesion rate
The other influence factor that could have an impact on the coating powder adhesion is
the liquid plasticizer sprayed on to the surface of the solid dosage forms. As shown in
Figure 5.10, when there was no liquid plasticizer sprayed, the coating powder adhesion
rate was only 38.7 % with a charging voltage of 60 kV, which is too low to produce a
good coating film. When increasing the liquid plasticizer spray time from 0 min to 2 min,
the coating powder adhesion rate significantly increased from 38.7 % to 82.7 %. Further
increase of the liquid plasticizer spray time to 3 and 4 min led to a slight increase of the
coating powder adhesion rate to 90.1 % and 93.9 %, respectively. However, surplus
liquid plasticizer (spraying time was 4 min) would lead to a sticky coating film although
the coating powder adhesion rate was increased. So, when the liquid plasticizer (TEC)
flowrate is 0.5 g/min, the spray time could be optimized as 3 min.
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From Figure 5.8, Figure 5.9 and Figure 5.10 it could be concluded that in the electrostatic
powder coating process, the coating powder adhesion could be influenced by both the
charging voltage of the electrostatic spray gun and the liquid plasticizer. For the charging
voltage of electrostatic spray gun, high voltage leads to back ionization while low voltage
couldn’t provide enough powder to obtain high powder adhesion rate. From the
experimental results, the charging voltage could be optimized as 60 kV according to
Figure 5.10. While for the liquid plasticizer, when the flow rate is 0.5 g/min, the spray
time needs to be 2 min or more than 2 min to guarantee that the electrical resistivity of
those elementary ODDS is close to or below 109 Ωm so as to achieve a high coating
powder adhesion rate. However, sticky film was observed when the spray time was
increased to 4 min. Consequently, the liquid plasticizer spray time could be optimized as
3 min with a flowrate of 0.5 g/min.

5.3.4 Film formation
The deformation and viscous flow of deposited polymer particles at the temperature
higher than the glass transition temperature (Tg) of the polymer result in the film
formation, which was called dry sintering theory in the previous literature [17]. In dry
powder coating process, after the powder adhesion, curing is a critical step for the
deposited polymer particles to coalesce together to form a uniform film.
An attempt was made here to disclose effects of curing time on the film formation of
polymer particles by using scanning electron micrographs. The SEM micrographs of the
coated osmotic pump tablets at different curing time intervals are shown in Figure 5.11.
From the figure we can conclude that a longer curing time allowed the deposited polymer
particles to form a better and smoother coating film. Before the curing started (Figure
5.11-A), we can clearly see the deposited polymer particles on the surface of the tablets
with a small portion of coalescence due to the high content of TEC in the powder
adhesion stage. With the curing time increased to 60 min (Figure 5.11-B), most of the
deposited particles disappeared and a larger extent of film was formed. However, we can
still see some uncured particles and the film was relatively rough. When the curing time
became 120 min (Figure 5.11-C), the film was smoother and more uniform in comparison
with those cured in 60 min.
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Figure 5.11 SEM micrographs of CA powder coated elementary ODDS
curing at 60 ◦C for different time intervals: (A) 0 min, (B) 60 min, (C) 120 min
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Figure 5.12 SEM micrographs of CA powder coated elementary ODDS
curing for 120 min at different temperatures: (A) 40 ◦C, (B) 50 ◦C, (C) 60 ◦C
Similar results were seen in Figure 5.12 with different curing temperatures. When the
curing temperature was increased from 40 to 50 and 60 ◦C, coating film became more and
more uniform. When the curing temperature was low (40 ◦C), the film formed after 120
min curing was very rough and not continuous. This is because the curing temperature is
still lower than the glass transition temperature of the coating polymer, making it difficult
for the movement of the polymer chains and segments of the chains. When the curing
temperature was increased to 50 ◦C, the coating film was still not continuous with obvious
pores and boundaries. When the curing temperature was further increased to 60 ◦C, the
coating film became uniform and continuous.
It could be concluded from Figure 5.11and Figure 5.12 that a continuous and uniform
coating film could be achieved after curing for 120 min at 60 ◦C. As shown in Figure
5.13, the coating film is quite smooth and uniform from a bigger view.

147

Figure 5.13 SEM micrographs of CA powder coated elementary ODDS
curing for 120 min at 60 ◦C (Coating level: 3 %)

Figure 5.14 SEM micrographs of cross section area of CA powder coated
elementary ODDS curing for 120 min at 60 ◦C (Coating level: 3 %)
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Figure 5.14 gives a SEM micrograph of cross section area of CA powder coated
elementary ODDS with a coating level of 3 %. The thickness of the coating film is
approximately 80 µm. Figure 5.15 and Figure 5.16 and show the pictures of CA powder
coated elementary ODDS before and after drug release.

Figure 5.15 Pictures of CA powder coated elementary ODDS curing for 120
min at 60 ◦C (Before release; coating level: 6.8%)

Figure 5.16 Pictures of CA powder coated elementary ODDS curing for 120
min at 60 ◦C (After release; coating level: 6.8%)
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5.4 Controlled release of salbutamol sulfate
Salbutamol sulfate (SS) is widely used to treat asthma and chronic bronchitis [18]. It is
absorbed through the gastrointestinal (GI) tract [19, 20] with an immediate release. With
a short elimination half-life (2-4 h), it may not be effective if it is not taken several time a
day. So there is a strong clinical need for a designed delivery system to control the release
of salbutamol sulfate at a desirable rate over a prolonged time period.
The release profiles of salbutamol sulfate from electrostatic dry powder coated
elementary ODDS tablets and its factors including coating level, orifice diameter, pH
value of dissolution media and agitation speed were studied with in vitro dissolution tests.

Orifice diameter: 500 m
pH: 7.2
Agitation speed: 50 r/min
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Figure 5.17 The effect of coating level on the release profiles of salbutamol
sulfate from powder coated elementary ODDS
(Orifice diameter: 500 µm, agitation speed: 50 r/min, pH: 7.2)
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Powder coated elementary ODDS with different coating levels (0%, 3%, 4% and 6.8%)
were used to investigate the effect of coating level on the drug release. As the Figure 5.17
showed, upon the bare tablets contacting with aqueous media, drug released immediately
and completely within 1 h. On the other hand, drug released 100% in 14 h, 80% in 24 h
and 25% in 24 h from the tablets with a coating level of 3%, 4% and 6.8%, respectively.
It was clearly evident that increased coating level resulted in an increase of membrane
thickness which led to reduced water influx and decreased drug release rate.

Table 5.6 Thickness of the coating film
Coating level

Thickness of tablet core, mm (SD)

3%
4%
6.8%

Thickness of coating film, mm (SD)
0.08 (0.01)

3.87 (0.01)

0.10 (0.01)
0.13 (0.02)

Unlike coating level, the size of drug delivery orifice had little effect on the release
profiles with the same coating level and same release conditions. As shown in Figure
5.19, there is no big difference between the release profiles of salbutamol sulfate from
electrostatic powder coated elementary ODDS. And the similarity factor f2 values
between each drug release profiles with different orifice diameter are 80.89, 82.63 and
81.54, all of which are bigger than 50, indicating that those drug release profiles are
similar with each other. In other words, release of salbutamol sulfate from electrostatic
powder coated elementary ODDS is independent with pH values of the release media.
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Figure 5.18 Micrograph of drug delivery orifice of powder coated
elementary ODDS with a diameter of 500 µm
As reported in the previous literature, there was a range for the size of delivery orifice,
which must be larger than a minimum size Amin to minimize hydrostatic pressure inside
the osmotic system for the reason that large hydrostatic pressure may lead to the
deformation of the ODDS, resulting in unpredictable drug delivery. Also it must be
sufficiently smaller than a maximum size Amax to minimize the solute diffusion through
the orifice [21]. Equations provided by Theeuwes [7] can be used to estimate the
minimum size Amin and maximum size Amax.
There are several methods that could be used to create the drug delivery orifice including
mechanical drilling [11], laser drilling [22] and indentation method [14].
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Figure 5.19 The effect of orifice diameter on the release profiles of
salbutamol sulfate from powder coated elementary ODDS
(Coating level: 4%, agitation speed: 50 r/min, pH: 7.2)

Table 5.7 Similarity factor f2 values between release profiles of salbutamol
sulfate from CA powder coated elementary ODDS
with different orifice diameter
f2
Orifice diameter 1&2

80.89

Orifice diameter 1&3

82.63

Orifice diameter 2&3

81.54
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Figure 5.20 The effect of pH value of dissolution media on the release
profiles of salbutamol sulfate from powder coated elementary ODDS
(Coating level: 3%, orifice diameter: 500 µm, agitation speed: 50 r/min)
The difference in pH value of drug release media apparently does not contribute
significantly to the variability in drug release properties, as samples with different pH
value of the release media have been shown to have a similar release profile in Figure
5.20. The similarity factor f2 values between each drug release profile with different pH
value are 83.36, 81.83 and 78.89, all of which are bigger than 50, indicating that those
drug release profiles are similar with each other. In other words, drug release from those
electrostatic powder coated elementary ODDS is independent with the pH value of the
release media.
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Table 5.8 Similarity factor f2 values between release profiles of salbutamol
sulfate from CA powder coated elementary ODDS with different pH values
f2
pH 1.2 & pH 5.8

83.36

pH 1.2 & pH 7.2

81.83

pH 5.8 & pH 7.2

78.89

Like the pH of drug release media, the agitation speed has little influence on the drug
release properties (As shown in Figure 5.21). The similarity factor f2 values between each
drug release profiles with different agitation speed are 79.02, 84.73 and 80.88, all of
which are bigger than 50, indicating that those drug release profiles are similar. So it can
be concluded that drug release from those electrostatic powder coated elementary ODDS
is almost independent of the agitation speed.
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Figure 5.21 The effect of agitation speed on the release profiles of
salbutamol sulfate from powder coated elementary ODDS (Coating level:
3%, orifice diameter: 500 µm, pH: 7.2)

Table 5.9 Similarity factor f2 values between release profiles of salbutamol
sulfate from CA powder coated elementary ODDS
with different agitation speed
f2
50 rpm & 100 rpm

79.02

50 rpm & 150 rpm

84.73

100 rpm & 150 rpm

80.88

5.5 Controlled release of ibuprofen
As an anti-inflammatory drug (NSAID), ibuprofen is widely used for treating pain, fever,
and inflammation [23, 24] with large demand all over the world. Previous studies
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reported that the usual therapeutic concentration of ibuprofen in human blood is around
50 mg/L, and the toxic effect appears above 250 mg/L [25]. If the plasma concentration is
too high, it will cause many problems such as depression of the central nervous system,
respiratory and gastrointestinal problems and acute renal failure [25]. So many drug
delivery systems have been developed to release ibuprofen at a controlled rate over a
desirable time period [26]. Ozdemir and Sahin [11] designed an ODDS for the release of
ibuprofen using organic solvent coating to achieve the semipermeable membrane.
While in the present study, a novel electrostatic powder coating technology was applied
to coat fine powders of cellulose acetate onto ODDS with ibuprofen to form a
semipermeable membrane so as to achieve a controlled release of ibuprofen.

120

Orifice diameter: 500 m;
Agitation speed: 50 r/min;
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Figure 5.22 The effect of coating level on the release profiles of ibuprofen
from powder coated elementary ODDS
(Orifice diameter: 500 µm, agitation speed: 50 r/min, pH: 7.2)
In order to investigate the effect of coating on the release of ibuprofen from electrostatic
powder coated elementary ODDS, drug release profiles with different coating levels (0%,
5.5%, 7.8% and 10.6%) were confirmed by dissolution tests and are shown in Figure
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5.22. For those uncoated ODDS, ibuprofen released immediately and completely within 1
h. On the other hand, drug released 100% in 12 h, 100% in 24 h and 50% in 24 h from the
tablets with coating levels of 5.5%, 7.8% and 10.6%, respectively. In other words, higher
coating level leads to a slower drug release rate, which means the release rate of
ibuprofen from those powder coated elementary ODDS could be adjusted by changing
the coating level of the semipermeable membrane.

Orifice diameter=200 m
Orifice diameter=500 m
Orifice diameter=900 m
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24

Time (h)
Figure 5.23 The effect of orifice diameter on the release profiles of
ibuprofen from powder coated elementary ODDS
(Coating level: 7.8 %, agitation speed: 50 r/min, pH: 7.2)
From part 4.6 we already know that the diameter of the delivery orifice has no influence
on the release rate of salbutamol sulfate from powder coated elementary ODDS. In this
part, ibuprofen was used as the model drug, which is water slightly soluble. Figure 5.23
shows the effect of the orifice diameter on the release of ibuprofen from powder coated
elementary ODDS. The overall release rate of ibuprofen from elementary ODDS with
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different orifice diameter is the same within 24 hours. However, larger orifice diameter
resulted in a slightly faster release rate during this period.
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Figure 5.24 The effect of pH value on the release profiles of ibuprofen from
powder coated elementary ODDS
(Coating level: 7.8 %, orifice diameter: 500 µm, agitation speed: 50 r/min)
Figure 5.24 shows that the difference in pH of release media does not contribute to the
variability in the release of ibuprofen from powder coated elementary ODDS, which
means that the release of ibuprofen from powder coated elementary ODDS is independent
of the pH of the release media.
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Figure 5.25 The effect of agitation speed on the release profiles of
ibuprofen from powder coated elementary ODDS
(Coating level: 4%, orifice diameter: 500 µm, pH: 7.2)
Similar to the pH of the release media, agitation speed also had no influence on the
release of ibuprofen from powder coated elementary ODDS, as can be seen in Figure
5.25. Therefore, it can be predicted that the mobility of the gastrointestinal tract hardly
affects the release of ibuprofen from powder coated elementary ODDS.
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Table 5.10 Similarity factor f2 values between release profiles of ibuprofen
from CA powder coated elementary ODDS
with different orifice diameters, pH value and agitation speed
f2
Orifice diameter 1&2

77.83

Orifice diameter 1&3

70.12

Orifice diameter 2&3

78.24

pH 1.2 & pH 5.8

78.63

pH 1.2 & pH 7.2

81.79

pH 5.8 & pH 7.2

82.68

50 rpm & 100 rpm

84.12

50 rpm & 150 rpm

83.91

100 rpm & 150 rpm

79.77

The similarity factor f2 values between each release profiles of ibuprofen from
electrostatic powder coated elementary ODDS with different orifice diameters, different
pH values and different agitation speed are bigger than 50, indicating that those release
profiles are similar with each other. So it can be concluded that the release of ibuprofen
from electrostatic powder coated elementary ODDS is independent of the orifice
diameter, pH and agitation speed.
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Figure 5.26 Relationship between drug release rate and coating level
Drug release from electrostatic powder coated osmotic tablets was independent with the
delivery orifice diameter and release conditions including pH of the release media and
agitation speed, while it varied with the difference of coating level. The relationship
between drug release rate and the coating level is shown as Figure 5.26. Compared with
Salbutamol sulfate (SS), a higher coating level was needed for controlling the release of
ibuprofen (IB) at a same release rate due to its low water solubility. By controlling the
coating level, a desirable drug release period such as 12 hours (8.33 %/h) or 24 hours
(4.167 %/h) could be achieved for both SS and IB.

5.6 Stability of powder coated elementary ODDS
The release profiles of salbutamol sulfate and ibuprofen from electrostatic dry powder
coated elementary ODDS (cured at 60 ◦C for 120 min) before and after storage are shown
in Figure 5.27 and Figure 5.28. The similarity factor f2 values are shown in Table 5.11
and Table 5.12.
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For salbutamol sulfate, the similarity factor f2 values are 83.19, 81.37 and 82.66 for the
coating level of 3%, 4% and 6.8%, respectively, which are bigger than 50, indicating that
those electrostatic dry powder coated elementary ODDS (salbutamol sulfate) with
micronized cellulose acetate exhibited an excellent stability over 1 month at 40 ◦C /75%
RH.
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Figure 5.27 Release profiles of salbutamol sulfate from CA powder coated
elementary ODDS cured at 60 ◦C, 120 min
(*: after storage at 40 ◦C, 75% RH for 1 month)
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Table 5.11 Similarity factor f2 values between release profiles of salbutamol
sulfate from powder coated elementary ODDS before and after storage
Coating level

f2

3%

83.19

4%

81.37

6.8%

82.66

While for ibuprofen, the similarity factor f2 values are 84.89, 82.44 and 83.57 for the
coating level of 5.5%, 7.8% and 10.6%, respectively, which are bigger than 50, also
indicating an excellent stability of those electrostatic dry powder coated elementary
ODDS (salbutamol sulfate) with micronized cellulose acetate exhibited over 1 month at

Cumulative release (%)

40 ◦C /75% RH.
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Figure 5.28 Release profiles of ibuprofen from CA powder coated
elementary ODDS cured at 60 ◦C, 120 min
(*: after storage at 40 ◦C, 75% RH for 1 month)
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Table 5.12 Similarity factor f2 values between release profiles of ibuprofen
from powder coated elementary ODDS before and after storage
Coating level

f2

5.5%

84.89

7.8%

82.44

10.6%

83.57

5.7 Kinetic modeling of drug release
In order to investigate drug release kinetics from those powder coated elementary ODDS,
the release data of both salbutamol sulfate and ibuprofen with different coating levels
were fitted to various mathematical models including Zero-order, First-order and Higuchi
model. The best goodness of fit test (highest R2) were taken as the criteria for selecting
the most appropriate model.

Table 5.13 Summary of the mathematical modeling on release profiles of
salbutamol sulfate and ibuprofen from powder coated elementary ODDS
Mathematical models
Drug

Salbutamol
sulfate

Ibuprofen

Coating level

Zero-order

First-order

Higuchi

R2

Slope

R2

Slope

R2

Slope

3%

0.997

7.29

0.942

-0.142

0.893

28.3

4%

0.997

3.55

0.958

-0.068

0.933

23.25

6.8%

0.998

1.18

0.994

-0.014

0.903

5.87

5.5%

0.986

9.23

0.901

-0.233

0.909

32.95

7.8%

0.993

4.46

0.937

-0.103

0.931

22.44

10.6%

0.999

2.31

0.995

-0.011

0.918

11.91
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As shown in Table 5.13, zero-order release model has the highest value of R2 among all
the kinetic models applied, which means that both salbutamol sulfate and ibuprofen
release from powder coated elementary ODDS with zero-order drug release kinetics.

5.8 Conclusion
In this chapter, elementary osmotic pump tablets were successfully coated using
electrostatic powder coating with powdered cellulose acetate (CA). This novel coating
technology utilized an electrostatic gun to spray coating powders, created an electrical
field between the gun and the osmotic pump tablets so as to direct the movement of
coating powders towards the tablets, leading to a better coating powder adhesion. Triethyl
citrate (TEC) was an effective liquid plasticizer for osmotic pump tablet coating due to its
high efficiency in reducing the glass transition temperature (Tg) of coating polymer (CA),
thus film formation could be achieved under a relatively low temperature. Also spraying
liquid plasticizer could increase the electrical conductivity of osmotic pump tablets so as
to promote the coating powder adhesion through the electrostatic gun. Film formation
could be influenced by the curing conditions such as curing time and temperature. Higher
curing temperature and longer curing time led to a better coating film.
Both water soluble drug (salbutamol sulfate) and water insoluble drug (ibuprofen) were
used as the model drugs in the elementary ODDS coating. Results of dissolution tests
indicated that the release rate of both drugs from electrostatic powder coated elementary
ODDS varied with different coating levels while was independent with the diameter of
delivery orifice, pH vale of the release media and the agitation speed. Results from the
kinetic modeling on drug release from electrostatic powder coated elementary ODDS
demonstrated that the release of both salbutamol sulfate and ibuprofen followed a zero
order drug release kinetics.
All the above results indicated that electrostatic powder coating is a promising alternative
for the ODDS coating in pharma industry. Considering that those osmotic dosage forms
currently can only be coated by organic solvent coating, this study has made a big
breakthrough on the ODDS coating, avoiding all the limitations related to organic
solvents.
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6

Osmotic Controlled Release- Porosity Tablet Coating

In the present study, a novel porosity osmotic drug delivery system was formed using an
electrostatic powder coating technology. Coating powders containing powdered cellulose
acetate (CA), pore forming agent and other excipients were electrostatically deposited
onto the surface of osmotic pump tablet cores with an electrostatic spray gun, followed by
a curing step to allow those deposited particles to coalesce and form a coating film. As a
liquid plasticizer, triethyl citrate (TEC) was used in the coating process to reduce the
glass transition temperature of the coating polymer (CA) and also to increase the
electrical conductivity of the osmotic pump tablet cores, both of which led to enhanced
powder adhesion and film formation. In the curing process, temperature and curing time
were found to be critical factors. SEM indicated that longer curing time and/ or higher
curing temperature resulted in more uniform and continuous coating film. The drug
release profiles showed that drug release from those powder coated porosity ODDS was
independent of pH of the release media and agitation speed. Modeling of the drug release
profiles indicate that drug release from powder coated porosity ODDS followed zeroorder drug release kinetics. The drug release rate could be controlled by adjusting the
coating level and/-or pore forming agent ratio in the coating formulation.

6.1 Introduction
As one of the most promising oral drug delivery systems, osmotic drug delivery system
(ODDS) has gained tremendous attention in recent years and a significantly increasing
number of articles and patents have been reported within this area. The original idea of
ODDS came from Rose and Nelson in 1955 [1]. Later it was improved by Higuchi and
Theeuwes in 1970s [2, 3]. The first practical ODDS was also developed by them, which
was called elementary osmotic pump tablet [4], in cooperation with the Alza Corporation
[5]. This elementary ODDS contains active agent, osmotic agent and other excipients,
coated with an outlay semipermeable membrane. A delivery orifice is necessary to be
drilled on the semipermeable membrane, through which the active agent is released.
Although this simple design and easy controlled ODDS led to a quite success in the
commercialization, it may cause irritation to the gastro-intestinal tract (GI tract) due to
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the dose dumping resulting from non-uniform coating and high local drug concentration
around the drug delivery orifice.
In order to overcome this problem, a novel osmotic drug delivery system has been
developed recently [6], which is called porosity osmotic drug delivery system (ODDS). In
this novel system, a semipermeable membrane contains water soluble leachable pore
forming agent. Micropores could be formed in situ immediately after the coated porosity
ODDS is exposed to water, through which the drug release could be achieved. The dose
dumping could be minimized or eliminated, and also the local drug concentration could
be decreased to a safe range due to the uniform distribution of the drug release aperture
on the semipermeable membrane.

Micropores as drug delivery orifices

Drug
Osmotic agent

Semipermeable membrane
Figure 6.1 Schematic representation of porosity ODDS

Presently the semipermeable membrane of the porosity ODDS is achieved by organic
solvent coating method, involving spraying a coating solution, which is formed by adding
coating polymers into an organic solvent, onto the surface of the porosity ODDS cores.
The coating film is formed after the organic solvent is evaporated out of the system.
Although this organic solvent coating could form a relatively uniform coating film, it
does cause many problems due to the toxicity and environmental related concerns. Also
the concentration of the coating solution cannot be too high due to the viscosity
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limitation, leading to a low coating efficiency. In addition, the organic solvent needs to be
vaporized in the coating process, which is energy and time consumptive and could
increase the overall cost.
In order to overcome the limitations of those earlier attempts, researchers from Western
University have developed a novel electrostatic dry powder coating technology [7]. In
this novel powder coating technology, an electrostatic spray gun is utilized to spray the
coating powder to the surface of the solid dosage forms, followed by a curing step to
allow deposited coating particles to coalesce and form a continuous coating film. An
electrical field between the electrostatic gun and the grounded substrate (solid dosage
forms) could be generated, directing the powder flow and enhancing the coating powder
adhesion. By using this novel technology, tablets have been successfully coated with
several commonly used coating materials to achieve immediate drug release [8],
sustained drug release [9] and delayed drug release [10], respectively.
The objective of the present study is to apply this electrostatic powder coating to form the
semipermeable membrane of the porosity ODDS and to characterize the coating process
including the coating powder adhesion and film formation and their influence factors, and
also to make the drug release rate more controllable by adjusting the pore forming agent
ratio in the coating formulation.
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Osmotic tablet core preparation

Mixing
Granulation
Compression

Coating formulation

Electrostatic powder coating
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Coating powder size reduction

Coating process

Temperature
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Coating level
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Dissolution test

Drug controlled release

Film formation

Figure 6.2 Schematic diagram of porosity ODDS study

6.2 Materials and methods
6.2.1 Materials
Salbutamol sulfate was provided by Nanjing Pharmaceutical Factory (Nanjing, China).
Cellulose Acetate was donated by the Eastman Chemical Company (Kingsport,
Tennessee, USA). Plasdone K-29/32 was purchased from ISP technologies, INC. Sodium
Chloride and Polyethylene Glycol 3350 (PEG 3350) were provided by EMD Chemicals
Inc. (Gibbstown, NJ, United States). Avicel® Microcrystalline cellulose PH-102 was
purchased from FMC Corporation (Philadelphia, Pennsylvania, United States) and
Magnesium Stearate was purchased from Alfa Aesar (Haverhill, Massachusetts, USA).
Placebo tablets were obtained from Patheon (Mississauga, Ontario, Canada). Triethyl
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citrate (TEC) was purchased from Caledon Laboratories Ltd. (Georgetown, Ontario,
Canada). Colloidal silicon dioxide (AEROSIL® 200 Pharma) was donated by Evonik
Degussa Corporation (Essen, North Rhine-Westphalia, Germany). Talc was purchased
from Mallinickrodt Baker Inc. (Center Valley, Pennsylvania, United States).

6.2.2 Preparation of the osmotic pump tablets
The component of the tablets core includes active ingredient (salbutamol sulfate), osmotic
agent (sodium chloride and lactose), microcrystalline cellulose, PVP and magnesium
stearate. The formulation of the osmotic pump tablets core can be seen as Table 6.1.

Table 6.1 Formulation of porosity ODDS core
Ingredient

% w/w

MCC

53%

Salbutamol sulfate

20%

NaCl

20%

PVP

6.5%

Magnesium stearate

0.5%

Those components were mixed and dry granulated using a high shear granulator
(Mechanomill MM-20N, OKADA SEIKO Co. Ltd, Iwate, Japan) with a speed of 300
rpm for 6 min, followed by adding magnesium stearate and mixing for another 3 min with
same speed. The ready formulation was then compressed into tablets by using a tablet
machine with one punch (5 mm in diameter) (Shanghai Tianxiang & Chentai
Pharmaceutical Machinery Co. Ltd, Shanghai, China). The weight for each tablet is
180±2 mg.
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6.2.3 Powder coating process
E

B

A

D

C

Ground

Figure 6.3 Schematic diagram of the electrostatic powder coating system
(A) Liquid plasticizer, (B) liquid plasticizer metering pump, (C) coating pan,
(D) electrostatic spray gun, (E) powder feeder
The coating process was performed in a laboratory scale electrostatic dry powder pan
coater system, which includes a coating pan, an electrostatic spray gun, a powder feeder
and a liquid spray system (atomizing nozzle and metering pump) (Figure 6.3). Osmotic
pump tablets (20 g) and placebo tablets (60 g) were firstly loaded into the coating pan and
preheated for a certain time period. Then liquid plasticizer was sprayed onto the surface
of those tablets, which was immediately followed by the spraying of the coating powders
by the electrostatic spray gun (Nordson Corporation, USA). By doing this coating powder
adhesion was achieved, after which there was a curing step under a certain temperature,
allowing those deposited coating particles to coalesce and form a continuous coating film.
The flowrate of liquid plasticizer can be controlled by a liquid metering pump (Fluid
Metering Inc., USA).
The coating level (%) of the osmotic pump tablets could be obtained from the weight gain
of coated tablets divided by the weight of uncoated tablets. Placebo tablets were used to
maintain the volume of substrates and conserve osmotic pump tablets at the same time.
The coating formulation contains cellulose acetate (CA), talc powder, nano silica and
pigment. The formulation can be seen in Table 6.2.
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Table 6.2 Formulation of the coating powder
Ingredient (% w/w)
Formulation

Cellulose acetate

PEG 3350

A

90%

0%

B

85%

5%

C

80%

10%

D

75%

15%

Talc

SiO2, Pigment

9%

0.5%, 0.5%

Table 6.3 Coating parameters of porosity ODDS coating process
Tablet loading

80 g

Charging voltage

0 kV, 20 kV, 40 kV, 60 kV, 80 kV

Liquid plasticizer flow rate

0.5 g/min

Liquid plasticizer spray time

0 min, 1 min, 2 min, 3 min and 4 min

Atomizing air pressure

300-320 kPa

Nozzle diameter

0.25 mm

Powder feed rate

3 g/min

Powder feed time

3 min

Pan speed during coating (rpm)

28-32

Pan speed during curing (rpm)

10-15

Curing temperature

40 ◦C, 50 ◦C and 60 ◦C

Curing time interval

0 min, 60 min and 120 min

6.2.4 Scanning electron micrographs
The surface morphology of the dry powder coated tablets with different coating
formulations and coating parameters was observed by using a scanning electron
microscopy (SEM, S-2600N Hitachi, Ontario, Canada). Before the observation, samples
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were firstly sputter coated with gold for 120 s using an Emitech K550 sputter coater
(Emitech Ltd., Ashford, UK).

6.2.5 Dissolution tests
The release of salbutamol sulfate from porosity ODDS before and after being coated with
various core formulations and different coating formulations and coating parameters were
investigated using the United States Pharmacopeia (USP) apparatus (Apparatus 2, paddle;
Huanghai Rcz-6c2, Shanghai, China). Phosphate buffer solution with different pH value
(1.2, 5.8 and 7.2) was chosen as the release media. The release tests with 6 tablets in 6
vessels with 900 ml release media were performed at 37 ◦C at a certain agitation speed.
Samples were withdrawn by using a 10 ml syringe from each vessel at predetermined
time intervals, followed by the injection with the same volume of fresh medium into the
vessels. Then those samples were assayed using an 8453 UV–Visible Spectrophotometer
(Agilent Technologies, Mississauga, Canada) at a wavelength of 276 nm for salbutamol
sulfate.

6.2.6 Stability test
Electrostatic dry powder coated porosity ODDS (cured at 60◦C for 120 minutes) were
placed in HDPE vials (75 mL) and sealed with aluminum film and then were stored at 40
◦

C /75% RH for 1 month. Dissolution tests of those porosity ODDS before and after

storage were carried out.

6.2.7 Statistical analysis
Similar with previous chapters, mean ± Standard Deviation (S.D.) values were also used
to express the experimental results in this chapter. And the “similarity factor” f2 was not
only used to compare the drug release profiles before and after storage in the stability
tests, but also was used to compare the drug release profiles with different release
conditions such as pH values of the release media and agitation speed. The value of f2 is
between 0 to 100, if f2 is larger than 50 (between 50 to 100), these two release profiles
were considered to be similar. If f2 is close to 100, the two release profiles were
considered as identical.
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The following equation could be used to calculate the value of “similarity factor” f2.
0.5


 1 n

2
f 2  50 log 1   Rt  Tt    100



 n t 1


(6.1)

In this equation, n is the total number of sampling times, Rt and Tt is the accumulated
drug release percentage at time point t for the reference and test products, respectively.

6.3 Coating powder adhesion
From chapter 5 we know that by spraying a certain amount of liquid plasticizer (TEC)
onto the surface of the osmotic pump tablets, the electrical resistivity of those tablets
could be reduced from 1×1015 Ωm to below 1×109 Ωm, which is suitable for the
electrostatic spray process [11].
In a powder coating process, in order to form a continuous and uniform coating film,
enough coating powders should be firstly deposited onto the surface of the substrate. In
the present study, the powder adhesion rate was the weight gain of the tablets after the
coating powder spraying process divided by the total weight of the sprayed coating
powders.
Powder adhesion rate=weight gain of the tablets/total weight of sprayed powders*100%
In the electrostatic powder coating process, the powder adhesion rate could be influenced
by many factors, among which, charging voltage of the electrostatic spray gun and liquid
plasticizers are the most critical ones.
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Table 6.4 The effect of charging voltage on the coating powder adhesion
rate (liquid plasticizer: 0.5 g/min for 3 min)
Charging voltage (kV)

Powder adhesion rate (%)

0

57.38

20

81.82

40

88.78

60

91.73

80

90.18

The influence of charging voltage of the electrostatic spray gun on the powder adhesion
rate is shown in Table 6.4. When the charging voltage was 0, the powder adhesion rate
was 57.38 %, which was contributed by the spraying of the liquid plasticizer [10, 12].
When increasing the charging voltage from 0 to 60 kV, the powder adhesion rate
increased to around 91.73 %, indicating that the coating powder adhesion was enhanced
by the electrical field between the tip of the electrostatic gun and the coating pan. Further
increasing of the charging voltage to 80 kV slightly reduced the powder adhesion rate to
90.18%. This is because the higher charging voltage could cause an increased cumulative
charge of the coating layer and back ionization, which could reduce the powder
deposition.
It could be concluded from these results that the charging voltage could be optimized as
60 kV in the coating process.
Besides the charging voltage of the electrostatic gun, liquid plasticizer could also play a
significant role to produce a good powder adhesion so as to achieve continuous and
uniform coating film. As shown in Table 6.5, without liquid plasticizer, the powder
adhesion rate was less than 34.81% with a charging voltage of 60 kV. By increasing the
liquid plasticizer spraying time from 0 to 3 min, the powder adhesion rate was
dramatically increased to around 91.73 %. This could be explained by the capillary force
between coating powders and the surface of those dosage forms caused by the liquid
plasticizers [8, 11, 13]. Although further increase of the spraying time of liquid plasticizer
(4 min) led to an increase of the powder adhesion rate, surplus liquid plasticizer caused

178

sticky film. So the spraying time of the liquid plasticizer (TEC) in this present study
could be optimized to 3 min with a flowrate of 0.5 g/min.

Table 6.5 The effect of liquid plasticizer on the coating powder adhesion
rate (Charging voltage: 60 kV)
Liquid plasticizer spray time (min, 0.5 g/min)

Powder adhesion rate (%)

0

34.81

1

64.44

2

79.99

3

91.73

4

92.49

6.4 Surface morphology of the coating film
In the electrostatic powder coating process, the film formation comes from the
deformation and viscous flow of deposited polymer particles at the temperature higher
than the glass transition temperature (Tg) of the polymer [11]. Consequently, it is critical
to have a curing step after the powder adhesion for the deposited polymer particles to
coalesce together to form a continuous and uniform coating film. And in this curing
process, temperature and time play a significant role in turning the deposited particles
into coating film. Scanning electron micrographs (SEM) was used to observe the surface
morphology of the coating film formed at different curing temperature with different
curing time periods.
As shown in Figure 6.4, a better coating film could be achieved with a longer curing time,
allowing the deposited coating particles to coalesce and form a better and smoother
coating film. The deposited particles could be clearly seen before the curing step was
started (Figure 6.4-A), which was disappeared gradually after cured for 60 min (Figure
6.4-B). After being cured for 120 min, most of those particles disappeared and a
continuous and uniform coating film was achieved (Figure 6.4-C).
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Figure 6.4 SEM micrographs of CA powder coated ODDS curing at 60◦C for
different time intervals: (A) 0 min, (B) 60 min, (C) 120 min
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The effect of curing temperatue on the film formation could be seen in Figure 6.5. The
curing time for all the three SEM pictures were same (120 min). It could be concluded
from this figure that higher curing temperature led to a more uniform coating film.

Figure 6.5 SEM micrographs of CA powder coated ODDS curing for 120 min
at different temperatures: (A) 40 ◦C, (B) 50 ◦C, (C) 60 ◦C

6.5 In vitro drug release
Drug release from porosity ODDS is controlled by various factors such as osmotic
pressure, coating thickness, pore forming agents in the core formulation, permeability of
the coating film and solubility of drug [14]. The release profiles of salbutamol sulfate
from electrostatic dry powder coated porosity ODDS and its factors including coating
level, osmotic agent ratio in the core formulation, permeability of the coating film, pH
value of dissolution media and agitation speed were studied with in vitro dissolution tests.
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The thicknesses of the coating film with different coating levels were measured by using
a digital vernier caliper, and the result is shown in Table 6.6.
Table 6.6 Thickness of the coating film
Coating level

Thickness of tablet core, mm (SD)

Thickness of coating film, mm (SD)

3.2%

0.07 (0.01)

4%

3.87 (0.01)

0.10 (0.01)

6.3%

0.13 (0.02)

Pore former ratio: 10 %
Agitation speed: 50 r/min
pH: 7.2

Cumulative release (%)

100

80

60

40

Bare tablets
Coating level 3.2%
Coating level 4%
coating level 6.3%

20

0
0

6

12

18

24

Time (h)

Figure 6.6 Effect of coating level on release of salbutamol sulfate from
electrostatic powder coated porosity ODDS
(Agitation speed: 50 r/min, pH: 7.2, pore former ratio: 10 %)
As shown in Figure 6.6, coating level (thickness of coating film) has a big impact on the
release rate of salbutamol sulfate from powder coated porosity ODDS. Drug release from
uncoated ODDS completed within 1 hour. Increase in the coating level resulted in
decrease of release rate of salbutamol sulfate. For the coating level of 3.2 %, drug release
was completed within 14 hours. When the coating level was increased to 4 %, the release
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of salbutamol sulfate was finished with 24 hours. When further increasing the coating
level to 6.3 %, only 70 % drug was released within 24 hours. The slower drug release rate
with higher coating level could be explained by the reduced water influx owing to the
thicker coating film.
Besides the thickness of coating film, the permeability of the coating film could also have
a big influence on the drug release rate from powder coated porosity ODDS. In order to
assess this effect, ODDS were coated with coating formulations containing different pore
former ratio. Drug release profiles from those coated porosity ODDS are shown as Figure
6.7. When there was no pore former in the coating formulation, the release of salbutamol
sulfate completed within 10 hours and there was burst release around 4 hours, indicating
that the coating film was broken at that moment. This is because the coating film cannot
withstand both the hydrostatic pressure and osmotic pressure caused by the water influx
inside the tablet core, leading to a film crack. When the pore former was added into the
coating formulation, the release of salbutamol sulfate from powder coated porosity
ODDS was well controlled. With the increase of the pore former ratio in the coating
formulation, the drug release became faster. As shown in Figure 6.7, when the pore
former ratio was 5 %, drug released only 55.31 % within 24 hours. After increasing the
pore former ratio to 10 % and 15 %, drug release completed within 24 hours and 12
hours, respectively.
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Agitation speed: 50 r/min
Coating level: 4%
pH: 7.2

Cumulative drug release (%)

100

80

60

40

Pore former 0%
Pore former 5%
Pore former 10%
Pore former 15%

20

0
0

4

8

12

16

20

24

28

Time (h)

Figure 6.7 The effect of pore former ratio in the coating formulation on the
release of salbutamol sulfate from electrostatic powder coated porosity
ODDS (Coating level: 4%; agitation speed: 50 r/min, pH: 7.2)
From results above, the release of salbutamol sulfate from powder coated porosity ODDS
could be controlled within 24 hours with a coating level of 4 % and 10 % pore former in
the coating formulation.
Figure 6.8 shows the SEM micrographs of CA powder coated porosity ODDS before and
after drug release with different pore former ratio in the coating formulation. Before drug
release, a continuous and uniform coating film was observed under SEM, while after the
drug completely released from the ODDS, micropores with a uniform distribution could
be seen clearly on the surface of the coating film. The increase of pore former ratio in the
coating formulation led to an increase of the micropores.
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Figure 6.8 SEM micrographs of CA powder coated porosity ODDS before
and after drug release with different pore former ratio
(A: before drug release, B: 5%, C: 10%, D: 15%)

The effect of pH value of the release media and agitation speed on the drug release from
powder coated porosity ODDS was also investigated, which are shown in Figure 6.9 and
Figure 6.10. Also the similarity factor f2 values between each pH value and agitation
condition are shown in Table 6.7 and Table 6.8. There is no large difference between
drug release profiles with different pH value of release media and agitation speed and
also the similarity factor f2 values are all larger than 50, indicating that the release of
salbutamol sulfate from electrostatic powder coated porosity ODDS is independent of the
pH of the release media and agitation speed.
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Cumulative drug release (%)

100

pH 1.2
pH 5.8
pH 7.2

80

60

40

Pore former: 10 %
Coating level: 4 %
Agitation speed: 50 r/min

20

0
0

6

12

18

24

Time (h)
Figure 6.9 Effect of pH of dissolution media on release of salbutamol
sulfate from electrostatic powder coated porosity ODDS (Coating level: 4%,
agitation speed: 50 r/min, pore former ratio: 10 %)

Table 6.7 Similarity factor f2 values between release profiles of salbutamol
sulfate from CA powder coated porosity ODDS with different pH values
f2
pH 1.2 & pH 5.8

80.44

pH 1.2 & pH 7.2

82.92

pH 5.8 & pH 7.2

84.84
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50 r/min
100 r/min
150 r/min

Cumulative drug release (%)

100

80

60

40

Pore former: 10 %
Coating level: 4 %
pH: 7.2

20

0
0

6

12

18

24

Time (h)
Figure 6.10 Effect of agitation speed on release of salbutamol sulfate from
electrostatic powder coated porosity ODDS
(Coating level: 4%, pH value: 7.2, pore former ratio: 10 %)

Table 6.8 Similarity factor f2 values between release profiles
of salbutamol sulfate from CA powder coated porosity ODDS
with different agitation speed
f2
50 rpm & 100 rpm

82.22

50 rpm & 150 rpm

84.24

100 rpm & 150 rpm

79.94
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6.6 Stability of powder coated porosity ODDS
The release profiles of salbutamol sulfate from electrostatic dry powder coated porosity
ODDS (cured at 60◦C for 120 min) before and after storage are shown in Figure 6.11. The
similarity factor f2 values are shown in Table 6.9. The similarity factor f2 values are 83.1,
81.33 and 78.67 for the coating level of 3.2 %, 4% and 6.3%, respectively. All the three
values are bigger than 50, indicating that those electrostatic dry powder coated porosity
ODDS with cellulose acetate exhibited an excellent stability over 1 month at 40◦C /75%
RH.

120

3.2 %
3.2 %(*)
4%

Cumulative drug release (%)

100

4 %(*)
6.3 %

80

6.3 %(*)

60

40

Pore former ratio: 5%
Agitation speed: 50 r/min
pH: 7.2

20

0
0

4

8

12

16

20

24

Time (h)
Figure 6.11 Release profiles of salbutamol sulfate
from CA powder coated porosity ODDS cured at 60 ◦C, 120 min
(*: after storage at 40 ◦C, 75% RH for 1 month)
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Table 6.9 Similarity factor f2 values between release profiles of salbutamol
sulfate from powder coated porosity ODDS before and after storage
Coating level

f2

3.2 %

83.1

4%

81.33

6.3%

78.67

6.7 Mathematical modeling of drug release profiles
In order to investigate the release kinetics of salbutamol sulfate from those powder coated
porosity ODDS, drug release data with different coating levels were fitted to various
mathematical models including Zero-order, First-order and Higuchi model. The best
goodness of fit test (R2) were taken as criteria for selecting the most appropriate model
[15]. As shown in Table 6.10, the value of R2 of Zero-order release model was found to
be highest among all the kinetic models applied, which means the release of salbutamol
sulfate from powder coated porosity ODDS is zero-order drug release kinetics.

Table 6.10 Summary of the mathematical modeling of release profiles of
salbutamol sulfate from powder coated porosity ODDS
Mathematical models
Coating levels

Zero-order

First-order

Higuchi

R2

Slope

R2

Slope

R2

Slope

3.2 %

0.994

7.7

0.890

-0.194

0.907

30.15

4%

0.984

4.54

0.932

-0.113

0.933

23.25

6.3%

0.994

3.04

0.982

-0.048

0.909

15.29
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6.8 Conclusion
In this chapter, porosity osmotic drug delivery systems were successfully formed using a
novel electrostatic dry powder coating technology. Coating powders containing
micronized cellulose acetate (CA) and pore former (PEG 3350) were electrostatically
deposited onto the surface of the ODDS cores with an electrostatic spray gun and
coalesced to a continuous coating film with a curing step. Liquid plasticizer played a key
in the coating process by reducing the glass transition temperature of the coating polymer
(CA) and also increasing the electrical conductivity of the ODDS cores, both of which
could enhance the coating powder adhesion and promote the film formation. Curing
temperature and time also had a big impact on the film formation. Higher curing
temperature and longer curing time led to more uniform and continuous coating film.
Results of dissolution tests indicated that drug release rate from electrostatic powder
coated porosity ODDS varied with different coating levels and different pore former ratio
in the coating formulation while it was independent with the pH vale of the release media
and the agitation speed. Drug release data with different coating levels were fitted with
different mathematical models including zero-order, first-order and Higuchi model. The
results indicated that zero order model gave the highest R2, which means the release of
salbutamol sulfate from those powder coated porosity ODDS followed a zero-order drug
release kinetics.
Based on those results, it can be concluded that porosity ODDS could be successfully
formed using electrostatic powder coating technology, eliminating limitations caused by
the organic solvent and water such as high energy consumption, long processing time and
health and environment related concerns.
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7

In-Depth Characterization of Powder Coating Process

In the previous chapters, a novel electrostatic powder coating technology has been
applied to coat solid dosage forms such as tablets and pellets as well as osmotic drug
delivery systems (ODDS) to modify drug release profiles. The present study aims to
provide a fully and more in-depth characterization on the electrostatic powder coating
process, providing a general discussion on the influence factors. Two main steps are
included in the coating process, coating powder adhesion and film formation. Using
elementary osmotic pump tablet coating and pellet coating as examples, this study
illustrated these two procedures and their influence factors including preheating, charging
voltage, liquid plasticizers, particle size of coating powders, curing temperature and
curing time. Also this study provided a screening method to choose liquid plasticizer for
different coating materials.

7.1 Brief introduction
Emerged from sugar coating, pharmaceutical coating process has generally been
transformed from solvent coating, which is based on the solution of coating materials in
an organic solvent, to an environmental friendly aqueous coating process. Organic
solvents are toxic and flammable, causing toxicity and environmental related issues. Also
the concentration of coating solution cannot be too high due to the viscosity limit,
otherwise it may block the spray nozzle. As a result, it takes a very long processing time
to achieve a thick coating film. In addition, the whole process needs a large amount of
organic solvents and the after-treatment and recovery of the organic solvent are very
expensive, which could significantly increase the overall cost.
Although aqueous coating can avoid theses disadvantages and begins to dominate the
pharmaceutical coating area, it still possesses many limitations. Firstly, evaporation of
water is energy and time consumptive, dramatically increasing the overall cost. Also for
the coating materials with high glass transition temperature, aqueous coating cannot be
applied because it is very difficult to form a film under a relatively low temperature.
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In order to overcome those limitations, many dry coating methods [1-5] have been
developed recently including compression coating [6-9], hot-melt coating [10-15],
supercritical fluid coating [16, 17], photocuring coating [18, 19] and dry powder coating
[20-26].
The novel electrostatic powder coating technology developed by Zhu’s group [27-31] has
been able to differentiate itself from other counterparts owing to its simpler coating
apparatus that can be easily adapted from the present apparatus such as pan coater
systems for liquid coating. By applying this novel electrostatic powder coating
technology, several coating formulations have been developed for tablet coating to
achieve immediate release [30], sustained release [31] and delayed release [32]. Also it
has been extended to coat novel dosage forms such as osmotic drug delivery systems
(ODDS) including elementary ODDS and porosity ODDS. Small solid dosage forms such
as pellets [27] also have been successfully coated by using this powder technology.
However, there are still some fundamental details in the electrostatic powder coating
process which remain unclear. For example, PEG 400 is widely used as the plasticizer for
cellulose acetate in liquid coating. However, it is not efficient when being used in this
powder coating process. Hence it is necessary to find a screening method for liquid
plasticizer, which is critical for this electrostatic powder coating. A full understanding on
the whole coating process could provide a better control to the whole electrostatic powder
coating process, bringing many benefits to the industrial applications and prospective
research in the future. Consequently, this chapter focused on the illustration and in-depth
characterization of the electrostatic powder coating process, including coating powder
adhesion and film formation mechanism and their influence factors.

7.2 Materials and methods
7.2.1 Materials
Piroxicam pellets with a particle size of 0.9 mm-1.18 mm were provided Gaocheng
Biotech& Health CO., LTD. Salbutamol sulfate was provided by Nanjing Pharmaceutical
Factory (Nanjing, China). Cellulose Acetate was donated by the Eastman Chemical
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Company (Kingsport, Tennessee, USA). Plasdone K-29/32 was purchased from ISP
technologies, INC. Eudragit® EPO, Eudragit® RS/RL and Colloidal silicon dioxide
(AEROSIL® 200 Pharma) were donated by Evonik Degussa Corporation (Essen, North
Rhine-Westphalia, Germany). Acryl EZE was provided by Colorcon, Inc. (US). Talc
powder was purchased from Mallinickrodt Baker Inc. (Canada). Plasdone K-29/32 was
purchased from ISP technologies, INC. Sodium Chloride and Polyethylene Glycol 400
(PEG 400) were provided by EMD Chemicals Inc. (Gibbstown, NJ, United States).
Avicel® Microcrystalline cellulose PH-102 was purchased from FMC Corporation
(Philadelphia, Pennsylvania, United States) and Magnesium Stearate was purchased from
Alfa Aesar (Haverhill, Massachusetts, USA). Placebo tablets were obtained from Patheon
(Mississauga, Ontario, Canada). Glycerol and triethyl citrate (TEC) were obtained from
Caledon Laboratories Ltd. (Georgetown, Ontario, Canada). Talc was purchased from
Mallinickrodt Baker Inc. (Center Valley, Pennsylvania, United States).

7.2.2 Particle size reduction and analysis
Before the coating process, the particle size of the coating materials was firstly reduced
by using a blade grind mill and then it was investigated by a particle size analyzer (TSI
Corporation, Model 3603, Shoreview, MN, USA). The average particle size in this study
is the size at 50 % of total weight fraction, which is given by Table 7.1.
Table 7.1 Average particle size of the coating materials
Coating materials

Average particle size (µm)

Cellulose acetate

26.7

Eudragit® EPO

23.3

Eudragit® RS

48.7

Eudragit® RL

39.7

Acryl EZE

20.8

Talc powder

28.9
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7.2.3 Preparation of the osmotic pump tablets
Table 7.2 shows the formulation of the osmotic tablet core, including drug (salbutamol
sulfate), osmotic agent (sodium chloride), microcrystalline cellulose, PVP and
magnesium stearate.
Table 7.2 Formulation of osmotic pump tablets core
Ingredient

% w/w

Salbutamol sulfate

20%

Sodium chloride

30%

Microcrystalline cellulose PH102

43%

PVP

6.5%

Magnesium stearate

0.5%

Those components were mixed using a granulator (Mechanomill MM-20N, OKADA
SEIKO Co. Ltd, Iwate, Japan) with a speed of 300 rpm for 6 min, followed by adding
magnesium stearate and mixing for another 3 min with same speed. The ready
formulation was then compressed into tablets by using a tablet machine with one punch
(Shanghai Tianxiang & Chentai Pharmaceutical Machinery Co. Ltd, Shanghai, China).

7.2.4 Contact angle measurements
The contact angles of the liquid plasticizers (Glycerol, TEC and PEG 400) on the osmotic
pump tablet cores and compacts of coating powders (CA) were determined by the sessile
drop method. In order to measure the contact angle of liquid plasticizer on the compact of
the coating powders, those coating powders were firstly compressed into flat-faced
compacts with a hardness of 6.0 N at a same compression force using a single punch
tablet machine (First Pharmacy Machine, Shanghai, China). When measuring the contact
angle, samples were firstly placed on an adjustable platform and then the droplets of
liquid plasticizers were dropped on the surface with a micrometer syringe. The contact
angle was determined by measuring the tangent to the curve of the droplet on the surface
of the sample (n=6).
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7.2.5 Electrostatic powder coating process
The electrostatic powder coating process was performed in a laboratory scale pan coating
system, which consists a rotatory coating pan, a powder feeder, an electrostatic spray gun
(Nordson Corporation, USA) and liquid plasticizer spray system. After being loaded into
the coating pan, tablets (60 g osmotic pump tablets) or pellets (60 g piroxicam pellets)
were preheated for 10 min at a certain temperature. Then a certain amount of liquid
plasticizer (TEC or PEG 400) was sprayed onto the surface of the solid dosage forms,
immediately followed by the spray of coating powders by the electrostatic spray gun to
achieve coating powder adhesion. The process of loading liquid plasticizer and coating
powder can be repeated several times to obtain a higher coating level. After finishing the
coating powder adhesion, keep the temperature of the coating pan for a certain period of
time to allow deposited coating particles to coalesce and form a uniform coating film.

D
B
A

C

Ground
Figure 7.1 Schematic of the electrostatic powder coating system
(A) liquid plasticizer spray system, (B) coating pan,
(C) electrostatic spray gun, (D) powder feeder
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Table 7.3 Coating powder formulations
Ingredients

Formulation (w/w, %)
A

B

C

D

Eudragit® EPO

20

0

0

0

Eudragit® RS

0

40

0

0

Eudragit® RL

0

40

0

0

Acryl EZE

0

0

80

0

Cellulose acetate

0

0

0

80

Talc powder
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19

19

19

Pigment

0.5

0.5

0.5

0.5

SiO2 (Nano)

0.5

0.5

0.5

0.5

7.2.6 Scanning electron micrographs
Scanning electron microscopy (SEM) was used to observe the coating film achieved by
the electrostatic powder coating process. Samples were firstly sputter coated with gold for
120 s using Emitech K550 sputter coater (Emitech Ltd., Ashford, UK) and then they were
observed with a scanning electron microscope at 5.0 kV (S-2600N Hitachi, Ontario,
Canada).

7.2.7 Dissolution test
Drug dissolution tests were performed by following the United States Pharmacopeia
(USP) apparatus (Apparatus 2, paddle; Huanghai Rcz-6c2, Shanghai, China). For osmotic
pump tablets, the release media was 900 mL of pH 7.2 phosphate buffer solution. By
using a 10 mL syringe, samples were withdrawn and filtered (refilled with the same
amount of fresh release medium) at predetermined intervals and assayed using an 8453
UV-Visible Spectrophotometer (Agilent Technologies, Mississauga, Canada) at a
wavelength of 276 nm. For pellets, the release media were 900 mL of 0.1N HCl solution
for Eudragit® EPO coated pellets and 900 mL of pH 7.2 phosphate buffer solution for
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Eudragit® RS/RL coated pellets. For Acryl EZE coated pellets, the release media were
750 mL of 0.1N HCl solution for the first 2 hours and then pH 6.8 phosphate buffer
solution by adding 250 mL of 0.2 M tribasic sodium phosphate solution for additional 2
hours. At predetermined intervals, samples were withdrawn by a 10 mL syringe and
followed by refills with the same amount of fresh release medium. After being filtered,
samples were assayed using an 8453 UV-Visible Spectrophotometer (Agilent
Technologies, Mississauga, Canada) at a wavelength of 334 nm, 354 nm and 353 nm at
pH 1.2 HCl solution (0.1N), pH 7.2 phosphate buffer solution and pH 6.8 phosphate
buffer solution, respectively.

7.3 Coating powder adhesion and influence factors
For dry powder coating, in order to achieve a continuous and uniform coating film,
coating powders need to be firstly deposited onto the surface of the solid dosage forms
with a uniform distribution. There should be enough binding force between the coating
particles and the surface of the solid dosage form so that those particles could be held
firmly and then turned into a coating film after coalescing. However, extra energy needs
to be provided in order to bind the coating particles and the solid dosage forms together.
Basically in the earlier attempts [21, 23, 33] of powder coating technology, heating and
liquid plasticizer are normally used to enhance the coating powder adhesion.
The extra-benefit that an electrostatic powder coating method could bring is better
powder adhesion due to the better controlling of coating powder spraying by using an
electrostatic spray gun. In the electrostatic powder coating process developed by Zhu’s
group, the coating powder adhesion is enhanced by the combination of preheating, liquid
plasticizers and electrostatic spray gun, which could be confirmed by the following
results. The coating powder adhesion rate could be calculated according to the following
equation.

Powder adhesion rate=

Tablet weight gain after spraying of coating powder
Total weight of the sprayed coating powders

*100%
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7.3.1 Preheating
In the electrostatic powder coating process, loaded solid dosage forms are firstly
preheated to a certain temperature. This would increase the surface temperature of the
solid dosage forms to a predetermined value, enhancing the deposition of the coating
powders. Figure 7.2 shows the influence of preheating time on the coating powder
adhesion rate during the pellet coating process. The weight of loaded pellets was 60g, the
predetermined temperature is 60 ◦C. The liquid plasticizers were PEG 400 and TEC with
a flowrate of 0.5 g/min for 2 min. The charging voltage of the electrostatic gun was 60
kV. Without preheating, the powder adhesion rates for all the three coating formulations
were very low (below 80 %). After preheating the uncoated pellets for 5 and 10 min, the
powder adhesion rate was significantly increased to more than 90 %. This is because the
surface temperature of the pellets increased, leading to a promoted coating particle
deposition. Further increasing the preheating time to 15 min and 20 min led to a slight
increase of the powder adhesion rate. Table 7.4 shows the relationship between the
surface temperature of the pellets and the preheating time. The surface temperature of
those loaded pellets reached 50 ◦C after being preheated for 10 min, indicating that 50 ◦C
is a suitable temperature for the pellet coating process with these three coating
formulations containing Eudragit® EPO, Eudragit® RS/RL and Acryl EZE.
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Figure 7.2 The influence of preheating time on the powder adhesion rate
during the pellet coating (Pellet loading: 60 g, plasticizer: 0.5 g/min for 2
min, charging voltage: 60 kV)

Table 7.4 The relationship between the preheating time and the surface
temperature of pellets
Preheating time (min)

Surface temperature of the pellets (◦C)

0

25

5

43

10

50

15

56

20

60
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7.3.2 Charging voltage of the electrostatic gun
In powder coating, coating powders are fed into the coating pan by using an electrostatic
spray gun, by which an electrical field could be created between the gun and the
grounded stainless steel coating pan, significantly promoting the movement of those
negatively charged coating particles towards to the surface of the solid dosage forms in
the pan. However, for this to occur, there is a prerequisite that those solid dosage forms
must possess enough electrical conductivity, because for more conductive cores, the
negative charge of the deposited particles will dissipate quickly due to grounding,
allowing additional layers of coating powder to deposit onto the surface of the dosage
forms. On the other hand, if the dosage forms are less conductive, the electrical charge
tends to build up on the surface so as to impede further particle deposition [30]. However,
most pharmaceutical dosage forms have low electrical conductivity due to containing the
excipients with high electrical resistivity [4]. Fortunately, liquid plasticizer could be used
to increase the electrical conductivity of the solid dosage forms during the coating
process.
While after ensuring the satisfactory requirements of electrical conductivity of the dosage
forms, charging voltage turns out to be a big impact factor that affects the coating powder
adhesion rate during the coating process. The influence of charging voltage on the coating
powder adhesion rate in the pellet coating is shown in Figure 7.3. When the charging
voltage was increased from 0 to 60 kV, coating powder adhesion rates for those three
different coating formulations dramatically increased from around 70 % to larger than
90%. While further increasing the charging voltage to 70 kV, the coating powder
adhesion rates didn’t increase any more. As discussed before, the coating powder
adhesion obtained at 0 V reflected the particle deposition caused by sprayed liquid
plasticizer. Spraying a certain amount of liquid plasticizer onto the surface of the tablets
could wet the dosage surface, generating capillary force between the interface of liquid
plasticizer and the coating powders so as to enhance the coating powder adhesion. A
higher coating powder adhesion rate obtained with increasing the charging voltage to 60
kV indicates that the coating powder adhesion was enhanced by the electrostatic force
generated by the electrical field between the tip of the electrostatic gun and the coating
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pan. However, the powder adhesion rate was not increased when further increasing the
charging voltage to 70 kV. This can be explained by the increased cumulative charge of
the coating layer and back ionization caused by the higher charging voltage, which could
reduce the powder deposition.
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Figure 7.3 Influence of charging voltage of electrostatic gun on the powder
adhesion rate during the pellet coating process (Pellet loading: 60 g,
temperature: 50 ◦C, plasticizer: 0.5 g/min for 2 min)

7.3.3 Liquid plasticizer
Based on the results of previous chapters it could be concluded that liquid plasticizer
plays a significant role in the electrostatic powder coating process. It can not only reduce
the electrical resistivity of the dosage form surface, but also could wet the surface of the
solid dosage forms and produce capillary force between the interface of liquid plasticizer
and coating powders so as to enhance the coating powder adhesion. Most importantly,
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spraying a certain amount of liquid plasticizer could dramatically reduce the glass
transition temperature of the coating materials so as to minimize the coating temperature,
protecting the drug from burning by high temperatures. For example, TEC and PEG 400
are effective plasticizers for cellulose acetate and Acryl EZE, respectively.
As shown in Figure 7.4, spraying TEC onto the surface of the ODDS forms could
significantly increase the coating powder adhesion rate. But the situations were totally
different for the other two plasticizers (PEG 400 and Glycerol). After spraying PEG 400
and glycerol for 2 min, there was just a slightly increase of the coating powder adhesion
rate from less than 20 % to 53 % and 32 %, respectively, which were much smaller than
the increase caused by spraying of TEC (more than 90 %).
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Figure 7.4 Influence of liquid plasticizers on the powder adhesion rate
during the elementary ODDS coating process (tablets loading: 60 g,
temperature: 60 ◦C, plasticizer: 0.5 g/min for 3 min, charging voltage: 60 kV)
This difference could be confirmed by the SEM micrographs. Figure 7.5 shows the SEM
micrographs of CA powder coated ODDS with different plasticizers, TEC, PEG 400 and
Glycerol, both without curing and after being cured for 120 min at 60 ◦C. For those CA
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powder coated ODDS without curing (Figure 7.5, part 1), the tablets were taken out
immediately after the coating powder adhesion and observed with SEM. When the
plasticizers were glycerol and PEG 400, the deposited coating particles are clearly there
on the surface of the dosage forms without any coalesce and film formation. On the other
hand, for TEC, there were already some coalesce and some the deposited coating particles
disappeared. This could be explained by the quick film formation caused by the
preheating and spraying liquid plasticizer. After 120 min curing step, the situation didn’t
change too much for the first two plasticizers (glycerol and PEG 400). Deposited coating
particles were still there and became even less. This might be caused by the tumbling of
the coating, reducing the number of the deposited coating particles from the surface of the
dosage forms. However, for TEC, a continuous and uniform coating film has been formed
after 120 min curing. All the above results indicated that TEC is the effective plasticizer
for the coating of ODDS forms with cellulose acetate.
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Figure 7.5 SEM micrographs of CA powder coated ODDS with different
plasticizers A: Glycerol, B: PEG 400, C: TEC
(1: without curing, 2: after curing for 120 min at 60 ◦C)
The plasticizers used in the pharmaceutical coating are usually small compounds with
low molecular weights and functional groups that can interact with the coating polymers
so as to decrease the intermolecular cohesive forces between polymer chains. As a result,
the polymer segmental mobility and free volume could be increased, and the glass
transition temperature of the polymer could be reduced [34]. To be effective, one
plasticizer must be compatible with the coating polymer [34, 35]. Several methods could
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be used to predict plasticizer-polymer compatibility including glass transition temperature
(Tg) measurement by DSC and testing the mechanical properties of the plasticized
polymer film.
While for powder coating, the situation is different. Taking the cellulose acetate for
example, PEG 400 is a widely used plasticizer for ODDS coating with cellulose acetate.
But the above results confirmed that PEG 400 was not efficient in powder coating for
cellulose acetate.
Those previous results suggested that coating powder adhesion is the key to achieve an
acceptable coating film. A suitable liquid plasticizer in powder coating not only could
reduce the glass transition temperature of the coating polymer, but also should be able to
enhance the coating powder adhesion. Consequently, the spreading behavior of a liquid
plasticizer on the surface of the dosage forms becomes critical.
Contact angles can provide information regarding the interactions between the surface of
the tablet core and the liquid plasticizers (i.e. spreading behavior and wettability) [32],
also the interactions between the coating powders and the liquid plasticizers (i.e.
compatibility) [34, 35].
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Figure 7.6 Contact angles of different liquid plasticizers
on the osmotic tablet cores and coating powder compacts
The spreading behavior of these three liquid plasticizers on both the surfaces of tablet
core and coating powder compact was investigated by measuring the contact angle. As
illustrated in Figure 7.6, TEC showed the lowest contact angles on both surfaces of the
tablet core (23o ± 1.6 o, n = 6) and the coating powder compacts (14 o ± 1.7 o, n = 6). PEG
400 showed significant increase in the contact angles on both surfaces of tablet cores (33 o
± 2.1 o) and compacts of coating powders (26 o ± 2.3 o), indicating that PEG 400 had less
affinity to both surfaces of tablet cores and coating powders than TEC. Compared to the
first two plasticizers, glycerol has the highest contact angles on both surfaces of the tablet
core (45 o ± 2.4 o, n = 6) and the coating powder compacts (35 o ± 2.1 o, n = 6), suggesting
that glycerol has the least affinity to both surfaces of tablet cores and coating powder
among those three plasticizers.
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Figure 7.7 Relationship between the contact angle on tablet core and the
powder adhesion rate in the ODDS coating process (Tablets loading: 60 g,
temperature: 60 ◦C, plasticizer: 0.5 g/min for 3 min, charging voltage: 60 kV)
In order to further investigate the influence of the spreading behavior of the liquid
plasticizers on the coating powder adhesion rate, the relationship between the contact angle
of the plasticizer on tablet core and the powder adhesion rate is shown as Figure 7.7. With
the lowest contact angle, spraying TEC in the coating process resulted in the highest powder
adhesion rate. While with the increase of the contact angle on the tablet core, the powder
adhesion rate decreased dramatically, indicating that the wetting of the polymer during the
process is critical, enhancing coating powder adhesion.
Consequently, in order to be an effective liquid plasticizer, the following requirements
should be considered. First, the liquid plasticizer should be able to reduce the glass
transition temperature (Tg) of the coating polymer. Second, spraying the liquid plasticizer
onto the surface of the dosage forms should increase the electrical conductivity of those
dosage forms. Also the liquid plasticizer needs to have a suitable spreading behavior
(wettability) on the surface of the dosage forms. These three requirements could be used
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as the screening criteria to select liquid plasticizer in powder coating with different
coating materials.

7.4 Film formation and influence factors
Similar to aqueous coating, film formation of dry powder coating also relies on the
deformation and viscous flow of coating polymers [21]. As being reported from previous
studies, the deposited coating particles have to coalesce during the curing step, allowing
the film formation during the dry powder coating process [2, 30]. The influence factors
include particle size of the coating materials, curing temperature and curing time.
Pellet coating with three different coating formulations was used to illustrate those
influence factors.

7.4.1 Particle size
Figure 7.8 shows the relationship between the particle size of the coating material (Acryl
EZE) and the acid resistance of the enteric coating film.
Characterized as the percent of drug release in 0.1 N HCl solution during the first 2 h,
acid resistance is the most important quality in enteric coating that qualifies the coating
film. And according to the United States Pharmacopoeia (USP), a good coating should
only allow less than 10 % of drug release in the first 2 h in the acid medium.
As shown in Figure 7.8, different particle size resulted totally different acid resistance of
those enteric coating films formed by Acryl EZE. When the particle size of the Acryl
EZE was 168 µm, the cumulative drug release for the first 2 h was more than 40 %,
which was too much for an enteric coating film. With the decrease of coating particle size
from 168 µm to 101 µm, the cumulative release was declined to 14 %. When further
reducing the particle size to 53 µm and 20.8 µm, the cumulative drug release was
decreased to 3 % and 0.3%, respectively, which is very good enteric coating film.
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Figure 7.8 Influence of particle size of the coating powders
on the acid resistance of enteric powder coated pellets
From Figure 7.8 it could be concluded that using finer particles in the electrostatic
powder coating process resulted in more uniform and smooth coating film with
satisfactory function of acid resistance. In the electrostatic powder coating process, those
deposited coating particles have to coalesce during the curing step so as to allow film
formation. For aqueous coating processes, coalescence is driven by the presence and
subsequent removal of water which creates capillary forces between each particle. The
process of coalescence for electrostatic dry powder coating is similar, although the
capillary force is achieved by the liquid plasticizer.
Huang [36] proposed an equation to evaluate the time (t) required for two powder
particles to coalesce during coating process, which is directly related to the viscosity of
the powder coating µ, the radius of the particles (dp) and the surface tension of the coating
γ where k is a constant describing the process [2].
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kd p



(7.1)

According to equation 7.1, diameter of the coating particles is positive related to the time
required for two particles to coalesce during the coating process. Larger particle size
would result in a longer time to coalesce, leading to rougher and non-uniform coating
film with the same curing time as finer coating particles. This could be confirmed by the
results of acid resistance of enteric coating film with different coating particle sizes.
Specifically for electrostatic powder coating, the particle size of the coating powders
could also influence the coating efficiency by affecting the charging efficiency during the
coating process. Misev [37] carried out a study on the relationship between charging
efficiency and particle size and obtained equation 7.2:

6 0 E 
 1
q
1  2 r

Charging efficiency    
 r  1 
 m max 0 d p 

(7.2)

In the equation, E is the electric field to which the particles are subjected, ε0 is the
permittivity of free space while εr is the relative permittivity of powder particles, ρ0 is the
density of the particle and dp is the coating particle diameter. According to this equation,
a higher charging efficiency could be achieved by using a smaller coating particle. Also a
smaller particle has a larger specific surface area, which could make the wetting much
easier by the liquid and softening and melting by heat, so as to enhance the coating
powder adhesion and film formation.

7.4.2 Curing time and curing temperature
The effect of curing time and curing temperature on the film formation can be illustrated
by the acid resistance test of Acryl EZE coated pellets. As shown in Figure 7.9, when the
curing temperature was 30 and 40 ◦C, drug released more than 80% and 60% (cured 60
min) and decreased some when the curing time was increased to 90 and 120 min, but still
more than 10%. That is because the curing temperature was lower than the Tg of the
coating polymer, which makes it hard for the deformation and viscous flow of deposited
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polymer powders. However, when the curing temperature was increased to 50◦C, which is
close to or higher than the glass transition temperature, film formation of deposited
polymer powders became much easier and the drug released only 12 % for a curing time
of 60 min and further reduced to 5 % and 0.4 % by increasing the curing time to 90 and
120 min. (Figure 7.9).
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Figure 7.9 Influence of curing time and temperature on the acid resistance
of Acryl EZE coated pellets (Curing level: 10.83%; Drug release media: 0.1N
HCl solution; Agitation speed: 100 rpm)

7.5 Conclusions
In this chapter, the electrostatic powder coating process was in-depth characterized,
providing a full and better understanding on the coating powder adhesion and film
formation during the coating process.
Using pellet coating as example, the coating powder adhesion process was analyzed and
the influence factors including preheating and charging voltage were investigated. The
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results indicated that preheating the loaded pellets for a certain time could provide extra
energy to enhance coating powder adhesion. Increasing the charging voltage could also
promote deposition of coating particles.
Using elementary osmotic pump tablet coating as an example, the influence of liquid
plasticizers on the powder adhesion rate was analyzed. It was found that different liquid
plasticizers resulted in totally different powder adhesion rate. Compared to glycerol and
PEG 400, TEC achieved the highest powder adhesion rates, which could be explained by
the polymer-plasticizer compatibility and the spreading behavior of liquid plasticizer on
the surface of the dosage forms. From the results of contact angle measurement and the
SEM micrographs, it could be concluded that of the three plasticizers, TEC has the best
compatibility with cellulose acetate and also has a wider spreading on the surface of the
dosage forms. By doing the contact angle measurement and SEM, a suitable liquid
plasticizer could be found for a certain coating material.
Using pellet coating as example, the film formation process was also illustrated in this
chapter. After coating particles being deposited on the surface of the dosage forms, a
curing step is needed to allow coating particles coalesce and form a continuous, uniform
and functional acceptable coating film. It was found that in the electrostatic coating
process, particle size and curing temperature and time are the main influence factors that
affect the film formation process. Finer coating powders, higher curing temperature and
longer curing time led to a more uniform and smoother coating film.
The above results indicated that this electrostatic powder coating technology could be
well controlled and is ready for the industrial application as long as those influence
factors could be manipulated including preheating, charging voltage of the electrostatic
spray gun, liquid plasticizers and their screening, particle size of coating powders, curing
temperature and curing time.
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8

Conclusions and Recommendations

8.1 Conclusions
A novel electrostatic powder coating technology was successfully utilized to coat
pharmaceutical solid dosage forms including tablets, small pellets and osmotic drug
delivery systems with different coating formulations. By doing so the drug release was
successfully modified as sustained release, controlled release and delayed release.
Compared with the liquid coating methods currently used in the present pharma industry,
this electrostatic powder coating technology eliminates the usage of organic solvent and
water so as to avoid all the limitations caused by those liquids such as toxicity, health and
environmental related concerns, high energy consumption, and long processing time. This
electrostatic powder coating also has many other advantages such as simpler coating
apparatus that can be easily adapted from the present ones such as pan coater systems for
liquid coating. Consequently, the proposed new technology, as a substitute of liquid
coating, is promising and readily acceptable in the pharmaceutical industry.
Electrostatic powder coating was firstly expanded to tablet coating for sustained drug
release with ethylcellulose (EC), which is difficult to coat due to its high glass transition
temperature (Tg). Lactose and triethyl citrate (TEC) are two effective plasticizers for EC,
which could dramatically reduce the Tg of EC, guaranteeing that the whole coating
process was under a relatively low temperature so as to protect drug from high
temperature. Spraying liquid plasticizer onto the surface of the tablets also increased the
electrical conductivity of those dosage forms, leading to an enhanced coating powder
adhesion with the electrostatic spray gun. With the support of these two plasticizers, a
continuous, uniform and functional acceptable coating film could be formed under 60 ◦C
for around 120 min. Pore forming agent (PVA-g-PEG) was added in the coating
formulation to increase the permeability of the EC coating film, leading to a faster drug
release rate. The drug release rate could be adjusted by changing the coating level and
pore forming agent ratio in the coating formulation. The stability tests indicated that EC
powder coated tablets using powder coating technology exhibited excellent stability over
1 month at 40 ◦C /75% RH.
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Small pellets were also successfully coated by electrostatic powder coating with
optimized coating parameters and curing conditions. Polyethylene glycol (PEG) 400 and
triethyl citrate (TEC) were used as the liquid plasticizers to reduce the Tg of the coating
polymers, as well as to decrease the electrical resistivity of the drug pellets, enhancing the
coating powder adhesion and promoting the film formation under a low curing
temperature. Three different coating formulations were developed for pellet powder
coatings containing Eudragit® EPO, Eudragit® RL/RS and Acryl EZE, achieving
immediate release, sustained release and delayed release, respectively. For immediate
release and delayed release, the results of dissolution tests indicated that coating level
didn’t contribute to the difference of surface morphology as well as drug release profiles.
However, for sustained release, coating level had a big impact on the drug release profiles
as well as the surface morphology. Higher coating level led to a better and more uniform
coating film and a slower drug release rate. For Eudragit® RL/RS powder coated pellets,
drug release rate could also be influenced by the ratio of Eudragit® RL/RS in the coating
formulation; more Eudragit® RL led to a faster drug release rate due to the high
permeability of the coating film formed by Eudragit® RL. Those powder coated pellets
with these three coating formulations by using dry powder coating technology exhibited
excellent stability, with 1 month at 40◦C /75% RH. Compared with pellet coating based
on organic solvent and water in a fluidized bed, powder coating of pellets could
significant reduce energy consumption without using large amounts of fluidizing hot air.
Particularly, as the most promising oral drug delivery system, osmotic drug delivery
systems (ODDS) were also successfully coated by applying powder coating, which is a
big breakthrough in pharma coating. Elementary osmotic pump tablets were firstly
prepared and coated with micronized cellulose acetate by using powder coating. Both
water soluble drug (salbutamol sulfate) and water slightly soluble drug (ibuprofen) were
used as the model drugs in the tablet core formulation. Triethyl citrate (TEC) was found
to be an efficient liquid plasticizer for ODDS coating with cellulose acetate, not only
reducing the glass transition temperature, but also increasing the conductivity of the
ODDS dosage forms. With the support of TEC, a continuous, uniform and functional
acceptable coating film was obtained with optimized coating conditions and curing
parameters. Controlled drug release with a desirable time period (12 hours and 24 hours)
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was achieved. Drug release rate from powder coated tablets varied with different coating
levels, while this was independent of the diameter of delivery orifice, pH of release media
and agitation speed. Results from the kinetic modeling on drug release from electrostatic
powder coated elementary ODDS demonstrated that both salbutamol sulfate and
ibuprofen released with zero order drug release kinetics.
Electrostatic powder coating was also utilized to form porosity osmotic drug delivery
systems (ODDS) by coating the ODDS core with a mixture of cellulose acetate and pore
forming agent (Polyethylene glycol 3350). Similar with elementary ODDS coating, TEC
was used as the liquid plasticizer to reduce the coating temperature and enhance the
coating powder adhesion. Drug controlled release with a desirable time period (12 hours
and 24 hours) was achieved by adjusting the coating level and pore former ratio in the
coating formulation. Drug release rate was independent of the pH of release media and
the agitation speed. After being fitted with different mathematical models including zeroorder, first-order and Higuchi model, it was found that the drug release from porosity
ODDS formed by powder coating followed zero-order drug release kinetics.
More in-depth characterization was carried out to fully illustrate powder coating process,
which is related to two steps: coating powder adhesion to the surface of the dosage forms
and film formation. It was found that coating powder adhesion was a prerequisite and
particularly critical to achieve an acceptable coating film. The adhesion of coating
powders could be improved by doing the following: preheating the loaded solid dosage
forms, applying a suitable liquid plasticizer in the coating process and utilizing the
electrostatic spray gun to feed the coating powders with a suitable charging voltage. After
adequate coating particles deposited on the surface of the dosage forms, a curing step is
needed to allow coating particles to coalesce and form a continuous, uniform and
functional acceptable coating film. It was found that in the powder coating, particle size,
curing temperature and time are the main influence factors that affect the film formation
process. Finer coating powders, higher curing temperature and longer curing time led to a
smoother and more uniform coating films.
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Liquid plasticizer plays a key role in the powder coating process, not only reducing the Tg
of coating polymers, but also increasing the electrical conductivity of the dosage forms,
both of which could enhance coating powder adhesion and promote film formation.
However, difficulties exist in selecting the most suitable liquid plasticizer for each
different coating polymer. The present study found that the contact angles of a liquid
plasticizer on the coating powder compact and surface of dosage forms not only reflect
the compatibility of this plasticizer with the coating polymer, but also indicate the
spreading behavior of this liquid plasticizer on the surface of dosage forms. Together with
differential scanning calorimetry (DSC) analysis and electrical resistivity test, contact
angle measurement could be used to screen liquid plasticizers for powder coating with
different coating materials.
Compared with previous coating technologies, the advantages of this powder coating
process include eliminating organic solvent and water currently used in the present
pharma coating, significant energy and time savings, significant reduction of air handling
and cleaning requirements. Consequently, the proposed new technology, as a substitute of
liquid coating, is promising and readily acceptable in the pharmaceutical industry.

8.2 Recommendations
Despite those comprehensive studies that have been done in the present study, further
experiments remain necessary for a thorough understanding of this electrostatic powder
coating technology. Some recommendations are listed below as future perspective.
Powder coating has been applied to most of the solid dosage forms including tablets,
pellets, osmotic pump tablets. Yet very small dosage forms, such as drug particles
(diameter < 800 µm), haven’t been tried so far. Considering the difference between small
drug particles and larger dosage forms, further studies need to be carried out.
In addition, moisture sensitive drugs always bring troubles to the current liquid coating
but they are very suitable for powder coating. Details need to be obtained on how to apply
powder coating to those moisture sensitive products, which may play a key role in
adopting this novel technology in the pharmaceutical industry.
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